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ABSTRACT 
Cutaneous leishmaniasis (CL) is a parasitic disease caused by several species of the 
protozoan parasite Leishmania and affects approximately 10 million people worldwide. 
The drugs currently available such as miltefosine, amphotericin B and pentavalent 
antimonials, are limited by high cost, considerable side effects and restricted efficacy. 
CL could potentially be treated by a topical formulation. In its simplest form CL consists 
of a single nodule or papule, typically on exposed body parts, with the parasites residing 
in the lower epidermis and dermis. A topical treatment would minimise possible adverse 
effects by reducing the amount of drug taken up in the systemic circulation and would be 
easy to apply which is important for patient compliance. 
The overall aim of the work described in this thesis was to explore the use of different 
drugs in a topical formulation to cure CL. To be efficacious, a topical treatment requires 
the permeation of the active ingredient through the stratum corneum and into the deeper 
layers of the skin where the Leishmania parasites resides. Intact skin is a highly effective 
barrier against xenobiotics. However many skin diseases are known to affect the skin 
barrier making it more or less permeable to drugs. An understanding of the permeability 
of the skin hosting the Leishmania parasites is a prerequisite when trying to optimize 
drug delivery to the skin. Therefore the barrier function of Leishmania infected skin in 
early stages of CL was characterised with respect to histology, transepidermal water loss 
and drug permeation. 
Suitable anti-leishmanial drugs with the potential to permeate into the skin were 
identified through literature review, taking into account the information obtained from the 
skin barrier characterisation. The leishmanicidal activity of the drugs was evaluated in an 
intracellular amastigote-macrophage model and potent compounds were selected for 
further work.  
First, the re-formulation of miltefosine, currently used to treat leishmaniasis via oral 
administration, into a topical formulation was explored. The effects of different solvents 
on its permeation through and disposition in the skin was evaluated using in vitro Franz 
diffusion cell permeation studies.  
 V 
 
Secondly, a drug discovery approach was used to identify lead benzoxaboroles, a set of 
interesting anti-leishmanial compounds. In the early stages, in vitro ADME studies were 
conducted to establish basic pharmacokinetic parameters of a range of benzoxaboroles. 
This information together with previously unpublished data was used to select 
compounds for further testing such as stability and binding in skin homogenate and 
permeation evaluation. The three most promising compounds were tested in vivo in a CL 
model. 
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1 INTRODUCTION 
Today many topical pharmaceutical formulations are on the market. A considerable 
number of these products are used to treat viral, bacterial or fungal infections whereas 
only one topical formulation is commercially available to treat cutaneous leishmaniasis 
(Leshcutan®; Teva, Israel).  
Cutaneous leishmaniasis (CL) is a widespread parasitic disease that affects 12 million 
people worldwide1 with 0.7-1.2 million new cases every year1. It is characterized by a 
variety of clinical symptoms ranging from defined nodular lesions to gross mucosal 
destruction. Non-complicated lesions tend to heal spontaneously but this process can 
take 3 to 18 months and nearly always leave a disfiguring scar2, 3. Available treatments 
are constrained by parenteral drug administration, toxicity, cost and limited efficacy. 
For example Leshcutan® ointment contains an aminoglycoside drug, paromomycin 
sulphate (PM) that is formulated with an excipient that solubilizes skin lipids and 
decreases the skin barrier function. This is necessary to enable the skin permeation of 
PM and thus treatment efficacy. The excipient is also the main cause of skin irritation 
that is often reported after application of the ointment4-6. Intrinsic insensitivity of 
Leishmania species to drugs may contribute to the variable cure rates observed3, 7-9.  
For localized diseases such as CL, a topical formulation would be easy to apply and 
local application would reduce the risk of adverse effects and resistance development.  
The skin has a unique composition and architecture that forms an efficient barrier that 
protects the internal environment from the ingress of xenobiotics. The section below 
describes the different skin layers and how their composition can restrict the permeation 
of molecules.  
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1.1 HEALTHY SKIN PHYSIOLOGY 
The skin is composed of three main layers (Figure 1-1) and depending on the drug that 
is being delivered, certain layers might present more of a barrier to permeation than 
others. The different skin layers and their compositions are described below.  
 
 
 
 
 
 
 
 
FIGURE 1-1. A CROSS-SECTION THROUGH HUMAN SKIN (ADAPTED FROM10) 
 
1.1.1 EPIDERMIS  
The epidermis is the most superficial layer of the skin (Figure 1-1). It contains different 
cell types including keratinocytes, Langerhans cells, Merkel cells and melanocytes. The 
keratinocytes represent 90-95% of the cell volume and their maturation appears as four 
histologically distinct layers of the epidermis11. From the inside out, they are as 
follows12: 
 Stratum basale or basal layer 
 Stratum spinosum or prickly layer 
 Stratum granulosum or granular layer 
 Stratum corneum (SC) or cornified layer 
The stratum corneum is the outermost layer and is considered the rate-controlling 
barrier for diffusion (outside-inside barrier). It is made up of 10 to 15 stratified layers of 
dead flattened and keratinized cells (also known as corneocytes) and is around 10-15 
μm thick13, 14. A complex mixture of intercellular lipids such as ceramides, free fatty 
acids, cholesterol and cholesterol sulphate is present between the corneocytes 15, 16. The 
Epidermis 
Dermis 
Subcutaneous tissue 
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lipids are structured into ordered bilayers creating both hydrophilic and hydrophobic 
regions. As the cells move outward and upward their structure, composition and 
function changes allowing desquamation.  
The viable epidermis is an avascular structure of around 50-100 μm and forms an 
indispensable barrier to water evaporation (inside-outside barrier)17. The stratum basale 
lies adjacent to the basement membrane that forms a well-defined border between the 
dermis and epidermis. The keratinocytes of the basal layer are attached to the basement 
membrane by hemidesmosomes. The cells in this layer are similar to cells in other body 
tissues as they contain typical cell organelles and they undergo mitotic cell division. 
From the two cells originating from replication, one daughter cell remains in the stratum 
basale whilst the other differentiates and moves upwards during the maturation process. 
The layer found above the stratum basale is the stratum spinosum. It is made up of 
several layers of polyhedral shaped keratinocytes that start to differentiate and 
synthesise keratins. As the keratinocytes pass to the stratum granulosum they continue 
to differentiate. The cells flatten and contain protein granules called keratohyalin 
granules12. This layer also contains enzymes that start the degradation of the living cell 
components such as nuclei and organelles18.  
1.1.2 DERMIS  
The dermis is 3 to 5 mm thick12. This layer consists of a fibrous network of connective 
tissue mainly collagen fibrils (70%) and elastic tissue, embedded in a semigel matrix of 
mucopolysaccharides19, 20. With regards to transdermal delivery this layer is considered 
as gelled water and might provide a barrier to highly lipophilic drugs21. The superficial 
dermis contains a rich capillary network and forms the first site of drug uptake into the 
systemic circulation.  
Furthermore, the dermis hosts several epidermally derived appendages such as hair 
follicles and glands, it contains sensory receptors and an extensive vascular network. 
The primary cell type is the fibroblast that migrates through the tissue while it produces 
the precursors of connective tissue components22. Other cells include mast cells; they 
originate in the bone marrow and are involved in the immune and inflammatory 
responses and melanocytes that are responsible for the production of the pigment 
melanin.   
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1.2 SKIN DRUG DELIVERY  
Topical and transdermal formulations deliver drugs across the SC but have a different 
target. Transdermal formulations are designed to achieve drug transport across the skin 
into the blood circulation with minimal drug retention in the skin. In contrast, topical 
products are designed to treat local skin diseases and the target is inside the skin23. 
Systemic exposure is avoided as this may not be needed and increases the risk of side 
effects.  
Both types of formulations rely on passive diffusion of the active molecule across the 
SC and into the epidermis and dermis. The different permeation routes are described 
below. 
1.2.1 SKIN PERMEATION ROUTES   
As mentioned above, the SC is designed to be a highly efficient barrier restricting the 
penetration of xenobiotics through skin. For most compounds this is the rate-controlling 
barrier for diffusion. Three different pathways for molecules to permeate through the 
SC: (i) transcellular route, (ii) intercellular route and (iii) transappendageal route are 
described in literature (Figure 1-2). 
 
 
 
 
 
FIGURE 1-2. SCHEMATIC REPRESENTATION OF THE PATHWAYS OF TOPICAL DRUG DELIVERY. 
Initially it was believed that the transcellular diffusion route was the main pathway for 
solutes to pass through the SC24. However following research and experimental 
evidence, it is now generally excepted that the transport through the is mainly by the 
intercellular route25. As described before, the SC is a dense layer of flattened, dead cells 
that are surrounded by a mixture of lipids, structured in bilayers. The intercellular 
pathway (Figure 1-2) therefore implies transport of the diffusant through the bilayers 
and thus through sequential hydrophilic and lipophilic domains26. Compared to 
transcellular transport where the molecule moves directly across the SC and the path 
Transcellular route 
Transappendageal route 
Intercellular route 
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length for permeation is considered the same as the SC thickness. The intercellular 
transport is highly tortuous and the permeation path length is greater than the SC 
thickness.  
The transappendageal route differs from the other two routes because this pathway 
circumvents the intact SC barrier using hair follicles and sweat ducts to permeate. It is 
suggested to be a significant pathway for large polar molecules during the early stages 
of passive diffusion27. 
1.2.2 PASSIVE DIFFUSION LAWS  
The main mechanism of drug permeation through skin is passive diffusion. Essentially, 
during the diffusion process there is a movement of molecules from a high to a low 
concentration (Figure 1-3). 
 
 
 
 
 
FIGURE 1-3. SCHEMATIC PRESENTATION OF THE PASSIVE DIFFUSION OF A DRUG ACROSS A MEMBRANE. 
 
Fick’s first law, applied when steady state conditions have been reached, states that the 
rate of transfer of the diffusing molecules per unit area is proportional to the 
concentration gradient measured across the membrane (Equation 1). 
 
EQUATION 1 
J is the flux of the permeant per unit area (in mol/(cm2·s)), K is the stratum corneum-
formulation partition coefficient, D is the diffusion coefficient of the permeant in the 
stratum corneum (in cm2/s), h is the path length (in cm), C0 is the concentration of drug 
applied to the skin surface (in mol/cm3) and Ci is the concentration inside the skin.  
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In most practical situations C0 >>>Ci
26 and the equation becomes (Equation 2): 
 
EQUATION 2 
After insertion of the permeability coefficient Kp = DK/h (in cm/s) the equation 
becomes (Equation 3): 
 
EQUATION 3  
The lag time can be obtained from extrapolation of the steady state portion to the 
intercept of the time axis (Figure 1-3).  
In order to apply the above equations to skin permeation, the experimental design 
should comply with some assumptions: 
 The stratum corneum is the rate-limiting barrier; 
 Permeation through the appendages is negligible and by passive diffusion only; 
 The nature of the stratum corneum is not changed by the application of the 
vehicle of the formulation and the stratum corneum is considered isotropic; 
 The diffusion is not dependent on concentration, time or distance; 
 The diffusing compound dissolves in the stratum corneum. 
However in real-life situations, patients are more likely to apply finite dose 
formulations. In time, the amount of drug that permeates through the stratum corneum 
will reach a plateau and remain constant (Equation 4). The diffusion is mathematically 
described as follows: 
 
EQUATION 4 
It is important to note that Equation 4 can only be used assuming a unidirectional 
diffusion through an isotropic membrane. 
  
J =
KD
h
C 0
J =KpC0
¶c
¶t
= D
¶2c
¶x2
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1.3 TOPICAL FORMULATIONS  
1.3.1 GENERAL COMPOSITION  
A drug is rarely applied to the skin as a pure compound, instead the drug is incorporated 
in a suitable carrier system.  
Topical formulation = active ingredient + non-active carrier system (vehicle+excipients) 
1.3.1.1  ACTIVE INGREDIENT  
Not all drugs permeate easily through skin. From Fick’s first law of diffusion (Equation 
1) it can be derived that the main physicochemical determinants of the passive diffusion 
process are solubility, partition behaviour and diffusion coefficient of the drug.  
In general, percutaneous absorption is considered as a series of partition and diffusion 
processes. Modelling these processes has given more insight in to which 
physicochemical drug parameters guide these processes. Potts and Guy modelled the 
permeation of a set of compounds using only the partition coefficient (Koct/water) and 
molecular weight (Mw) to explain the permeability of the range of compounds28. In 
fact, in vitro studies that evaluated the permeability of steroids through skin have shown 
that smaller molecules permeated quicker than large molecules29. This inverse 
relationship between skin permeation flux and molecular weight was confirmed by later 
research30 and is now generally accepted. More recent research evaluated the molecular 
weight of drugs that are currently available in topical formulations and found a 
molecular weight below 500 g/mol for the majority of drugs31.  
As mentioned before the intercellular route is considered the main route for drug 
permeation. This involves the permeant to partition and diffuse through the sequential 
lipophilic and hydrophilic regions of the intercellular lipids and requires thus both 
lipoidal and aqueous solubilities. In vivo studies involving compounds with a variety of 
lipophilicities indicated an optimal log Koct/water of 2.5 and a range of 1-3 is appropriate 
for topical drugs32.  
Due to their nature, the partitioning behaviour and solubility of a drug are inversely 
related. Compounds with a high log Koct/water, often have a lower aqueous solubility 
compared to compounds with a low log Koct/water. Passive permeation benefits from a 
slightly lipophilic compound and therefore a compromise between log Koct/water and 
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solubility are required. Furthermore research has led to believe that a higher solubility is 
related to a lower melting point33.  
Further extension of modelling techniques to bigger data sets and thus a wider variety of 
chemical compounds revealed that a delay in percutaneous permeation could be linked 
to the presence of H-bonding groups34. Moreover functional groups behaving as H-bond 
donor appeared to have a higher impact on permeation than H-bond acceptors and 
adding a third H-bond donor group to a molecule, resulted in a large reduction of the 
diffusion of a compound35.  
Briefly to optimise permeation, a given drug should comply with the following 
physicochemical properties 26, 34-37: 
 molecular weight < 500 g/mol31 
 log Koctanol/water between 1 – 335 
 low melting point (< 200°C)38  
 aqueous solubility > 1 mg/ml37 
 hydrogen bonding groups < 239 
1.3.1.2  NON-ACTIVE CARRIER SYSTE M  
The carrier system is regarded as the sum of the ingredients in which the drug is 
delivered (i.e. the formulation matrix or vehicle and excipients) and is important as it 
influences the drug delivery, product performance and tolerance profiles of topical 
formulations. The ideal carrier system is easy to apply and remove, nontoxic, non-
irritant, non-allergenic, chemically stable, homogeneous, bacteriostatic, cosmetically 
acceptable, pharmacologically inert, and should readily release the drug into the stratum 
corneum 40.  
According to the European Pharmacopeia, vehicles are divided in three main types: the 
solids (sticks, powders and patches), semi-solids (ointments, creams and gels) and 
liquids (solutions, suspensions and lotions). When choosing the vehicle type it is 
important to consider:  
 Skin type: a richer vehicle is preferred for a dry skin for example a 
water-in-oil cream or an ointment; 
 Skin site: when applied on the face the formulation should be 
aesthetically acceptable; 
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 Wound type: wet wounds require an absorbing formulation type for 
instance a gel; 
 Compatibility: ionic active ingredients should be compatible with the 
vehicle components for example when ionic surfactants are used; 
 Environmental factors: warm and humid climate increases instability of 
creams and emulsions.  
An excipient is part of a formulation as a non-medical agent and help to keep the 
formulation and active ingredient stable throughout the shelf life, efficacious and safe. It 
is important that this compound is compatible with the other ingredients of the 
formulation. The function of excipients can vary widely and sometimes one excipient 
has multiple functions as indicted in Table 1-1. 
TABLE 1-1. TOPICAL FORMULATION EXCIPIENTS AND THEIR FUNCTION(S). 
Excipient function Use Example 
Humectant Avoids water evaporation 
from the formulation 
Propylene glycol, PEG 400, 
glycerol 
Solvent Dissolve and increase the 
solubility of a compound 
Propylene glycol, alcohol, 
glycerol 
Antioxidant Prevent oxidation Ascorbic acid, tocopherol, 
butylated hydroxyanisole 
Preservative Prevent growth of micro-
organisms 
Methylparaben, benzoic acid 
Buffer Weak acid or base that 
maintains the pH around a 
certain value 
Sodium hydroxide, ascorbic 
acid, citric acid 
Thickening agent Increase the viscosity of the 
vehicle 
Methylcellulose, Carbomer, 
tragacanth 
Chemical penetration 
enhancer  
Promote the permeation of 
the active ingredient through 
the SC 
Propylene glycol, dimethyl 
isosorbide, isopropyl myristate 
 
1.3.2 SKIN PENETRATION ENHANCEMENT  
A lot of effort is made to try and circumvent the barrier property and enhance the 
permeation of drugs. The different strategies can be divided in two main categories: 
chemical and physical methods41. In physical modulation methods a form of electrical, 
mechanical, magnetic or thermal energy is applied to disrupt the skin barrier42. Some 
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examples include the use of electric current in iontophoresis43, 44 and electroporation45, 
ultrasound46 and use of micro needles47, 48. Drug permeation enhancement via physical 
methods is not the subject of this project, and physical methods are therefore not 
discussed further. 
This project focuses on chemical modulation of topical permeation enhancement. From 
Fick’s first law (Equation 1 and Equation 2), it is clear that enhanced flux of the drug 
across the skin can be accomplished by: 
 Increasing C0 by aiming for maximum thermodynamic activity of the permeant 
in the vehicle or by supersaturation; 
 Increasing the diffusion (D) of the drug across the stratum corneum  
 Increasing the solubility of the permeant in the stratum corneum (K) 
 Reducing the path length of permeation for instance by tape stripping. 
Above, the effects of solvents on the permeation of drugs were categorised, however, 
practically the mechanisms of action are much more complex and solvents can increase 
the permeation of a drug by a number of mechanisms.  
Increase of diffusivity. Azone®, oleic acid, octyl salicylate and surfactants are examples 
of chemical penetration enhancers (CPEs) that increase the diffusion of a permeant 
across the SC by disruption or interaction with skin lipids. 
Octyl salicylate (OSAL) is a lipophilic compound that is used as sunscreen in topical 
formulations and is considered safe in concentrations up to 5%49. Its enhancing effect on 
percutaneous permeation was first described in the 1990’s50, 51. OSAL increased the flux 
of testosterone in vitro using porcine skin, when used alone and in combination with 
PG52. It was also reported to increase the permeation of fentanyl in spray formulations 
by enhancing the drug diffusion across the SC53. However when using differential 
scanning calorimetry (DSC) and attenuated total reflectance Fourier transform infrared 
spectroscopy (ATR-FTIR), no changes in lipid fluidity or molecular conformation in the 
SC were observed and so it was suggested that OSAL disturbs the skin lipid formation 
by forming a pool in the SC rather than intercalating with the skin lipids, a mechanism 
previously described for oleic acid53, 54. 
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Increase partitioning. A second category of CPEs increases the solubility of the drug in 
the outer layers of the skin enhancing the partitioning of the drug into the skin for 
example propylene glycol and Transcutol®.  
Propylene glycol (PG) exhibits mild permeation enhancer properties and is used as a co-
solvent to increase solubility of poorly soluble drugs55-57. As PG is a small hydrophilic 
molecule, it is suggested that it readily permeates the skin upon application58-61, and 
modifies the solubility of the drug in the SC, thereby enhancing the permeation57, 62. 
Furthermore research has shown that the permeation of drugs can synergistically be 
enhanced by combining CPEs that influence the diffusivity of the drug and the 
partitioning of the drug in the SC. For example, a combination of oleic acid and PG was 
shown to synergistically enhance the permeation of tenoxicam compared to the single 
solvents62. The same synergistic effect was observed when using PG in combination 
with other fatty acids63-65. This is also the reason why PG is often used as a vehicle for 
other enhancers rather than a standalone permeation enhancer.  
Other chemical compounds have shown an effect on the drug flux across the skin but 
the precise mechanism of action remains unclear. An example would be dimethyl 
isosorbide (DMI). It has been shown to increase dermal delivery of hydrophilic drugs66. 
Research found it to permeate the skin60 but no interruption of the intercellular packing 
was observed and therefore it is thought to not change the skin barrier and the 
diffusivity of permeants67.  
Water is incorporated in nearly every formulation on the market and the water content 
of the human skin was shown to influence the permeation of both lipophilic68 and 
hydrophilic permeants69, 70. The precise mechanism of percutaneous permeation 
increase by hydration is not known yet. From differential scanning calorimetry (DSC) 
data, it was initially hypothesized that skin permeation enhancement was caused by 
intercellular lipid disorder and loosening of the intracellular keratin structure. However 
later this theory was challenged when Bouwstra et al conducted X-ray diffraction 
studies and found no changes to the lipid and protein organisation of the SC in the 
presence of water71, 72. These findings were supported by Fourier transform infrared data 
obtained from skin samples with different levels of hydration73. 
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Like other penetration enhancers, water in the SC can alter the solubility of the 
permeant in the SC and therefore affect its partitioning from the vehicle into the SC. 
However this mechanism does not explain the effect of hydration and the enhanced 
delivery of lipophilic compounds. Others however, suggested that the intercellular lipid 
domains of a highly hydrated SC contain water pools 74. 
In order to enhance permeation, CPEs are added to the formulation and are in contact 
with the skin for a considerable amount of time. Therefore the ideal penetration 
enhancer complies with the following properties 51, 75: 
 It should have no pharmacological activity of its own. 
 It should not cause allergies, be irritating or toxic. 
 It should work directly and its effect (duration and activity) should be 
reproducible and predictable. 
 The activity should be reversible meaning that the barrier function of the SC 
should return to normal once the penetration enhancer is removed. 
 It should work unidirectional, meaning that it allows the therapeutic agents to 
enter through skin without endogenous substances leaving the body. 
 It should be odourless, tasteless and colourless. 
 It should be compatible with the active ingredients and excipients of the 
formulation. 
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1.4 DISEASED SKIN  
Although topical treatments are often evaluated using healthy skin, they are designed 
and developed to treat diseased skin. Many pathological disorders alter the physiology 
and barrier function of the skin and therefore influence the delivery of drugs to their 
target site. Research into drug delivery to diseased skin has mainly focused on non-
infectious diseases such as atopic dermatitis, psoriasis and eczema. Infectious skin 
diseases caused by pathogens such as herpes, Tinea and Candida albicans have been 
investigated, but to a lesser extent. Limited data on the permeability of cutaneous 
leishmaniasis-affected skin is available. However this information is vital when trying 
to develop a topical formulation for the disease. Below three different techniques are 
described that were used in this project to investigate the barrier function of cutaneous 
leishmaniasis-affected skin.  
1.4.1 TRANSEPIDERMAL WATER LOSS  
Transepidermal water loss (TEWL) represents the water that migrates through the 
epidermis from inside the body to the external environment.  
In clinical settings, non-invasive TEWL measurements allow the evaluation of the skin 
barrier integrity76. Healthy skin is a good barrier that retains water inside the body. 
However in diseased skin, the barrier is compromised and TEWL values are increased 
(Figure 1-4). Some of the frequently cited pathologies for which an increase of TEWL 
values was recorded, are atopic dermatitis77-79, psoriasis80, 81, ichtyosis82, 83 and xerosis84, 
85. 
 
 
 
 
 
FIGURE 1-4. A SCHEMATIC OF INCREASED TRANSEPIDERMAL WATER LOSS IN IN HEALTHY AND DISEASED 
SKIN. 
Two types of equipment have been designed to measure water evaporation from the 
skin surface: open and closed chamber tools. The main limitation of an equipment using 
the open chamber method is the vulnerability to disturbances from ambient air 
Healthy skin Diseased skin 
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movements. Practically, this means that this type of equipment can only be used in well 
controlled laboratories and on horizontal surfaces. In closed chamber equipment, the 
water evaporation is determined from the time rate of rise of humidity in this chamber.  
The Aquaflux AF200 (Biox, UK) used in this study is a ventilated condenser chamber 
instrument. The condenser is maintained at low temperature and acts as a water vapour 
sink that maintains a low humidity (Figure 1-5). The test surface acts as a vapour source 
and creates a higher humidity in the chamber. Basically vapour moves from the test 
surface to the chamber (sink condition) by passive diffusion and a continuous flux can 
be measured without purging the chamber.  
 
FIGURE 1-5. SCHEMATIC OF A CONDENSOR CHAMBER (ADAPTED FROM WWW.BIOX.BIZ). 
1.4.2 HISTOLOGY  
Histopathological investigation allows an in depth understanding of the pathological 
changes of the skin at microscopic level. A variety of stains are available and can be 
used depending on the target. Haematoxylin and eosin stain (H&E) is a commonly used 
stain that provides structural information. It colours nucleic acids purplish and proteins 
such as in the cytoplasm and extracellular matrices pink.  
Immunohistochemistry (ICH) is another useful technique that combines immunological 
and biochemical reactions whereby specific antibodies tagged with a visible label bind 
to target antigens. This allows the visualization of the distribution and localization of the 
target within cells and tissues.  
Both techniques give a variety of information and are widely used. However the sample 
preparation is time consuming and in the process the sample is altered restricting its use 
for other scientific purposes. Furthermore histology does not give 
dermatopharmacokinetic or -dynamic information. 
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1.4.3 SKIN PERMEATION  
As mentioned in the previous section, pathological skin disorders have been reported to 
change the cutaneous barrier and pharmacokinetics and dynamics of a topical 
formulation in vitro and in vivo. This highlights the importance of efficacy evaluation of 
a topical formulation on the target population. This is not always possible in early drug 
development stages due to legal and ethical issues and thus the development and 
characterization of a model that presents the same cutaneous changes as the target 
population is essential.  
Many models were developed in an attempt to mimic diseased skin and its impaired 
barrier to drug delivery86, 87. However in most models an impaired skin barrier was 
obtained by mechanically or chemically modifying the SC and are not specific to a 
particular disease. An extensive review of these methods is written by Chiang et al87.  
Briefly, mechanical damage involves: (i) abrasion that causes the SC to loosen as seen 
by transmission electron microscopy and (ii) tape stripping that involves removal of SC 
layers. Freezing the skin also seems to damage the skin barrier integrity and the effect 
appears to be storage-time dependent88-90.  
The SC consists of corneocytes that are embedded in a matrix of lipids. Therefore it is 
not surprising that extraction of these intercellular lipids results in increased drug 
permeation. Several chemical reagents have been reported to de-lipidise the skin and 
effect its barrier integrity. For example, when evaluating the permeation of skin that was 
exposed to a chloroform-methanol mixture prior to the experiment using Franz diffusion 
cells an increase of permeation for drug compounds was observed91, 92. This increase 
was higher for hydrophilic compared to lipophilic compounds. The same was observed 
when treating the skin with acetone prior to evaluating the permeation of drugs93.  
Diseases such as atopic dermatitis, psoriasis and skin cancer were reported to increase 
skin permeability. For example when evaluating permeability of psoriasis affected skin 
in vitro, an increase in anthralin94 and 8-methoxypsoralen95 permeation was recorded. 
Shani et al compared the penetration of electrolytes through skin of healthy and 
psoriatic patients after bathing in the Dead Sea and found increased electrolyte levels 
only in the psoriatic group96. Other in vivo studies showed an increase in permeation of 
a range of molecules indicating that the permeation in psoriatic skin is often increased87.  
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Differences may exist in different diseases and with various severity levels within one 
disease. Moreover data obtained using animal models are not always translatable to 
humans because of differences in the skin physiology, hair follicle density and even 
metabolism. Therefore care should be taken of extrapolating from these results.  
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1.5 LEISHMANIASIS  
The leishmaniases are a group of poverty-related diseases with clinical manifestations 
ranging from small cutaneous nodules to fatal visceral infections.  
The parasites are transmitted by the bite of a female sandfly of the genus Phlebotomus 
(in the Old World) or Lutzomyia (in the New World). Approximately 100-1000 
promastigotes97 are injected in the skin and engulfed by neutrophils, that are rapidly 
recruited to the site of infection. Some of the parasites survive in the neutrophils and are 
internalized in their phagolysosome, where they transform into amastigotes (Figure 
1-6). In fact, neutorophils act as a transient host for the amastigotes before they are 
taken up by macrophages where they replicate98-100. Research suggested that the 
presence of the amastigotes in the phagolysosome (pH 5-5.5) of the macrophage inhibits 
apoptosis and necrosis of the host cell101-104 and hence, contributes to the survival of the 
parasites. Eventually the macrophage ruptures, releasing the pathogens to infect other 
macrophages. The parasites can stay in the skin or migrate to inner organs (liver, spleen 
and bone marrow) leading to cutaneous (CL) or visceral leishmaniasis (VL) 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-6. THE LIFE CYCLE OF LEISHMANIA  PARASITES (ADAPTED FROM 105). 
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The transmission of Leishmania species can either be zoonotic when the parasites are 
transmitted from animal to man or anthroponotic when transmitted from man to man. L. 
tropica and L. donovani typically involve anthroponotic transmission.  
1.5.1 DISTRIBUTION  
Leishmaniasis is endemic in 98 countries over 5 continents and 350 million people are 
at risk of infection1. The reported incidence of VL and CL patients is approximately 58 
000 and 220 000 cases a year respectively1. The overall magnitude of the problem, 
however, is estimated to be much higher due to underreporting. The majority (90%) of 
VL cases are found in six countries: India, Bangladesh, Sudan, South Sudan, Brazil and 
Ethiopia. In contrast, CL is more widely distributed, with 70-75% of the estimated cases 
occurring in Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, 
Costa Rica and Peru (Figure 1-7)1. CL affects an estimated 10 million people and 0.7-
1.2 million new cases occur every year106.  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-7. DISTRIBUTION OF CL IN 2013  (ADAPTED FROM 107).  
The distribution of leishmaniasis has spread over time. This is in part due to 
environmental changes that favour the dispersion of the reservoir hosts and vector but 
also importation, travel and emigration108-111.  
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1.5.2 CLINICAL SYMPTOMS  
Based on the symptoms, leishmaniasis cases can be divided in two groups: VL and CL. 
Despite this simple classification, a wide spectrum of clinical manifestations are 
observed. 
1.5.2.1  V ISCERAL LEISHMANIASIS  
Visceral leishmaniasis (also called kala azar) (Figure 1-8 - blue) is the most severe form 
of leishmaniasis with a fatal outcome if untreated. 70% of VL patients are children 
younger than 15 years old, who suffer from malnutrition and other illnesses112. L. 
donovani (Asia and Africa) and L. infantum (Europe, Asia and South America) are the 
two species causing VL.  
Clinical features vary; the infection can remain asymptomatic (patient is infected but 
shows no signs or symptoms of disease) or can follow an acute or chronic course. The 
onset of the disease usually occurs two to four months after infection however this can 
vary. Prolonged and irregular fever, splenomegaly, hepatomegaly, progressive anemia 
and weight loss are among the major clinical symptoms of an active visceral infection 
113.  
The further content will focus on cutaneous leishmaniasis.  
1.5.2.2  CUTANEOUS LEISHMANIAS IS  
The clinical features of cutaneous leishmaniasis vary in severity and depend on host, 
parasite and vector related factors. Old World (Europe, Middle-East, Central Asia and 
Africa) CL is mainly caused by L. major, L. tropica and L. aethiopica, whereas New 
World (Central and South-America) species are L. mexicana, L. amazonensis, L. 
panamensis and L. braziliensis. 
In its simplest form, CL consists of a single local lesion (marked in green in Figure 1-8). 
The first sign of a localized infection is a small, itchy erythema at the site of the insect 
bite. As the erythema develops into a papule*, amastigotes continue to proliferate and 
multiply in the dermis. The papule expands into a nodule** that reaches its final form 
and size about two weeks to six months later. When the crust falls off an ulcer typically 
with raised edges is exposed. 
*  Papules are solid elevated lesions which may be up to 5mm in diameter 
** Nodules are a form of papules, but are larger and deeper. They are usually 5mm or more in diameter. 
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FIGURE 1-8. TAXONOMY OF LEISHMANIA  PARASITES LINKED TO CLINICAL CL SYMPTOMS (ADAPTED 
FROM 114). 
Specific species might be associated with a typical clinical form but this can vary. For 
instance infection with L. tropica can evolve to leishmaniasis recidivans a chronic form 
of CL where satellite lesions (Figure 1-8 – purple) appear in the edges of the initial 
healing lesion. This form is characterized by a sparsity of parasites and can last for 
years115-117.  
L. aethiopica can cause diffuse cutaneous leishmaniasis (DCL), a form that is 
characterized by widely disseminated non-ulcerated papules, nodules, plaques or by 
diffuse infiltration of the skin (Figure 1-8- red). In the New World, this anergic form is 
typically caused by L. (L.) mexicana and L. (L.) amazonensis118.This disease does not 
heal spontaneously and relapses frequently after treatment119. 
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Mucocutaneous leishmaniasis (MCL), also called Espundia, occurs mainly after 
infection with L. (V.) braziliensis and L. (V.) panamensis117, 120 (Figure 1-8 - yellow). 
The majority of the cases present in Bolivia, Brazil and Peru. This form, characterized 
by destruction of the oral-nasal and pharyngeal cavities can appear years after the onset 
of CL. Nasal lesions are always present and although the initial symptoms such as nasal 
inflammation are mild, the disease will evolve leading to infiltration of the anterior 
cartilaginous septum and later perforation of the septum with collapse and broadening 
of the nose. The final stage is obstruction and destruction of the nose, pharynx and 
larynx.  
Post-kala-azar dermal leishmaniasis (PKDL) (Figure 1-8 - pink) is a cutaneous sequel 
of visceral leishmaniasis. This form usually develops when the initial VL infection is 
cured, although it can appear while the initial VL infection is still active. The clinical 
spectrum of PKDL varies depending on the geographical area. In Sudan about 50% of 
the VL cases result in PKDL and mostly affects children121, 122, while in India 5-10% of 
VL patients, especially young adults, develop PKDL123, 124. 
1.5.3 CURRENTLY AVAILABLE TREATMENTS  
CL is a non-fatal disease, but can cause substantial morbidity and social stigma, related 
to deformities and disfiguring scars125, 126. Furthermore a small percentage of cases 
advances to long term morbidities like MCL or DCL127. The main aim of treatment is to 
speed up healing and reduce scar formation, and to prevent relapse or parasite 
dissemination.  
The available chemotherapeutics to treat CL can be divided in two groups; (i) systemic 
treatments, where the drug is taken up in the blood and transported to the target tissue 
and (ii) local treatments, where the formulation is directly applied to the site of action 
i.e. the CL lesion. Systemic treatments comes with a higher risk of adverse effects and is 
therefore typically reserved for patients with more severe or complex form of CL118 
such as: 
  Multiple (> 4)  or large (> 5cm) lesions 
  Disfiguring or disabling lesions typically located on the joints or on the face 
  Lesions that are difficult to treat locally (eye, lips, ears)  
  CL that does not respond to local treatment 
  Leishmaniasis recidivans or diffuse CL 
Chapter 1 – Introduction 
 
 
 
22 
1.5.3.1  SYSTEMIC TREATMENTS  
 PENTAVALENT ANTIMONIALS  
The pentavalent antimonials: sodium stibogluconate (SSG) (Pentostam, 
GlaxoSmithKline and generic product) and meglumine antimoniate (MA) (Figure 1-9) 
(Glucantime™, Sanofi) have been first line treatment for CL since their discovery in the 
1940s.  
 
FIGURE 1-9.  CHEMICAL STRUCTURE OF SODIUM STIBOGLUCONATE (PENTOSTAM) (LEFT) AND 
MEGLUMINE ANTIMONIATE (GLUCANTIME™) (RIGHT). 
Mechanism of action. The mechanism of action is still not completely understood. Some 
data suggest that the trivalent form SbIII disturbs the amastigotes’ ability to maintain the 
redox homeostasis by interfering with the trypanothione/trypanothione reductase system 
that protects the parasite from oxidative damage and toxic heavy metals128, 129. Other 
reported DNA fragmentation and externalization of phosphatidylserine on the surface of 
the plasma membrane of amastigotes treated with SbIII, leading to parasite apoptosis130, 
131. This suggests that pentavalent antimonials (SbV) only act as prodrugs and thus 
require biological reduction to SbIII.  
However, other studies indicate an intrinsic anti-leishmanial activity for SbV as it forms 
a complex with adenine ribonucleoside that indirectly inhibits type I DNA 
topoisomerase causing a depletion of intracellular ATP possibly via inhibition of the 
glycolysis and fatty acid β–oxidation in the amastigotes132. This leads to inhibition of 
the biosynthesis of macromolecules in amastigotes133-135. 
Administration and treatment regimen. Pentavalent antimonials can be administered 
locally or systemically depending on the severity of the disease. Local treatment 
consists of intralesional administration alone (Figure 1-10) or in combination with 
cryotherapy118. During each session, 1-5 ml of pentavalent antimonials is injected in the 
edges of the lesion, followed by application of liquid nitrogen (-195 °C) if preferred. 
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The injections with or without liquid nitrogen application can be repeated up to 5 times 
every 3 to 7 days. Local injections prevent or limit systemic adverse effects; however, 
these injections are painful and burning, itching and inflammation at the injection site 
are amongst the reported adverse effects136.  
Antimonials are given systemically through intravenous or intramuscular administration 
(20 mg/kg per day for 10-20 consecutive days) when patients present with more 
complex CL114, 118. Serious side effects such as hepato- and cardiotoxicity are reported 
and require patient monitoring135. 
 
FIGURE 1-10. INTRALESIONAL INJECTION OF A CL LESION WITH ANTIMONIALS137. 
Efficacy. Randomised controlled trials (RCTs) to compare the efficacy of a pentavalent 
antimonial treatment against placebo are absent or sparse and efficacy-based evidence 
of pentavalent antimonials against certain species is lacking136, 138. In vitro studies 
confirmed species variation in drug sensitivity when tested in promastigotes139 and 
intracellular amastigotes140, 141. Moreover an in vivo study testing the efficacy of 
pentostam against L. braziliensis and L. mexicana showed a statistically significant 
higher cure rate for L. braziliensis142. It is hypothesised that this variability in drug 
susceptibility between different Leishmania species is responsible for subcurative 
treatment in certain cases and consequently resistance development. 
 AMPHOTERICIN B 
Amphotericin B (AmB) is the gold standard drug to treat systemic fungal infections and 
is administered intravenously. It is reserved as second line treatment for CL. 
Mechanism of action. AmB is a macrocyclic polyene antifungal drug. Its main 
mechanism of action is based on the amphiphilic nature of the molecule (Figure 1-11) as 
the hydrophobic polyene region complexes with sterols in the parasite membrane 
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forming a transmembrane channel leading to loss of small molecules. Selectivity is 
obtained because AmB has a higher affinity for the double bonds of ergosterol 
compared to mammalian cholesterol143, 144.  
 
 
 
 
FIGURE 1-11. CHEMICAL STRUCTURE AND PROPERTIES145 OF AMPHOTERICIN B. 
Administration and treatment regimen. As a treatment for CL, AmB is reserved for 
complex forms such as PKDL and mucocutaneous leishmaniasis138, 146 and is typically 
administered through slow intraveneous infusion. Amphotericin B deoxycholate is 
given at 0.7 mg/kg/day for 25-30 doses and liposomal amphotericin B at 2-3 mg/kg/day 
for a total dose of 20-40 mg/kg. The conventional amphotericin B deoxycholate 
formulation (Fungizone®) causes acute toxic reactions including renal toxicity, which 
lipid formulations were developed to reduce. The main disadvantage of these 
formulations is the high price. Research has been mainly conducted on three lipid 
formulations: 
 Liposomal amphotericin B (AmBisome®) 
 A phospholipid complex (Abelcet®) 
 A colloidal dispersion with sodium cholesteryl sulphate (Amphocil™) 
A study conducted by Yardley and Croft evaluated the in vivo and in vitro efficacy of 
four amphotericin B formulations (AmBisome®, Fungizone®, Amphocil™ and 
Abelcet®) against L. major JISH 118 in mice147. The in vitro assay results showed that 
Fungizone® was significantly more active against intracellular amastigotes than 
AmBisome® and Abelcet® and showed a similar level of activity with Amphocil™. In 
vivo results in mice demonstrated a significant reduction in lesion size for Amphocil™ 
(30%) and AmBisome® (40%) compared to the untreated control after 2 weeks of 
pKa 5.7 and 10 
Mol weight (g/mol) 924 
Log P -0.66 
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treatment with the same total dose of AmB. Complete cure, defined as no visible lesion, 
was not observed and lesions relapsed after stopping the treatment. Fungizone®, 
Abelcet® and the standard antimonial sodium stibogluconate (400mg SbV/kg) showed 
no decrease in lesion size and were found inactive147.  
Efficacy. There is a lack of RCTs that compare AmB treatment with placebo or 
pentavalent antimonial treatment even though it has successfully been used to treat 
patients with mucocutaneous leishmaniasis138, 146, 148. One RCT compared AmB to AmB 
in combination with itraconazole but did not report cure rates149. In another more recent 
study, 75% of the patients dropped out due to the obligatory ‘20 day’ admission in the 
hospital and no cure rate was reported for the patients that completed the study150. 
 MILTEFOSINE  
Miltefosine is the only oral treatment currently available against CL and VL. Initially, 
phospholipid derivatives were developed as anti-cancer drugs because they were found 
to inhibit enzymes involved in cell proliferation and growth factor signal 
transduction151. In the 1980s, a number of research groups independently showed an 
anti-leishmanial activity for miltefosine and other phospholipid compounds152-154. 
Mechanism of action. Miltefosine, also called hexadecylphosphocholine, is a 
phospholipid derivative that is structurally related to the phospholipid components of 
the cell membrane. It interferes with the synthesis of sterols and phospholipids in 
Leishmania parasites and because of its amphiphilic nature (Figure 1-12) it can directly 
interact with the parasite membrane155.  
 
 
 
 
FIGURE 1-12. CHEMICAL STRUCTURE AND PROPERTIES156 OF MILTEFOSINE. 
Administration and treatment regimen. Miltefosine is given orally at 2.5 mg/kg/day for 
28 days. Gastro-intestinal problems such as vomiting and diarrhoea are the most 
common side effects. Furthermore it is teratogenic, consequently women of 
pKa 2 
Mol weight (g/mol) 408 
Log P -2.38 
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childbearing age are required to take contraception and pregnancy is contraindicated114. 
The long residence time of the drug in the organism (half-life:150-200 hours) and the 
long treatment course lead to poor compliance and resistance development157, 158.  
Efficacy. As for the pentavalent antimonials, a difference in intrinsic sensitivity of 
Leishmania species to miltefosine was seen in the laboratory159, 160 and might explain 
the variability in clinical response seen in clinical trials conducted in different regions. 
For example an RCT conducted in Colombia, where L. panamensis is most common 
resulted in a cure rate of 91% compared to 38% for placebo treatment. In contrast in 
Guatemala, where L.mexicana and L.braziliensis were identified as CL causing species, 
the cure rate for miltefosine treatment was only 53% compared to 32% in the placebo 
group161. Another RCT was conducted in Iran and compared the efficacy of oral 
miltefosine with intramuscular administration of meglumine antimoniate against CL 
caused by L. major. It showed a similar cure rate of approximately 81% for both 
groups162. Miltefosine was also successfully used to treat PKDL in India with a cure rate 
of 91% after 1 year of treatment163.  
 PENTAMIDINE ISETHION ATE  
Pentamidine (PMID) (Figure 1-13) is used as alternative treatment for New World CL 
caused by L. guyanensis and L. panamensis118. The use of this drug is limited and 
progressively abandoned because of adverse effects such as diabetes mellitus, severe 
hypoglycemia, shock, myocarditis and renal toxicity118.  
 
 
 
 
FIGURE 1-13. CHEMICAL STRUCTURE AND PROPERTIES164 OF PENTAMIDINE ISETHIONATE. 
Mechanism of action. The mechanism of action is not fully understood but it is thought 
to interfere with Leishmania DNA synthesis, modify the morphology of the kinetoplast 
and promote the fragmentation of the mitochondrial membrane117.  
pKa 11.5 and 12.9 
Mol weight (g/mol) 592.7 
Log P 4 
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Administration and treatment regimen. 4 mg PMID salt/kg is administered 
intramuscularly or preferably by intravenous infusion every other day for 3 doses.  
Efficacy. In Peru a RCT comprising 80 people compared the treatment efficacies of 
intravenous administration of pentamidine isethionate (4 mg/kg/every two days for 7 
doses) and meglumine antimoniate (20 mg/kg/day for 20 days) against CL caused by L. 
braziliensis. The meglumine antimoniate treatment was significantly more effective 
with 78% of the patients cured and 17% relapsed compared to 35% cured and 58% 
relapsed in the pentamidine group165. A recent trial evaluated the efficacy of pentavalent 
antimony treatment with pentamidine against CL caused by L.guyanensis and obtained a 
similar cure rate for both treatments of around 55-58%150.  
 AZOLES  
Mechanism of action. The azoles were initially developed to treat fungal infections. 
Like fungi, Leishmania parasites require ergosterol for their cell membrane 
biosynthesis. Azoles inhibit the ergosterol synthesis and increase the permeability of the 
Leishmania membrane leading to death3. 
Administration and treatment regimen. Fluconazole and ketoconazole are administered 
orally at 200 mg /day for 6 weeks and 600 mg/day for 28 days respectively. Fluconazole 
was found efficacious in only one RCT conducted in Saudi Arabia and is therefore only 
recommended for the treatment of CL caused by L. major. Ketoconazole is 
recommended for the treatment of L. mexicana only118.  
Efficacy. Two RCT trials compared the effect of oral ketoconazole to pentavalent 
antimonials (i.m. MA and i.v. SSG) and placebo in L. mexicana, L. panamensis and L. 
braziliensis infection. In both studies the ketoconazole group scored significantly higher 
than placebo and pentavalent antimonial treatments142, 166. Moreover fewer adverse 
effects were reported for the ketoconazole treatment compared to the pentavalent 
antimonials. Another study compared the anti-leishmanial effect of oral ketoconazole to 
intralesional MA in Old World CL. The ketoconazole group showed a significant better 
cure167. Fluconazole also seemed effective against Old World CL. After 6 weeks of oral 
treatment, 59% of complete cure was reported compared with 21% in the placebo 
group168. 
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1.5.3.2  LOCAL TREATMENTS  
 PAROMOMYCIN SULPHATE  
Paromomycin (PM) (monomycin or aminosidine) is an aminoglycoside antibiotic that 
acts by binding on the small ribosomal unit leading to misreading of the mRNA and 
inhibition of the protein synthesis in bacteria. In the 1960’s it was identified to have 
antileishmanial activity169.  
 
 
 
 
  
FIGURE 1-14. CHEMICAL STRUCTURE  AND PROPERTIES170 OF PAROMOMYCIN SULPHATE (LEFT) AND THE 
COMMERCIALLY AVAILABLE LESHCUTAN® (TEVA, ISRAEL). 
Mechanism of action. The mechanism of action of paromomycin against Leishmania 
parasites is not fully understood. Previous research comparing protein expression levels 
between PM-resistant and -susceptible L. donovani promastigotes suggested that PM 
reduced the protein synthesis by inhibiting the dissociation of the ribosomal subunits171. 
Other studies in L. mexicana promastigotes confirmed these results and suggested that 
PM also led to induction of mistranslation errors172 and thus altered the accuracy of 
protein synthesis in Leishmania parasites. This increased level of misreading results in 
defective proteins that affect parasite survival172, 173. PM is also believed to affect other 
cell processes. For example, it was shown to change the lipid metabolism and affect 
membrane fluidity and alter uptake properties leading to growth arrest of the 
parasites174. Furthermore, dysfunction of the energetic metabolism of the cell caused by 
defects in the respiratory function was found after exposure of promastigotes to PM175. 
pKa 8.6; 7.6; 5.7; 8.1 and 8.8 
Mol weight (g/mol) 714 
Log P -2.9 
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Administration and treatment regimen. PM is a hydrophilic molecule with a high 
molecular weight (714 g/mol) (Figure 1-14) resulting in poor oral availability. Therefore 
a parenteral formulation was developed and is mainly used to treat VL and sometimes 
CL. The majority of CL patients are treated topically with Leshcutan® ointment (Teva, 
Israel), the only currently available topical formulation that contains 15% PM and 12% 
methylbenzethonium chloride (MBCL) in soft white paraffin. The efficacy of another 
topical formulation WR279,396, containing 15% PM and 0.5% gentamycin, was tested 
in phase 3 clinical trials in 2013. The vehicle of this formulation is more hydrophilic 
(oil-in-water cream); the ingredients are shown in Table 1-2.  
TABLE 1-2. INGREDIENTS OF WR279,396  AND THEIR FUNCTION. 
CHEMICAL COMPOUND FUNCTION 
Isopropyl palmitate Penetration enhancer 
Lactic acid Soothing agent 
Propylene glycol Solvent, humectant, penetration enhancer 
Sodium lauryl sulfate Anionic surfactant (emulsifier) 
Sorbitol Humectant 
Stearyl alcohol Non-ionic emulsifier (fatty alcohol) 
Urea Moisturizing and keratolytic agent 
Water Hydrophilic phase 
White petrolatum Lipophilic phase 
Methyl and propyl paraben Preservative 
Paromomycin sulphate/gentamycin Active ingredients 
 
Efficacy. The topical formulation composed of 15% PM and 12% MBCL in soft 
paraffin was first tested in vivo in mice by El-on et al in the early 1980’s176. A month 
after the treatment (two times a day for 10 days) all lesions caused by L. major in 
BALB/C and C/C3H mice were cured. All formulations containing DMSO or 
quaternary ammonium compounds such as MBCL resulted in cure of the CL lesion in 
mice but none was more efficient than MBCL. Quaternary ammonium compounds and 
DMSO are reported to damage the skin by solubilizing SC lipids and hence facilitate 
drug permeation into the skin (also see chapter 6). This might explain the efficacy of the 
treatment because based on the physicochemical properties PM is unlikely to go through 
skin. Moreover MBCL has been shown to be active against L. major amastigotes when 
tested in vitro (ED100 = 5 µg/ml). Further research tested the efficacy of the formulation 
against New World CL caused by L. mexicana and showed no visible lesions after 
treatment. The formulation only reduced the lesion size in CL caused by L. panamensis 
and L. amazonensis in BALB/mice and relapse occurred177 178.  
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Analyses of the subsequent clinical trials (Table 1-3) indicate a higher cure rate for PM  
with MBCL treatment compared to placebo in patients infected with L. mexicana, L. 
braziliensis and L. major 136, 138, 179. However it is important to note that the ointment 
was applied after manually removing the debris and scab of the wound and hence in the 
absence of the SC that is the rate limiting membrane to permeation for the majority of 
topically applied drugs. Because PM has a high molecular weight and physicochemical 
properties that are unfavourable for skin permeation, the absence of the SC might 
enhance the permeation of the drug to the bioactive site in the skin. These trial 
conditions do not reflect the cure rate in patients at onset of the disease where the 
lesions are still in the nodular stage.  
Efficacy data against other species are lacking because of several reasons: (i) trials were 
not conducted, (ii) causal Leishmania species were not identified or (iii) results were 
inconclusive due to poorly-designed trials.  
Local side effects such as burning and irritation of the skin upon application of the PM 
plus MBCL formulation, have led to the development of a formulation with 15% PM 
and 10% urea in soft white paraffin5. When tested in clinical trials, the formulation 
showed no higher cure rate over placebo treatment180, 181 or intralesional MA. The 
ointment was reported to be safer with fewer adverse effects compared to the ointment 
containing MBCL182, 183.  
Another more complex paromomycin formulation was developed by the US army. The 
formulation contains 15% PM and 0.5% gentamycin in a hydrophilic vehicle (also 
referred to as WR279,396) (Table 1-2). Gentamycin was included in the formulation 
because the combination of gentamycin (0.5%) with PM (15%) demonstrated a higher 
efficacy against experimental CL caused by L. major compared to PM (15%) alone176. 
Moreover, WR279,396 was more active against experimental CL due to L. major, L. 
mexicana, L. panamensis and L. amazonensis compared to the PM (15%) plus MBCL 
formulation184.  
As WR279,396 has a hydrophilic base, the aminoglycosides are expected to be more 
soluble in this formulation compared to the paraffin base used in the previous 
formulations (15%PM+12%MBCL and 15%PM+10% urea in soft white paraffin). This 
increases the concentration gradient (Fick’s Law - Equation 1) of the drug across the SC 
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and hence can promote the permeation of the active compounds into the SC. The 
importance of the vehicle on the permeation of PM was previously demonstrated by 
Gomes et al in an in vitro permeation assay. The PM permeation through a SC that was 
mechanically damaged by tape stripping was higher for hydrophilic vehicles compared 
to lipophilic vehicles such as ointments185.  
In clinical studies, the WR279,396 formulation was applied and occluded after cleaning 
the wound bed of the lesion. Phase 2 and 3 trials, conducted in Tunisia, have shown a 
statistically significant higher cure rate for WR279,396 compared to vehicle control in 
CL patients infected with L. major186, 187. The phase 3 trial data analysis did not indicate 
a difference in cure rate for the WR279,396 and PM alone formulation. In contrast, a 
trial in Colombia did not show beneficial effects for the WR279,396 treatment, when 
applied twice daily, compared to placebo188. A study was conducted in Panama where 
the causative species was L. panamensis; the cure rates for the WR279,396 and PM 
alone formulation were 87% and 53.3% respectively189.  
Briefly, these clinical trials (Table 1-3) indicate that WR279,396 and PM alone are 
more active than placebo treatment against CL caused by L. major but there is a lack of 
evidence to suggest that the addition of gentamycin to PM enhances treatment. 
Moreover results obtained from New World CL patients, do not indicate a higher cure 
rate for WR279,396 compared to placebo even though the efficacy of the formulation 
was occluded during testing. This technique is known to enhance the permeation of 
many drugs69. Furthermore it should be mentioned that no trials investigated the 
efficacy of WR279,396 against intralesional MA or PM plus MBCL. When taking into 
account all the evidence, the WHO decided to only include the PM plus MBCL 
formulation in their approved CL treatment list.  
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TABLE 1-3. SUMMARY OF RANDOMIZED CONTROLLED STUDIES EVALUATING TOPICAL PAROMOMYCIN FORMULATIONS IN HUMANS. 
Country 
Leishmania 
spp 
Patients per 
group 
Experimental/ placebo groups Treatment regimen per group Outcome per group Ref 
Iran L. major  
L. tropica 
1. 126 
2. 125 
1. 15%PM+10% urea 
2. Placebo 
1. 2/day for 14 days 
2. 2/day for 14 days 
1. 63.5% 
2. 63.2% 
Cure (= complete re-epithelialisation) 2.5 
months after treatment 
180 
Iran L. major 1. 20 
2. 20 
3. 20 
1. 15%PM+12%MBCL 
2. Phototherapy 
3. placebo topical 
1. 2/day for 28days 
2. 1/week for 4 weeks 
3. 2/day for 28days 
1. 41.2% 
3. 13.3% 
Cure (= neg. smear and normal skin texture) 
2 months after treatment 
190 
Iran L. major 1. 117 
2. 116 
1. 15%PM+10%urea 
2. 15%PM+10%urea 
1. 2/days for 7 days 
2. 2/day for 14 days +14 days 
placebo 
1. 50% 
2. 37% 
Cure (= 50% re-epithelialisation or more) 
2.5 months after treatment 
191 
Iran L. major 1. 48 
2. 48 
1. 15%PM+10%urea 
2. intralesional MA 
1. 2/days for 45 days (mean)  
2. 1.5g/5ml 
1. 16.6% 
2. 41.7% 
Cure (= complete re-epithelialisation) 2 
months after treatment 
182 
Iran L. major 1. 29 
2. 27 
1. 15%PM+10%urea 
2. intralesional MA 
1. 2/day for 20 days 
2. 20 days 
 
1. 66.7% 
2. 60% 
Cure (= complete re-epithelialisation) one 
week after treatment 
183 
Tunisia L. major 1. 66 
2. 66 
1. 15%PM+10%urea 
2. placebo 
1. 2/day for 14 days 
2. 2/day for 14 days 
1. 60.6% 
2. 60.6% 
Cure (= neg. smear and culture, re-
epithelialisation and 50% reduction of lesion 
size) after 2.5months after treatment 
181 
Iran No spec 1. 40 
2. 40 
1. 15%PM+10%urea 
2. placebo 
1. 2/day for 30 days 
2. 2/day for 30 days 
1. 12.5% 
2. 17.5% 
Cure (= neg. smear and reduction of lesion 
size and induration by 85%) 1 month after 
treatment 
192 
Turkey L. tropica 1. 40 
2. 32 
1. 15%PM+12%MBCL 
2. oral ketoconazole 
1. 2/day for 15 days 
2. 400mg/day for 30 days 
1. 37.5% 
2. 0%  
Cure (= complete re-epithelialisation) 1 
month after treatment 
193 
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Tunisia L. major 1. 50 
2.42 
1. WR279,396 
2. Vehicle placebo 
1. 2/day for 20 days 
2. 2/day for 20 days 
1. 94% 
2. 71% 
Cure (= 50% or more reduction of ulcerative 
size of index lesion by day56 and complete 
re-epithelialisation) 3 months after treatment 
186 
Not 
mentioned 
L. major 1+2. 32  
3+4. 11 
 
1. 15%PM+12%MBCL (2/day for 20 days)+placebo (2/ days for 10 
days) 
2. placebo (2/ days for 10 days)+ 15%PM+12%MBCL (2/day for 10 
days) + placebo (2/ days for 10 days) 
3. 15%PM+5% MBCL (2/day for 20 days)+placebo (2/ days for 10 
days) 
4. placebo (2/ days for 10 days)+15%PM+5%MBCL (2/day for 10 
days) +placebo (2/ days for 10 days) 
1. 93.1%  
2. 76.6% 
3. 66.1% 
4. not mentioned 
Cure (no parasites in lesion after treatment 
and healing lesions 1-4 weeks after 
treatment) 
4 
Guatemala L. braziliensis  
L.mexicana 
1. 35 
2. 33 
1. 15%PM+12%MBCL 
2. Placebo 
1. 2/day for  20 days 
2. 2/day for  20 days 
1. 91.4% 
2. 39.4% 
Cure (= complete re-epithelialisation and no 
induration/inflammation by week 13) after 
treatment 
7 
Honduras L. mexicana  
L. chagasi 
1. 13 
2. 22 
1. 15%PM+10%urea 
2. placebo 
1. 3/day for 4 weeks 
2. 3/day for 4 weeks 
1. 4.3% 
2. 3.3% 
Cure (= complete re-epithelialisation) 2.5 
months after treatment 
6 
Ecuador Not specified 1. 40 
2. 40 
3. 40 
1. 15%PM+12%MBCL 
2. 15%PM+10%urea 
3. i.m. MA 
1. 2/day for 30 days 
2. for 30 days 
3. 20mg/kg/day for 10 days 
1. 79.3% 
2. 70% 
3. 91.7% 
Cure (+ complete re-epithelialisation of all 
lesions 12 weeks after the start of the 
treatment with no relapse during 52 weeks) 
194 
Colombia L.braziliensis 
L. panamensis 
1. 59 
2. 30 
3. 30 
4. 31 
1. 15%PM+12%MBCL+i.v.MA 
2. 15%PM+12%MBCL+i.v.MA 
3. topical placebo+i.v.MA 
4. i.v.MA 
1. 2/day for 10 days +i.v.MA for 
7 days 
2. 2/day for 10 days +i.v.MA for 
3 days 
3. 2/day for 10 days +i.v.MA for 
7 days 
4. 20 days 
1. 58% 
2. 20% 
3. 53% 
4. 84% 
Cure (= complete re-epithelialisation 
without relapse) 1.5 months after treatment 
195 
Colombia L. panamensis 1. 33 
2. 12 
1. WR 279,396 
2. Placebo  
1. 2/day for 20 days 
2. 2/day for 20 days 
1. 61% 
2. 55% 
Cure (= complete re-epithelialisation 
188 
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without relaps) 6 months after treatment 
Panama L.panamensis 1. 15 
2. 15 
1. WR 279,396 
2. PM (15%) alone 
1. 2/day for 20 days 
2. 2/day for 20 days 
1. 87% 
2.53.3% 
Cure (= 50% or more re-epithelialisation of 
index lesion by day 63 and no relaps) 6 
months after treatment 
189 
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Besides the three formulations discussed above, other PM containing formulations were 
developed in an attempt to enhance PM delivery into the skin for example PM 
encapsulated in nanoparticles. Nanoparticles as drug carrier have shown to enhance 
drug permeation through skin196-198. However, the ability of nanoparticles to permeate 
skin as a whole is under discussion and subject of further current research199, 200.  
The level of penetration of liposomes into the epidermis and dermis varies and depends 
amongst other factors on the type and concentration of phospholipids, the concentration 
of penetration enhancer that is used and the size of the liposomes201. In vitro Franz 
diffusion cell (FDC) permeation studies conducted with tape stripped hairless mouse 
skin to mimic impaired skin barrier indicated a lower permeation for the liposomal 
formulations compared to the PM solution. In contrast, the PM concentration retained in 
the skin was 0.8-1.7% higher for the liposomal formulation202. Jaafari et al. showed that 
treatment with liposomal PM formulations containing 10 or 15% PM (LPMF) (4 weeks; 
twice daily) induced complete cure of the lesions caused by L. major in susceptible 
BALB/c mice203. The difference was statistically significant compared to the vehicle 
control consisting of empty liposomes or PBS but no liposome-free PM only group was 
included. Further in vitro FDC studies showed a high percentage i.e. over 10% of the 
PM from the LPMFs permeated across mouse skin after eight hours. To conclude 
liposomes seem an interesting carrier in order to increase the permeation of PM through 
skin. 
Another approach used to increase the permeation of PM is the use of ion pairing. 
Molecules with an opposite charge are linked to PM forming a PM salt that is less 
hydrophilic and more likely to permeate through skin. Noguiera et al compared the 
permeation of PM free base with PM salts using Franz diffusion cells with full-
thickness stripped and intact pig skin204. Neither PM free base nor the salt permeated 
through healthy skin, which is not surprising given its physicochemical characteristics. 
In skin with reduced barrier properties, the permeation of some PM salts increased 
significantly compared to the PM free base204. It would be interesting to test these 
formulations in vivo in experimental CL models. 
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 LOCAL PHYSICAL TREATMENTS –  CRYO-AND THERMOTHERAPY  
Cryotherapy and thermotherapy are the most frequently used physical therapies. During 
cryotherapy a cotton swab with liquid nitrogen is applied on the wound and wound 
edges for about 10-25 seconds. This treatment is commonly used to treat wart infections 
but clinical trials have shown it also enhances CL cure. Two studies in Iran were 
conducted to compare the effect of three different treatments for CL: cryotherapy alone, 
a combination of cryotherapy with intralesional MA and intralesional MA alone8, 205. 
The first and second studies reported complete cure of patients in 52%, 80% and 52% 
and 67%, 89% and 75% respectively in the 3 respective groups. The researchers 
concluded that the combination therapy was significantly better than the two 
monotherapies. Based on these trials, cryotherapy alone seems to be as effective as 
intralesional MA alone.  
Thermotherapy involves the induction of heat in the superficial layers of the skin. This 
can be done in several ways for instance by using a radiofrequency generator, 
ultrasound or infrared radiation. In Iran a randomized controlled study compared 
thermotherapy and intralesional MA for 4 weeks206. In order to localize the warmth a 
probe was placed on the skin; the resistance of skin to current creates warmth. Warmth 
of 50°C was applied to the lesions for 30 seconds. This was done once a week for four 
weeks. Six months after the treatment, 80% of the participants in the thermotherapy 
group showed complete cure compared with 56% in the intralesional MA group. These 
results were in agreement with previous studies conducted in Iran.  
A trial conducted in Afghanistan compared intralesional SSG for 29 days (2-5 ml every 
5-7 days), daily i.m. sodium SSG (20 mg/kg/day) for 21 days and thermotherapy based 
on radiofrequency (1 session with ≥1 applications of 1 minute of 50°C) for the 
treatment of CL caused by L. tropica207. Two months after the treatment the complete 
cure of patients in the three groups was 47%, 18% and 54% respectively. Treatment 
with thermotherapy was significantly better than i.m. SSG therapy however no 
significant difference with intralesional SSG was observed. Some patients that had 
received thermotherapy experienced superficial second degree burn wounds. 
Thermotherapy was also used to treat New World CL. One trial208 compared 
thermotherapy (30 seconds of 50°C, 1 session per week for 3 weeks) with i.m. MA (850 
mg MA/day for 15 days) with placebo thermotherapy (no heat generation) as potential 
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treatment for CL. 73%, 59% and 27% of the participants in the respective groups were 
completely cured two months after the treatment. Again thermotherapy gave 
significantly better results against CL than the other therapies. Overall the randomised 
controlled trials (RCTs) showed good results and thermotherapy seems a good treatment 
option as it is active against all species. However the main limiting factor is the 
requirement of expensive equipment and electricity which might be unavailable in rural 
settings. Additionally, thermotherapy requires experienced personnel to apply the 
treatment to the patient. 
 IMMUNOTHERAPY  
Research has suggested that immunotherapy can provide a useful adjuvant to 
chemotherapy in the treatment of CL. In contrast to chemotherapy that aims to kill the 
parasite, immunotherapy stimulates the host’s own immune response in order to clear 
the parasite from its system.  
Imiquimod is an imidazoquinoline and acts as a potent immunomodulator. It is the 
active ingredient in a topical cream Aldara™ (Meda Pharma, UK) that is used to treat 
cervical warts caused by human papilloma virus. In vitro studies have shown that 
imiquimod induces a leishmanicidal activity in macrophages209. In vivo mouse studies 
compared the Aldara™ cream with a placebo cream without imiquimod and found that 
the group treated with Aldara™ cream showed a significant reduction in footpad 
swelling when compared to the placebo group. Furthermore the cream halted the 
development of visible lesions on the footpad in contrast to the placebo treatment 
group209. 
 
FIGURE 1-15. CHEMICAL STRUCTURE OF IMIQUIMOD 
After successful results in mice, imiquimod cream proceeded to clinical trials. Two 
trials, conducted in Peru compared the activity of standard intraveneous pentavalent 
animonials (SSG or MA) combined with topical imiquimod to treatment with 
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antimonials only in patients who had not responded to previous treatment with 
antimonials only. Both trials indicated that treatment with imiquimod is safe and 
significantly increased the cure rate compared with antimonials alone in patients. 
Furthermore imiquimod reduced the residual scarring210, 211.  
Another promising immune adjuvant is the cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF). It is a monomeric glycoprotein of 127 amino acids212 and 
an approximate 14 kDa212 that is secreted by a variety of cell types such as T cells, 
fibroblasts and macrophages. It is used to prevent neutropenia in cancer patients on 
chemotherapy and patients that underwent bone marrow transplantation and is 
administered through subcutaneous injection or intravenous infusion.  
GM-CSF seems an interesting immune adjuvant as it can promote proliferation, 
activation and differentiation of macrophages and dendritic cells213. Moreover human 
studies report increased wound healing and scar formation in diverse wound types upon 
topical application214-218.  
Regarding leishmaniasis, pretreatment of macrophages with GM-CSF enhanced killing 
of intracellular L. tropica219, L. major220 and L. amazonensis221 in vitro. In mice, GM-
CSF indicated anti-leishmanial activity by mobilisation of neutrophils and 
monocytes222. RCTs conducted in Brazil have indicated that GM-CSF both after oral223 
or topical224 administration reduced the healing time of CL lesions when given in 
combination with intraveneous animonials.  
1.5.4 EXPERIMENTAL TOPICAL TREATMENTS  
In this section, new drugs that have been tested topically against CL but are currently 
not recommended by the World Health Organisation due to a lack of efficacy or poorly 
designed experiments with inconclusive results are discussed. 
1.5.4.1  ANTIMONIAL DRUGS  
El-On was the first to evaluate the efficacy of a range of drugs with in vitro 
leishmanicidal activity against experimental CL upon topical application176. Amongst 
others, antimonial formulations containing either 1.7% SSG (SbV) or 15% stibophen 
(SbIII) with 12% of MBCL, a penetration enhancer in soft paraffin were evaluated176. A 
month after the last dosing, a mean lesion size of 45.6 and 91.1 mm2 was reported for 
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SSG and stibophen respectively compared to a mean lesion size of 40 mm2 for the 
untreated control. This suggests that i) the SSG formulation had no activity against CL 
and ii) the stibophen formulation caused CL to progress. This however does not 
consider the irritant effect of MBCl that is likely to cause an increase in lesion size. 
Moreover the stibophen formulation showed toxic effects causing 1 mouse to die during 
the treatment and an additional 3 to die within 1 month after treatment. Based on the 
lesion size, death by CL infection should not be excluded.  
1.5.4.2  AMPHOTERICIN B 
A 15% AmB deoxycholate (Fungizone®) and 12% methylbenzethonium choloride 
formulation in a soft paraffin base was also tested in mice. The formulation was applied 
twice a day for 12 days. Thirty days after treatment none of the lesions were cured176.  
Another study tested the topical application of Fungizone®, Amphocil™ and an AmB 
phospholipid complex in a range of solvents against experimental CL225. The 
application started 24 hours after s.c injection of L. major parasites and consisted of 10 
µl of a 2 mg AmB (as Fungizone®, Amphocil™ or AmB phospholipid complex)/ml 
formulation per day for 3 weeks. The application of AmB did not prevent lesion 
development but a statistically significant reduction in lesion size was measured for 
Amphocil™ and AmB phospholipid complex, but not Fungizone®, when dispersed in 
10% ethanol (EtOH) respectively at the end of the treatment compared to the untreated 
control. There is no mention of a follow up period.  
The use of volatile solvents that evaporate quickly after application potentially increase 
the thermodynamic activity of the drug, also the driving force for permeation. Ethanol 
evaporation increased the permeation of fentanyl through this mechanism226 and might 
explain the enhanced activity of ethanolic formulations compared to the other solvents 
used for example glycerol and propylene glycol (PG). Topical application of ethanol is 
also reported to remove lipids from the skin in humans what potentially can lead to 
reduced barrier function227-229.  
The effect of a colloidal dispersion of Amphocil™ (5 mg/ml) in 5% ethanol (without 
glucose) on ulcerated CL lesions in humans was tested. This single blind study was 
designed so that the placebo and drug-treated ulcers were on the same patient. Nineteen 
patients were asked to apply the dispersion three times a day. The size of the lesions 
was used as a measurement of disease progress. All the AmB treated lesions healed 
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faster than the placebo treated lesions except for one extremely deep lesion230. Some 
case studies also reported successful treatments with topical AmB formulations231.  
Based on its physicochemical profile, AmB is assumed not to permeate into the skin. It 
(i) has a molecular weight of 924 g/mol; (ii) is amphiphilic at physiological pH; (iii) 
shows limited water solubility (1µg/ml at ambient temperature); (iv) has a large number 
of groups capable of hydrogen bonding and (v) has a distribution coefficient of -1.41 at 
pH 7.4232. A possible explanation for the enhanced cure rate seen in some of the studies 
might be the absence of the SC in ulcers. Because the main barrier to skin permeation is 
absent, the applied drug can freely diffuse into the dermis and kill the parasite.  
The inability of AmB to permeate through skin was shown in both in vitro233, 234 (also 
see chapter 3) and in vivo225, 235, 236 studies. An in vitro study reported limited 
permeation through rat skin after application of AmB nanoparticles233. It should be 
mentioned that the rat skin tissue was wiped with isopropyl alcohol and the receptor 
phase contained 2% DMSO. Both solvents can solubilize skin lipids resulting in a 
damaged barrier function of the skin and possibly enhance permeation. Rat skin is also 
known to be more permeable than human skin237, 238. Another study tested the efficacy 
of a gel containing AmB-cyclodextrin against CL caused by L. amazonensis in 
hamsters. After 21 days of treatment with the gel (0.125% AmB – twice a day) the 
growth of the lesion had halted but increased again after treatment was stopped235.  
In conclusion, AmB is a poor drug candidate for topical administration. As explained 
above, its physicochemical profile is not conducive to skin permeation and in vitro 
studies indicate little or no permeation through healthy skin and only limited permeation 
through damaged skin. Sometimes low rate of permeation is reported after application 
on damaged skin239 or by the use of aggressive solvents as indicated by a study234, 
where a number of AmB formulations were tested. AmB permeation through rat skin 
was only reported for an AmB in DMSO/methanol solution.  
Evidence seems to suggest that AmB is not active against CL when applied topically 
and even if AmB manages to cross the SC, the hydrophilic viable epidermis and dermis 
can pose a major barrier before it reaches the parasites. In contrast local administration 
with circumvention of the skin barrier might be a useful approach to treat CL. In fact, 
Corware et al have shown the activity of an AmB formulation against an early stage and 
established CL lesion in BALB/c mice upon intradermal administration240. In both 
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models, the formulation was injected 3 times over a 1 or 3 week period in the footpad 
where the parasites resided, and led to resolution of the CL lesion and a parasite 
reduction greater than 3 log10
240.  
1.5.4.3  M ILTEFOSINE  
Miltefosine first came to the market as a topical solution (Miltex®- composition Table 
1-4) to treat breast cancer metastases. This solution was tested on mice from three 
different strains (C57BL/6, CBA/J and BALB/c) to evaluate its activity against L. major 
and L. mexicana parasites241. Treatment for L. major and L. mexicana were started 
respectively 3 weeks and 5 months after infections. One drop of Miltex®, containing 
approximately 1.5 mg miltefosine, was applied 5 days per week for 5 weeks in C57BL/6 
and CBA/J mice and for 2 weeks in the BALB/c mice.  
After the treatment protocol was finished, no mice showed visible palpable lesions and 
for BALB/c and C57BL/6 mice the parasite levels in the spleen and the draining lymph 
nodes were below the assay detection limit, which was not the case for all CBA/J 
mice241. Unfortunately, these results were not reproducible (Yardley and Croft, 
unpublished data). 
TABLE 1-4. COMPOSITION OF MILTEX®. 
Chemical compound Per 100 ml Miltex® 
miltefosine 6 g 
NaOH 0.227 g 
citric acid 0.484 g 
3-propyloxypropylene glycol 31.6 g 
3-hexyloxypropylene glycol 15.8 g 
3-nonyloxypropylene glycol 15.8 g 
purified water 30.9 g 
 
1.5.4.4  BUPARVAQUONE  
Buparvaquone (BPQ) (Figure 1-16) a hydroxynaphthoquinone is the gold standard 
treatment against a protozoan disease in cattle called theileriosis. It is a structural 
analogue of ubiquinone which is also known as coenzyme Q. The latter functions as a 
carrier of electrons within the mitochondrial membrane in ATP synthesis. Due to its 
structural resemblance to ubiquinone, BPQ is believed to reduce the intracellular ATP 
and inhibit the respiratory chain in Leishmania parasites242. 
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FIGURE 1-16. CHEMICAL STRUCTURE OF BUPARVAQUONE  
BPQ demonstrated an activity in the nanomolar and low micromolar range when tested 
in vitro against Leishmania species that cause CL or VL243. Despite its potent in vitro 
activity, BPQ demonstrated poor in vivo efficacy against VL upon oral or subcutaneous 
administration244. This is most likely due to the poor bioavailability and distribution that 
is related to the low water solubility (<1 mg/L).  
Further in vitro studies showed no human skin permeation for BPQ after topical 
application243. The use of lipophilic vehicles resulted in BPQ permeation but the rate 
remained low245. In an effort to increase skin permeation, more water soluble anti-
leishmanial prodrugs were synthesised. Four optimised topical formulations of BPQ and 
its prodrug 3-phosphonooxymethyl-BPQ (3-POM-BPQ) were then tested in vivo against 
CL in BALB/c mice induced by L. major. The application commenced when the 
average diameter of the CL lesions measured approximately 2mm. At the end of the 
treatment, none of the groups showed a statistically significant reduction of the lesion 
size or parasite load when compared to the untreated control246. 
1.5.5 TREATMENT CHALLENGES  
As generally known, all current CL treatments are unsatisfactory. Rather than to 
criticize them the aim of this section is to highlight the complexity of the challenges that 
are faced when developing a safe effective and reliable CL treatment, knowing that 
some are easier to tackle than others.  
Drug repurposing. In the 1990’s concern was raised about the lack of new chemical 
entities registered for neglected diseases. The development of an NCE is a long process 
that takes 9-12 years on average and costs an estimated 802 million US dollars247, 248. 
The pharmaceutical industry is not keen to invest this amount of money in a neglected 
disease that only offers low return. A study published in the Lancet revealed that only 
four new chemical entities and 25 products with new indication or formulation for 
neglected diseases were registered during 2000-2011249.  
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Drug repurposing is one of the strategies to overcome the high development costs for a 
new drug or chemical entity (NCE). It includes drug repositioning, where a known drug 
is applied to treat a different disease, also referred to as therapeutic switching, and drug 
reformulation, a process that focusses on the reformulation of the active ingredient in 
order to administer through a different route. From 2000 to 2011, all three drugs 
approved to treat leishmaniasis (of which one for CL) were repurposed molecules that 
were initially used for a different indication. For example, miltefosine was first brought 
on the market as an anti-cancer drug, amphotericin B was previously used to treat 
fungal infections and paromomycin that was available as an oral treatment for intestinal 
amoeba infections was reformulated to a parenteral solution and topical formulation to 
treat VL and CL respectively.  
Actually most of the research conducted on topical formulation development for CL, 
focusses on reformulating an already existing anti-leishmanial drug. For example DNDi 
is trying to develop a topical amphotericin B formulation, while Novartis puts effort in 
reformulating antimonials in a topical preparation.  
Even though reformulation of drugs is a useful technique that has led to new treatments, 
it should be born in mind that the activity of a drug is influenced by the route of 
administration and different routes impose different physicochemical requirements on a 
drug. From the previous section it is clear that oral or parenteral drugs are not always 
the best topical drug candidates and a screening of molecules can prevent time, effort 
and cost into projects that are likely to lead to partial or unsuccessful results. For 
example paromomycin, the active drug in Leshcutan®, requires manual removal of the 
scab prior to application and co-formulation with an aggressive penetration enhancers to 
increase drug delivery to the bioactive sites in the skin. In vitro permeation studies have 
shown that PM does not penetrate healthy skin and clinical trials using formulations 
other than PM plus MBCL show limited results. In addition, the combination with 
MBCL is irritating as it damages the skin but at the same time this agent seems to be 
necessary for the formulation to be active.  
The permeation of amphotericin B from a range of topical formulations was tested but 
did not show high permeation. Again this is not surprising when comparing the 
physicochemical properties of amphotericin B with these of compounds that easily 
permeate the skin such as caffeine and ibuprofen. To conclude, there is no doubt that 
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new drugs to treat CL are required. However, a careful screening of the available 
information and drug properties can indicate the feasibility of reformulation for 
different routes of administration.  
One treatment for CL. Depending on host and parasite factors, CL shows a variety of 
clinical manifestations. One of the main problems of treatment development is finding a 
treatment that is active against all Leishmania parasites. Biochemical and molecular 
differences between Leishmania species lead to differences in drug susceptibility in 
vitro. This correlates with variability in clinical response that is observed when 
comparing the success rates of treatments given in different geographical regions. Often 
Old World CL is more responsive to treatment compared to New World CL. However 
even within Old World CL causing species the sensitivity to drugs varies. Is it possible 
to find one treatment to treat all CL patients? And if not, will the pharmaceutical 
industry be interested in manufacturing a treatment that is only active against one 
species and thus present a smaller market?  
Logistics. There are several logistic factors that complicate the development of a 
treatment for CL. Firstly, CL occurs in tropical climates with sometimes a high 
humidity. Both a high temperature and humidity are known to cause instability of drug 
formulations, especially for emulsions and creams that are, by nature, physically 
unstable systems. Secondly, primary health centres that offer treatment for CL patients 
can be difficult to reach for people living in rural areas and even when reached, 
medication availability is not guaranteed.  
Cost.  
Table 1-5 shows the price per CL treatment estimated by the WHO. This is only the 
direct cost of the treatment and indirect costs such as inability to work are not included. 
Moreover Alvar et al reported that the annual income per person in areas that are greatly 
affected by CL range from 82 to 200 US$. This means that the price of a treatment can 
exceed the monthly salary for some patients. 
TABLE 1-5. PRICE PER CUTANEOUS LEISHMANIASIS TREATMENT(JANUARY 2010)-ADAPTED FROM 118. 
Compound Treatment regimen Drug cost in US $* 
SSG systemic, 20 mg/kg/day 20 days 37 
SSG intralesional** Until lesion is healed 12 
MA systemic, 20 mg/kg/day 20 days 40 
MA intralesional** Until lesion is healed 13 
Pentamidine Up to 4 months Free (donation program) 
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* For a patient weighing 35kg (leishmaniasis patients often suffer from impaired nutritional status). 
Calculations for sodium stibogluconate based on exchange rate of 1 GBP= US$ 1.41 (Price based on 
generic SSG). ** Intralesional treatment is commonly estimated at a third of the cost of systemic treatment. 
Treatment seeking behaviour. Patients often seek treatment late after the appearance of 
the first symptoms because effective and safe treatments are lacking and many patients 
postpone seeking help by trying herbal or home-made remedies. Only after multiple 
treatment failures and thus progression of the lesion, they will visit primary health care 
centres. Research into the treatment seeking behaviour of CL patients reports variable 
delays between the onset of the symptoms and seeking treatment. A study in Syria 
reported 2.4 months on average250, while in Paraguay this was 1-6 months251. By this 
time, the lesion might have progressed to an ulcer which makes it more difficult to treat 
and increases the risk of scar formation.  
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1.6 TOPICAL TREATMENTS - RATIONALE  
Risk-benefit analysis leads us to conclude that systemic treatment should only be given 
for the more severe cases with (i) numerous, (ii) large or (iii) disfiguring lesions, (iv) 
patients at risk of diffuse CL or leishmaniasis recidivans, (v) lesions on places that makes 
it difficult to treat locally or (vi) when local treatment has failed. This means that about 
25-50% of all CL cases worldwide, representing around 150 000 to 550 000 patients 
require systemic treatment252 and about 50-75% of all CL patients can be treated with 
local treatments. 
We aim to treat in the early stages of the disease, when the papule is still covered with 
intact skin mainly because treatment at the onset of the disease might (i) increase the 
chance of successful treatment; (ii) avoid scar formation by preventing the lesion to 
progress into an open ulcer; and (iii) reduce spread of the parasites and thus the 
possibility of satellite lesion development.  
Figure 1-17 shows a section of Leishmania infected skin and indicates that the parasites 
reside in the dermis (Figure 1-17).  
 
FIGURE 1-17. (A) SHOWS THE ROUTE OF THE ACTIVE INGREDIENT THROUGH LEISHMANIA  INFECTED 
BALB/C MOUSE SKIN BEFORE REACHING THE; (B) AMASTIGOTES SITUATED IN THE DERMIS. 
The location of Leishmania parasites is lower compared to other pathogens that cause 
skin infections and are treated topically. For example fungi that cause skin infections 
typically reside in the stratum corneum where they can degrade keratin. Only superficial 
bacterial infections that are limited to the epidermis are treated topically. Infections that 
extend into deeper skin layers are treated systemically. Herpes simplex is a viral skin 
infection that originates in the basal layers of the epidermis253. Topical treatments are 
active  
compound 
formulation 
permeation dermis 
epidermis 
A 
Leishmania 
amastigotes 
B 
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available indicating that the drug is able to reach the lower layers of the epidermis. For a 
topical formulation to be active against CL, the drug will have to permeate through the 
stratum corneum, into the dermis and through the macrophage membrane to reach the 
parasites that are situated in the phagolysome.  
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2 AIMS AND OBJECTIVES  
The overall aim of this project is to develop a topical treatment for CL. As discussed in 
the introduction, skin diseases often affect the barrier function of the skin. When 
targeting the skin, it is thus essential to characterize the impact and extent of the barrier 
impairment on drug delivery.  
In the first experimental chapter, Leishmania infected skin was compared with uninfected 
skin in three ways: 
 Histology sections of BALB/c mouse skin infected with Leishmania parasites 
were examined for microscopical changes in skin structure.  
 The inside-outside barrier integrity was evaluated by repeatedly measuring TEWL 
as the CL lesion progressed.  
 The outside-inside skin barrier impairment was established by measuring the 
permeation of different model drugs and anti-leishmanial compounds through 
infected and uninfected skin.  
In the second experimental chapter, the influence of different solvents on the permeation 
of miltefosine was determined. The reformulation of miltefosine, already on the market 
as oral drug, is an attractive development strategy that could save a considerable amount 
of time and money. It is particularly useful if it concerns neglected diseases that is a 
domain with poor interest to the pharmaceutical industry.  
In the third experimental chapter, a drug discovery approach was used to evaluate 
compounds from 4 different structural classes of benzoxaboroles, for their anti-
leishmanial activity and suitability for topical treatment of CL. An array of in vitro 
ADME studies were performed and allowed the selection of 3 favourable compounds.  
The fourth experimental chapter, describes how the oral and topical activities of these 
compounds was evaluated in vivo in BALB/c mice infected with L. major  
 
Chapter 3 – The barrier integrity of Leishmania infected mouse skin 
 
 
 
 
49 
3 THE BARRIER INTEGRITY OF LEISHMANIA INFECTED 
MOUSE SKIN - CHARACTERISATION 
The skin maintains homeostasis between the inner and outer environment. To do so, it 
functions as a barrier that prevents water loss and permeation of chemical and infectious 
agents. It is the largest organ of the body and covers a big surface making it vulnerable 
to disruption.  
By altering the skin physiology, pathological disorders can disrupt the barrier integrity 
resulting in increased or decreased drug delivery from topical formulations to their 
target site in the skin254-256. For example psoriasis is a common non-infectious skin 
disorder caused by an uncontrolled division and acceleration of keratinocytes and is 
characterised by erythematous plaques with overlying silvery scales. Research has 
shown loss of skin barrier integrity and increase of drug permeation in psoriatic plaques 
compared to healthy skin95, 257.  
Expanding further, infectious skin disorders were also found to disrupt the physiology 
and barrier function of the skin. For example, tinea, a fungal skin infection, is caused by 
dermatophytes that are found on top and in the superficial layers of the epidermis. 
Evaluation of the barrier integrity in tinea-affected skin reported a reduced SC 
hydration, enhanced proliferation and disturbed differentiation of the epidermis255.  
This chapter describes the skin physiology changes that occur after infection with 
Leishmania parasites and how they influence the skin barrier integrity and thus the 
delivery of drugs to the skin. This is especially important because the overall aim of this 
PhD project is the development of topical formulations to treat CL. The information 
provided by the experiments described in this chapter can be used to produce more 
target specific active compounds and better adapted formulations to increase the chance 
of successful treatment. 
First, a histological evaluation of the structural differences between uninfected and 
Leishmania infected skin was performed. The common haematoxylin and eosin (H&E) 
stain was used to evaluate the different skin tissue layers, whereas an elastic-Van 
Gieson stain was performed to visualise elastic fibres and collagen, which are 2 dermal 
components that are important for the support and elasticity of the skin. Finally, a more 
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specific immunostaining technique was used to see the invasion of macrophage-like 
cells to the place of infection. 
The transepidermal water loss (TEWL) was measured as a function of barrier integrity 
(section 1.4.1). This technique is a non-invasive method that quantifies the outward 
diffusion of water through the stratum corneum (SC). Damaged skin is less able to 
control water movement from the interior to the exterior which translates in a higher 
TEWL value when compared to healthy skin that is able to restrict water flow. In 
parallel, skin hydration was measured258.  
The skin pH was measured as it contributes to the maintenance of SC integrity, 
cohesion and desquamation and seems to be related to the permeability homeostasis of 
the skin259-261. In fact, skin infections caused by fungi such as Candida262 and 
Dermatophytes263 have been linked to pH increase. Two key serine proteases in the 
desquamation process, kallikrein 5 and 7 show optimal activity at neutral pH264-266, 
whereas β-glucocerebrosidae and acidic sphingomyelinase are active at pH 5.6 and 4.5 
respectively267. The latter are important enzymes in the synthesis of ceramide, an 
essential skin lipid that contributes to the SC barrier. When the pH increases, the serine 
proteases are activated and the activity of the ceramide generating enzymes is reduced 
by ten-fold261 causing increased skin desquamation and SC thinning leading to barrier 
perturbation268.  
Finally, the permeation of two model compounds with different lipophilicities, caffeine 
(log P = -0.08) and ibuprofen (log D = 3.97) through infected and uninfected skin were 
compared and subsequently the permeability of three anti-leishmanial drugs 
amphotericin B, paromomycin sulphate and buparvaquone were evaluated. In contrast 
to the models commonly used to test drug permeation through diseased skin (section 
1.4.3), this model has the advantage of being CL specific.  
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3.1 MATERIAL AND METHODS  
3.1.1 TEST COMPOUNDS AND OTHER REAGENTS  
Details and suppliers of the chemicals and solvents used for the experiments of this 
chapter are listed in the table below (Table 3-1).  
TABLE 3-1. DETAILS OF CHEMICALS AND SOLVENTS USED FOR EXPERIMENTS OF THE INFECTED VS. 
UNINFECTED MODEL  
Compound Specifications Supplier 
Test compounds 
Caffeine 
Ibuprofen 
Amphotericin B 
Buparvaquone 
Paromomycin sulfate 
 
ReagentPlus®; ≥ 99% purity 
≥ 98% purity 
Molekula, ≥ 99% purity 
Vetranal™, analytical standard 
≥ 98% purity 
 
Sigma Aldrich 
Sigma Aldrich 
VWR international 
Sigma Aldrich 
Sigma Aldrich 
Chemicals 
Phosphate buffered saline 
 
 
β-cyclodextrin 
Formalin solution 
 
Tablets, dissolved in 200 ml H2O - 0.01 M 
phosphate buffer, 0.0027 M KCl, 0.137 M 
NaCl, pH 7.4 at 25ºC 
Hydroxypropyl- β-cyclodextrin 
10% formalin (approx. 4% formaldehide) 
 
Sigma Aldrich 
 
 
Sigma Aldrich 
Sigma Aldrich 
HPLC solvents/chemicals 
Trifluoroacetic acid 
Disodium EDTA 
Acetic acid 
Water 
Acetonitrile 
Methanol 
 
Chromasolv®, HPLC grade 
Disodium dihydrate EDTA, HPLC grade 
HPLC grade 
HPLC grade 
HPLC grade 
HPLC grade 
 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Fisher Scientific 
Fisher Scientific 
Fisher Scientific 
Radiolabeled compound/ 
scintillation fluid  
Optiphase™ supermix cocktail 
[3H]-paromomycin sulfate 
 
 
 
 
N/A 
Specific activity: 0.2 Ci/mmol; 
radiochemical purity: 99.8%; radioactive 
concentration: 500 µCi/ml; solvent: water 
 
 
Perkin Elmer 
Moravek Biochemicals 
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3.1.2 PARASITE STRAIN AND ANIMALS  
Leishmania major (MHOM/SA/85/JISH118) amastigotes were obtained and isolated 
from mouse skin lesions. They were allowed to transform to promastigotes and were 
maintained in Schneiders insect medium (Sigma Aldrich, UK) supplemented with 10% 
HiFCS (Harlan, UK) at 26°C. The parasites were routinely passaged through BALB/c 
mice and low passage number promastigotes (typically below passage number 3) were 
used for this experiment as infectivity was shown to decrease with time of parasite 
cultivation. 
Female BALB/c mice of about 6-8 weeks old, were purchased from Charles River 
(Margate, UK) and housed in a controlled environment of 55% relative humidity and 
26°C. They were provided with tap water and a standard laboratory diet. All in vivo 
experiments were carried out under license (PPL 70/6997) at the London School of 
Hygiene and Tropical Medicine (LSHTM) after discussion with the veterinarian and 
according to UK Home Office regulations. 
3.1.3 IN VIVO CL  MODEL  
Five female BALB/c mice (6-8 weeks old; Charles River Ltd., UK) were shaved and 
one day later, injected with 2x107 stationary phase L. major JISH118 promastigotes 
(200 µl) subcutaneously on the rump above the tail. This inoculum size was selected as 
previous injection in BALB/c mice had resulted in producible infections in terms of 
onset of the disease, progression and lesion size evolution. Three control mice were 
injected with medium that did not contain parasites. The mice were inspected daily for 
the presence of a papule. After about 7 days, a small papule at the site of injection was 
visible in the infected mice.  
The lesion size was measured every day using digital callipers. Every other day, various 
skin parameters such as TEWL, SC hydration and skin pH were measured while the 
mouse was anaesthetised as explained in detail below (section 3.1.5). When an average 
lesion diameter of 5 mm was reached, the mice were sacrificed and the papule was 
excised for further histological evaluation or for use in FDC permeation studies. For 
these permeation studies, uninfected control tissue from above the CL nodule on the 
back of the same donor mouse was excised (Figure 3-1). Control skin parameter 
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measurements and histology samples were obtained from mice which received 200 µl of 
medium without parasites.  
 
FIGURE 3-1. SCHEMATIC PRESENTATION OF THE ORIGIN OF SKIN USED IN THE FRANZ DIFFUSION CELL 
PERMEATION ASSAYS.  
3.1.4 HISTOLOGY  
Skin samples of the infected (papule; ±5 mm diameter) and uninfected skin (mice 
injected with medium without parasites) were collected and fixed in 10% neutral 
formalin solutions until they were further processed at the UCL Institute of Neurology 
(Queen Square, London).  
Briefly, the samples were dehydrated using ascending concentrations of ethanol and 
clear xylene prior to paraffin embedding. The samples were then cut and sections were 
mounted on slides and stained to allow histological examination by light microscopy. 
Images were taken using a Leica DMRB microscope (Leica, Germany) (eye piece 
magnification x1, x1.6, x2.5, x5 and lens magnification x10, x40, x100) equipped with a 
Leica DFC 420 camera controlled by Leica Application Suite (version 3.1). 
3.1.5 TEWL  -  AQUAFLUX AF102 
Transepidermal water loss (TEWL) was measured every other day using the AquaFlux 
AF102 (Biox, London). The equipment was calibrated (flux density calibration) 
according to the manufacturer’s guidelines prior to starting the experiment and was 
baseline calibrated prior to use each day.  
Mice were left to acclimatise in the room (temperature: 21-22˚C / relative humidity: 50-
54% relative humidity) for 1 hour before they were placed in the induction chamber. 
Anaesthesia were induced at 3% isoflurane with 100% oxygen at a flow rate of 2.5 
l/min until no movement was observed. The mice were then removed from the chamber 
uninfected   
(control) 
C 
control 
infected 
(papule) 
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and placed on tissue with their snout covered by a mask to maintain anaesthesia 
exposure with 2% isoflurane and 100% oxygen at 2.5 l/min. The probe was placed over 
the papule and the measurement was recorded when the TEWL stabilised (approx. 30-
60 seconds later). For recovery from the anaesthesia, the mask was removed and the 
mice were gently placed on a warm plate (37˚C) and observed until first movements 
before being placed back in their cage. Statistical analysis were performed using SPSS 
software version 19.0. 
3.1.6 SKIN HYDRATION AND PH 
Skin hydration was recorded after the TEWL measurement but prior to determining the 
skin pH while the mouse was still anaesthetised. The probe (MY-808S, moisture 
checker, Scalar, Japan) was cleaned carefully and applied to the skin surface, where the 
parasites had been injected. The value was registered. 
Afterwards the Skin-pH-Meter® PH 905 from CK electronics (Köln, Germany) that was 
calibrated (using pH 4.0 and pH 7.0 buffer solutions) prior to starting the experiment, 
was rinsed with distilled water. The moist probe was applied to the mouse skin and six 
consecutive measurements were taken and averaged.  
3.1.7 INVESTIGATION INTO PERMEABILITY OF INFECTED VS 
UNINFECTED SKIN  
3.1.7.1  PREPARATION OF DONOR AND RECEPTOR SOLUTIO NS  
Saturated donor solutions for caffeine, ibuprofen, paromomycin sulphate and 
buparvaquone were prepared by adding an excess amount of drug to PBS. A magnetic 
stirrer bar was added to the vial and the mixture was left to stir at 32˚C for 48 hours 
prior to the experiment. For paromomycin sulphate, the drug suspension was 
centrifuged at 13000 rpm for 30 minutes and the supernatant was removed and spiked 
so that it would contain 10 µCi of [3H]-paromomycin sulfate per Franz diffusion cell. 
Due to stability issues, the amphotericin B donor solution was prepared by adding an 
excess amount of drug to PBS followed by 1 hour of sonication. 
The receptor fluid consisted of a PBS solution that was sonicated for 30 minutes to 
remove air bubbles prior to adding it to the Franz cell device. For the permeation of the 
more lipophilic compounds, buparvaquone and amphotericin B, PBS was supplemented 
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with 2% hydroxypropyl-β-cyclodextrin245 (CD) in order to ensure sink conditions 
during the experiment. 
3.1.7.2  PERMEATION EQUIPMENT AND DIFFUSION CELLS  
For this experiment, Franz cell devices (Figure 3-2) with narrow diameter were 
developed (Soham Scientific, Fordham, UK) in order to measure the permeation of a 
drug through a Leishmania infected skin area (diameter of receptor and donor 
compartment: 5 mm). Furthermore the volume of the receptor compartment was 
approximately 2 ml. 
 
 
 
 
 
FIGURE 3-2. SCHEMATIC REPRESENTATION OF A FRANZ DIFFUSION CELL (WITH DIMENSIONS).  
 
The cells were placed in a plexiglass waterbath equipped with an immersion thermostat 
and a Variomag 60 position stirrer supplied by CamLab Ltd. Teflon coated magnetic 
stirrer bars were obtained from VWR international Ltd. (Leicestershire, UK). 
3.1.7.3  SOLUBILITY DETERMINATION OF THE TEST DRUGS  
The solubility of the drug compounds in PBS (with or without 2%CD) was determined 
by adding an excess amount of drug to the appropriate solvent in a clean vial. A 
magnetic stirrer was added before carefully sealing the vial and the suspension was left 
to stir for 48 hours at 32°C as per269. An aliquot of this mixture containing some solid 
drug particles was centrifuged at 13000 rpm at 32°C for 15 minutes. The supernatant 
was taken and analysed by HPLC-UV. This was done in triplicate for each test drug. 
HPLC-UV analysis for paromomycin sulfate was not possible due to the absence of 
chromophores. The solubility in PBS was determined by adding weighed amounts of 
drugs to a vial containing the appropriate solvent and a magnetic stirrer. Every 2-3 
hours the status of the mixture was observed and when a visibly clear solution was 
obtained a small amount of drug was added. Afterwards the vial was carefully sealed 
and returned to the warm water bath (32°C). The approximate solubility of the drug was 
Donor 
Receptor 
Skin/ Papule 
Magnetic stirrer 
Sampling port 
5 mm 
15 mm 
20 mm 
45 mm 
25 mm 
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calculated by taking the sum of the drug added to the solvent until visible drug particles 
remained present and no longer dissolved. 
3.1.7.4  STABILITY OF THE TEST DRUGS IN THE RECEPTO R AND DONOR 
SOLUTIONS  
In order to ensure drug stability during the experiment (32ºC - PBS) and storage (4ºC 
±2%CD), drug solutions were prepared in MilliQ water and PBS with or without 
2%CD. An aliquot was removed and analysed for the initial concentration at time 0 (t0) 
and the remaining solution was either left at 32 ºC in a warm water bath or stored in the 
fridge protected from light. An aliquot was taken at different time points and analysed 
by HPLC-UV. Stability was defined as the retention of 90-110% of the initial drug 
concentration. Paromomycin sulphate was stable for 5 days at 37 ºC according to the 
supplier.  
3.1.7.5  IN VITRO DIFFUSION AS SAY  
 
 
 
FIGURE 3-3. AN IMAGE OF THE FRANZ CELL DEVICE USED FOR THE PERMEATION STUDIES. 
The full-thickness skin pieces, both the control and papule part, were inspected for 
macroscopic damage and muscle and fat tissue were carefully removed using forceps. 
Skin pieces were cut in circular discs of about 2 cm diameter. They were then mounted 
between the donor and receptor compartment of the Franz cell device and kept in place 
by a clamp (Figure 3-3). The receiver fluid, PBS or water with 2%CD, was sonicated 
for 30 minutes prior to the experiment before adding to the receptor compartment. A 
small magnetic stirrer was introduced through the sampling arm, taking care not to 
introduce bubbles. When ready the cells were incubated in a warm water bath until the 
skin temperature measured 32°C. The magnetic stirrer plate was set at a speed of 800 
rpm. After 1 hour, each cell was checked for leakage and the presence of air bubbles. 
Clamp 
Donor compartment with narrow diameter 
Sampling port 
Receptor compartment 
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250 µl of the donor solution was applied to each donor compartment. Receptor fluid 
samples were taken at regular time intervals and analyzed by HPLC-UV (Table 3-2) or 
by liquid scintillation counting. Flux and lag time were calculated using the linear 
portion of the graph when plotting the cumulative amount of drug permeated in function 
of time. Kp was determined according to Equation 3. Statistical analysis were performed 
using SPSS software version 19.0. 
3.1.7.6  DRUG QUANTIFICATION  
HPLC-UV. All compounds, except for paromomycin sulphate, were analysed in 
duplicate using a 1260 Infinity Agilent HPLC system. The column and settings used to 
separate and detect the compounds are summarised below (Table 3-2). The validations 
of the HPLC-UV methods are described in the Appendix 1. 
Liquid scintillation counting. Because paromomycin sulfate lacks ultraviolet absorbing 
chromophore functions HPLC-UV could not be used to analyse the permeation samples. 
Therefore the donor solution was spiked with radiolabeled paromomycin sulfate and 
permeation samples were analysed using liquid scintillation counting. Thus 100 µl of 
receptor fluid and 100 µl of Optiphase™ supermix cocktail were added to a 96 well 
flexible PET microplate (Perkin Elmer, Buckinghamshire, UK). The plates were 
incubated on a plate shaker for 1 hour at room temperature. After this they were fitted in 
an appropriate support cassette and placed in the MicroBeta® Trilux with two detectors 
for scintillation counting (1 minute/well).  
Each plate included 3 blanks containing water that had been in contact with mouse skin 
(100 µl of water), 3 negative controls (100 µl of paromomycin sulfate saturated solution 
without radiolabeled compound) and 12 standards prepared by serially diluting one in 
five. Additionally 3 samples of the donor solution were analysed to confirm 
homogeneous distribution of the radiolabeled compound in the solution. The cpm 
readings obtained for the samples were converted to mg of paromomycin sulfate/ml 
using the standard curve.  
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TABLE 3-2. HPLC-UV METHOD SPECIFICATIONS (FOR METHOD VALIDATION SEE APPENDIX 1). 
Compound 
ID 
HPLC column 
Injection 
volume  
(µl) 
Flow rate (ml/min) / Mobile phase Detector 
wavelength 
(nm) 
Retention time 
(min) condition A B 
Caffeine 
Phenomenex; Synergi–Hydro RP 
(250x4.6 mm; 5 µm) 
20 1.3 / Isocratic 0.1% TFA in water (15%) ACN (85%) 273 5.8 
Ibuprofen 
Phenomenex; Synergi–Hydro RP 
(250x4.6 mm; 5 µm) 
20 1 / Isocratic 0.1% TFA in water (30%) ACN (70%) 227 5.6 
Amphotericin 
B 
Phenomenex; Synergi–Hydro RP 
(250x4.6 mm; 5 µm) 
80 1/ Isocratic 
2.5mM EDTA in water 
(68%) 
ACN (37%) 407 8.2 
Buparvaquon
e 
Luna C18 (4.6x250 mm; 5 µm) 
with Luna guard column 
20 1.7 / Isocratic 
5% Water+ acetic acid 
(pH3.5) (5%) 
MeOH (95%) 250 5.4 
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3.2 RESULTS AND DISCUSSION 
3.2.1 EVALUATION OF HISTOLOGICAL SECTIONS OF INFECTED AND 
UNINFECTED MOUSE SKIN  
A histological examination of the epidermal and dermal layers was performed to 
identify skin structure changes upon infection with Leishmania parasites. Figure 3-4 
shows an H&E stain of BALB/c mouse skin approximately 11 days after injection with 
either plain medium (A) or medium containing Leishmania major promastigotes (C). 
The magnification shown in Figure 3-4 (E) confirms infection characterised by the 
presence of amastigotes in the lower layers of the skin; the arrow points towards one 
amastigote out of many situated in the phagolysosome of the macrophage (circle).  
 
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3-4. RUMP SKIN HISTOLOGY. HISTOLOGICAL SECTIONS OF UNINFECTED (N=3) AND LEISHMANIA  
INFECTED (N=5)  BALB/C MOUSE SKIN (H&E STAIN). (A AND B) UNINFECTED SKIN AT DAY 11  AFTER 
INJECTION WITH PLAIN MEDIUM. (C AND D) INFECTED SKIN AT DAY 11  AFTER INFECTION WITH 2X107 L.  
MAJOR  PROMASTIGOTES. (E) SHOWS THE PRESENCE OF L. MAJOR  AMASTIGOTES IN THE MACROPHAGES 
(CIRCLES) SITUATED IN THE LOWER LAYERS OF INFECTED SKIN. 
A 
B 
50µm 
7.8µm 
D 
C 
E 
7.8µm 
50µm 
7.8µm 
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Figure 3-4 (D) and (B) are a magnification of the epidermis of infected and uninfected 
skin respectively. When comparing the number of cell layers (layers between the half 
brackets) in the epidermis, the infected skin counts more than the uninfected skin 
suggesting epidermal hyperplasia.  
Infected skin also shows a high infiltration of inflammatory cells in the dermis and 
underlying tissue and are stained dark blue-purplish by the H&E stain (indicated with 
ovals in Figure 3-4 (C)). To confirm these findings, an immunostaining with the IBA-1 
antibody, a marker for macrophage-like cells was performed. Figure 3-5 (B) shows a 
high level of macrophages indicated by an abundant brown staining present in the 
dermis and deeper lying tissues of infected skin compared to uninfected skin (A).  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
FIGURE 3-5. RUMP SKIN HISTOLOGY. HISTOLOGICAL SECTION OF UNINFECTED (N=3,  A AND C) AND 
LEISHMANIA  INFECTED (N=5,  B  AND D) BALB/C MOUSE SKIN AT DAY 11  AFTER INFECTION WITH L. 
MAJOR  PROMASTIGOTES. (A AND B) IMMUNOSTAINING WITH IBA-1  ANTIBODIES AND (C AND D) ELASTIC 
VAN GIESON STAINING. 
Elastic and connective tissue in uninfected and infected skin was visualised using an 
elastic Van Gieson stain (Figure 3-5 (C) and (D) respectively). Collagen and other 
connective tissue is stained red while elastic fibres are coloured dark blue-black. In 
uninfected skin, the connected collagen fibres form a dense network with little gaps 
C 
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25µm 
50µm 
A B 
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characterised by intense red staining as seen in Figure 3-5 (C). On the contrary, infected 
skin shows a reduced density of collagen fibres as indicated by less intense red staining. 
The increased space (black arrows, Figure 3-5 (D)) between the fibres is probably due 
to the infiltration of inflammatory cells.  
The elastic fibres are scattered among collagen bundles in the dermis of the uninfected 
skin (blue arrows, Figure 3-5 (C)). Elastic fibres also seem to be less densely located in 
infected skin (blue arrows, Figure 3-5 (D)) compared to uninfected skin. However a 
higher magnification does not allow clear visibility. 
3.2.2 COMPARISON OF PH  VALUES AND HYDRATION FOR INFECTED 
AND UNINFECTED SKIN  
Figure 3-6 shows the skin hydration and pH as the infection progressed. A one-way 
repeated measures ANOVA was conducted to compare values of skin pH and hydration 
between uninfected and infected skin at day 0, 2, 4, 6, 8 and 10 post-infection. There 
was no significant difference in pH or hydration between the infected and uninfected 
mice (p>0.05). 
 
FIGURE 3-6. THE MEAN SKIN PH AND HYDRATION (%) VALUES FOR INFECTED (MEAN±SD; N=5) AND 
UNINFECTED (MEAN±SD, N=3) MICE AS A FUNCTION OF TIME POST-INFECTION (DAYS) (ONE-WAY 
ANOVA,  P > 0.05). 
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3.2.3 COMPARISON OF TEWL  VALUES FOR INFECTED AND 
UNINFECTED SKIN  
There was no statistical difference in TEWL values for infected and uninfected mice of 
on day 0 (independent sample t-test; p>0.05) (Figure 3-7).  
 
FIGURE 3-7. THE TEWL VALUE (G/(M2H)) AND LESION SIZE (MM) OF L. MAJOR  INFECTED (MEAN±SD; 
N=5) AND UNINFECTED (MEAN±SD; N=3) MICE AS A FUNCTION OF TIME POST-INFECTION (REPEATED-
MEASURES ANOVA,  P < 0.05). 
By day 10, when the infected mice had developed a papule with an approximate 
diameter of 5 mm, the mean TEWL values in the infected group had significantly 
increased compared to the uninfected group (repeated measures ANOVA, p<0.05) 
(Figure 3-7). Moreover, an increase of the mean TEWL values for infected mice at day 
0 and day 10 was found (paired t-test, p < 0.05).  
The relationship between TEWL values and lesion size was investigated using a 
pearson correlation coefficient. There was no statistically significant correlation 
between the two variables (r=0.218, p>0.05) while a strong correlation was expected as 
both lesion size and TEWL increase in time in the infected group. Therefore the 
relationship between TEWL and time and lesion size and time was investigated. There 
was no significant correlation between TEWL and time (r=0.186, p>0.05), however 
there was a strong positive correlation for lesion size and time (r=0.882, p<0.05). 
Furthermore the correlation between TEWL and hydration was investigated but was 
weak and not significant (r=-0.124, p>0.05).  
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3.2.4 EVALUATION OF THE PERMEABILITY OF INFECTED AND 
UNINFECTED SKIN  
3.2.4.1  MODEL COMPOUNDS :  CAFFEINE AND IBUPROFEN  
Stability. Stability studies performed prior to the permeation studies showed that both 
compounds, caffeine and ibuprofen were stable in water for 72 hours at 32ºC and in 
PBS for 4 days at 4ºC allowing sufficient time for analysis.  
Solubility. Caffeine has a partition coefficient of -0.08 and a water solubility of 
approximately 26 mg/ml, while ibuprofen has a partition coefficient of 3.57 and a water 
solubility of 0.15 mg/ml (Table 3-3).  
TABLE 3-3. PHYSICO-CHEMICAL PROPERTIES FOR CAFFEINE AND IBUPROFEN (N=3,  MEAN±SD). 
 Caffeine Ibuprofen 
Solubility (mg/ml) 
PBS (pH 7.4) 
 
22.74±5.26 
 
0.15±0.01 
Log Poct/water -0.08* 3.57* 
Mol. weight (g/mol) 194* 206* 
H-bond donor 0 1 
*Calculated using the software ChemBioDraw Ultra 13.0 (PerkinElmer) 
Permeability. The cumulative amount of caffeine and ibuprofen permeated through 
infected and uninfected mouse skin is shown in Figure 3-8 and Figure 3-9 respectively. 
It can be seen that more caffeine and ibuprofen permeated through infected than 
uninfected skin. A paired sample t-test was conducted to evaluate the impact of 
infection on the permeation of caffeine. There was a statistically significant higher 
caffeine permeation through infected skin compared to uninfected skin after 48 hours 
(paired sample t-test, p<0.05). The same was observed for ibuprofen (paired sample t-
test, p<0.05).  
At the end of the experiment, the cumulative amount of caffeine that had permeated 
through infected skin was 1.8 to 47.3 times higher compared to uninfected skin (one-
way ANOVA, p < 0.05). For ibuprofen this difference was more modest (1.7 to 3.1 
higher) but it was still significant (one-way ANOVA, p < 0.05).  
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FIGURE 3-8. THE CUMULATIVE AMOUNT OF CAFFEINE PERMEATED PER SURFACE AREA (µG/CM2) 
THROUGH UNINFECTED (N=5) AND INFECTED (N=5) SKIN AS A FUNCTION OF TIME (H) (PAIRED T-TEST, P 
<0.05). 
 
FIGURE 3-9.  THE CUMULATIVE AMOUNT OF IBUPROFEN PERMEATED PER SURFACE AREA (µG/CM2) 
THROUGH UNINFECTED (N=5) AND INFECTED (N=5) SKIN AS A FUNCTION OF TIME (H) (PAIRED T-TEST, P 
<0.05). 
There was no statistically significant difference in lag time for the model drugs (Table 
3-4) for infected skin compared to uninfected skin (independent sample t-test, p >0.05).  
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The flux of caffeine and ibuprofen through infected skin was respectively about 66 and 
2 times higher compared to the uninfected skin (independent sample t-test, p<0.05) 
(Table 3-4). Both compounds also had a significant higher permeability coefficient for 
infected compared to uninfected skin (independent sample t-test, p<0.05) (Table 3-4). 
However, the difference in permeability coefficient for infected compared to uninfected 
skin was 50 times higher for caffeine while it was only two times higher for ibuprofen. 
This indicated that both drugs had a higher permeation through infected skin compared 
to uninfected skin but it also suggested that Leishmania infection of the skin enhanced 
the permeation of hydrophilic drugs to a greater extent than that of lipophilic drugs. 
TABLE 3-4. FLUX, LAG TIME AND PERMEABILITY COEFFICIENT FOR CAFFEINE AND IBUPROFEN 
(MEAN±SD, N=5; INDEPENDENT SAMPLE T- TEST, P<0.05). 
 Caffeine Ibuprofen 
Flux (µg/cm2/h) 
uninfected 
infected 
 
0.6±0.1 
40.1±43.8 
 
7.3±1.16 
15.0±3.7 
Lag time (h) 
uninfected 
infected 
 
14.9±5.2 
12.7±3.5 
 
11.4±1.1 
10.7±0.5 
Kp (cm/h) 
uninfected 
infected 
 
2.3E-05±5.5E-06 
1.1E-03±8.5E-04 
 
0.1±0.0 
0.1±0.0 
 
3.2.4.2  ANTI-LEISHMANIAL DRUGS :  AMPHOTERICIN B,  BUPARVAQUONE AND 
PAROMOMYCIN SULFATE  
Stability. Amphotericin B and buparvaquone were stable in PBS at 32ºC for 24 hours 
and 48 hours respectively. Buparvaquone was stable for 4 days at 4ºC in PBS 
supplemented with 2% CD whereas amphotericin B was not. Therefore the stability 
study for amphotericin B in 2% CD was repeated but samples were kept at -20ºC. The 
amphotericin B samples were stable for 3 days at -20ºC. Paromomycin sulphate was 
stable for 5 days at 32ºC according to the supplier.  
Solubility. The solubility of the test compounds is indicated in Table 3-5. Paromomycin 
sulphate was highly soluble in PBS. On the contrary, the solubility of buparvaquone and 
amphotericin B in PBS was low and could not be quantified because it was below the 
limit of quantification. In an effort to maintain sink condition during the permeation, 2% 
CD was added to the receptor phase. The solubility of amphotericin B and 
buparvaquone was 37 and 853 µg/ml in PBS with 2% CD.  
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TABLE 3-5. PHYSICO-CHEMICAL PROPERTIES FOR PAROMOMYCIN SULPHATE, AMPHOTERICIN B  AND 
BUPARVAQUONE (N=3,  MEAN±SD). 
 Paromomycin 
sulphate 
Amphotericin 
B 
buparvaquone 
Solubility (µg/ml) 
PBS (pH 7.4) 
PBS+2%CD 
 
>650000 
N/A 
 
< 0.75 
37±4 
 
<0.1 
853±25 
Log Poct/water -2.9* -0.66* 3.56* 
Mol. weight (g/mol) 714* 924* 326* 
H-bond donor 13* 12* 1* 
*Calculated using the software ChemBioDraw Ultra 13.0 (PerkinElmer) 
Permeation – amphotericin B. Amphotericin B could not be quantified in any of the 
permeation samples taken (limit of quantification – 750 ng/ml, Appendix 1). 
Amphotericin B is a large molecule (mol. weight, 924 g/mol) and is practically 
insoluble in water. Hence it was not expected to permeate through infected or 
uninfected skin. As discussed in the introduction (section 1.5.4.2), previous studies in 
mice reported no cure of leishmaniasis lesions after application of amphotericin B 
topically176, while it was effective when given intravenously. This led to conclude that 
amphotericin B as a molecule is unable to permeate through mouse skin. This in vitro 
permeation experiment confirms these findings and suggest that even diseased skin 
remains impermeable to large molecules. 
Permeation – buparvaquone. Buparvaquone did not permeate through uninfected skin 
(Figure 3-10). Small amounts did permeate through infected skin, however, 
buparvaquone was only detected in the receptor solution 30 hours after the application 
of the donor solution. After 48 hours of the permeation study, the mean cumulative 
amount permeated per surface (n=5) area was 4.5±4.15 µg/cm2. These results indicate 
very limited permeation and confirm the limited in vitro permeation reported 
previously245, 246. Buparvaquone is a very hydrophobic molecule with a log P of 3.56 
and its low water solubility is thought to be an important factor in its limited 
permeability245. 
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FIGURE 3-10. THE CUMULATIVE AMOUNT OF BUPARVAQUONE PERMEATED PER SURFACE AREA (µG/CM2) 
THROUGH UNINFECTED AND INFECTED SKIN OF EACH MOUSE AS A FUNCTION OF TIME (H) (FILLED AND 
UNFILLED MARKERS REPRESENT VALUES OBTAINED FOR INFECTED AND UNINFECTED MOUSE SKIN 
RESPECTIVELY, PAIRED T-TEST, P <0.05). 
Permeation – paromomycin sulphate. During the entire experiment, paromomycin 
sulfate did not permeate through uninfected skin. In contrast, it showed a high 
permeation through infected skin except for one infected skin sample where no 
permeation was observed (Figure 3-11).  
 
FIGURE 3-11. THE CUMULATIVE AMOUNT OF PAROMOMYCIN SULPHATE PERMEATED PER SURFACE AREA 
(µG/CM2) THROUGH UNINFECTED AND INFECTED SKIN OF EACH MOUSE AS A FUNCTION OF TIME (H) 
(FILLED AND UNFILLED MARKERS REPRESENT VALUES OBTAINED FOR INFECTED AND UNINFECTED 
MOUSE SKIN RESPECTIVELY, PAIRED T-TEST, P <0.05). 
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Flux, lag time and approximate Kp value were only determined for the permeation of 
paromomycin sulphate and buparvaquone through infected skin (Table 3-6) because no 
anti-leishmanial drug permeated through uninfected skin.  
TABLE 3-6. FLUX, PERMEABILITY COEFFICIENT (KP) AND LAG TIME FOR PAROMOMYCIN SULPHATE, 
AMPHOTERICIN B  AND BUPARVAQUONE (MEAN±SD, N=5  EXCEPT FOR PM  WHERE N=4). 
 
Paromomycin 
sulphate 
Amphotericin 
B 
Buparvaquone 
Flux (µg/cm2/h) 
uninfected 
infected 
 
- 
548±201 
 
- 
- 
 
- 
0.2±0.1 
Lag time (h) 
uninfected 
infected 
 
- 
15.4±4.0 
 
- 
- 
 
- 
25.3±3.1 
Kp (cm/h) 
uninfected 
infected 
 
- 
7.0E-04 
 
- 
- 
 
- 
1.8±1.0 
A one-way between-group analysis of variance was conducted to explore the influence 
of infected skin on the permeation parameters (flux, lag time and Kp) of the different 
tested drugs. There was a statistically significant difference at the p<0.05 level in flux 
for paromomycin sulphate compared to caffeine and the more lipophilic drugs 
buparvaquone and ibuprofen but there was no statistical significant difference for 
caffeine compared to buparvaquone and ibuprofen (p>0.05).  
The lag time and permeability coefficient (Kp) for buparvaquone permeation through 
infected skin was significantly higher compared to paromomycin, caffeine and 
ibuprofen (p>0.05 for lag time and Kp). A high permeability coefficient indicates a 
higher affinity for the membrane than for the vehicle favouring partitioning into the 
skin. Here it suggests that buparvaquone partitions quickly into the SC but it does not 
permeate through the skin quickly as is reflected by the low flux. Research already 
suggested that a highly lipophilic compounds like buparvaquone remain in the stratum 
corneum and do not tend to permeate into the more hydrophilic dermis245. 
From these findings, it can be hypothesized that the presence of Leishmania parasites in 
the skin triggers a cascade of reactions resulting in inflammation and release of 
chemokines98, 270 that subsequently induce oedema because additional fluid accumulates 
in the interstitial spaces. This hydrophilic environment consequently facilitates 
permeation of hydrophilic compounds such as caffeine and paromomycin while the 
permeation of highly lipophilic compounds such as buparvaquone (log P= 3.56) is 
delayed. 
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Another possible reason for the enhanced permeation of hydrophilic compounds might 
be explained using Fick’s law. All drugs were applied as saturated solutions and 
therefore all had the same thermodynamic activity of 1. Furthermore, the permeation 
rate of the diffusing molecules through a membrane is proportional to the concentration 
gradient measured over this membrane. In the case of the highly water soluble 
paromomycin sulfate, this gradient is nearly 25 times higher compared to caffeine and 
more than 4000 times higher compared to ibuprofen. This is likely to contribute to this 
increased permeation for more hydrophilic compounds. 
Our results are similar to the findings obtained by Tsai et al. who investigated the effect 
of compound lipophilicity on permeation through acetone damaged mouse skin93. 
Acetone treatment extracts lipids from the skin and was reported to increase TEWL 
indicating skin barrier damage. The results showed a higher permeation of hydrophilic 
and amphoteric molecules through damaged skin. The increase in permeation was more 
modest for lipophilic compounds compared to the hydrophilic compounds. It was 
hypothesised that the dermis was the rate limiting membrane for permeation of 
lipophilic compounds and damage to the SC therefore impacted their permeation to a 
lesser extent than compared to hydrophilic compounds for which the SC is the rate 
limiting barrier to permeation.  
Furthermore it should be mentioned that the variation for permeation experiments 
described in this chapter was high but this is not uncommon. Intra- and inter-individual 
variations as high as 45% were reported in in vivo studies in humans271-273. This was due 
to differences in skin lipid composition, SC thickness etc. For in vitro permeation 
studies, even larger variations were reported because of the additional modifications 
introduced by storage and experimental manipulations274, 275. Besides the variation 
between mice, the permeation experiments described in this chapter included an 
additional factor of variability that is induced by the progression of the infection and 
was likely to have contributed in the variation observed in these results. An effort was 
made to try and limit variation by using an inbred strain of mice (BALB/c) and by 
inducing infection using a standard inoculum of L. major parasites.  
How these results translate to human skin and particularly to in vivo drug permeation is 
unclear because mouse skin is different from human skin. For example, mouse skin has 
no sweat glands but has more hair follicles compared to human skin and human skin is 
thicker than mouse skin (see 6.4)276 .  
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3.3 CONCLUSIONS  
This chapter describes how we looked at some vital parameters that influence the 
pharmacokinetics of CL affected skin.  
Different stains were used to evaluate skin sections of both infected and uninfected skin 
and were compared to identify the skin changes in skin physiology upon Leishmania 
infection. It revealed an increase in epidermal cell layers suggesting epidermal 
hyperplasia. Immunohistochemical staining using IBA-1 antibodies, showed an 
abundant infiltration of the dermal layer with inflammatory cells and an elastic Van 
Gieson stain indicated disruption of the connective tissue. 
Furthermore, the TEWL, an indicator of barrier integrity was measured and was 
significantly higher for infected skin compared to uninfected skin indicating the inside-
outside barrier was damaged.  
Finally the influence of CL drug delivery was evaluated by measuring the permeation of 
2 model compounds, caffeine and ibuprofen, and 3 anti-leishmanial drugs, 
paromomycin sulphate, amphotericin B and buparvaquone through infected and 
uninfected skin. The permeation of caffeine and ibuprofen was enhanced through 
infected skin compared to uninfected skin. However, the flux of caffeine was 66 times 
higher through infected skin while this was only 2-fold higher for ibuprofen. 
Amphotericin B did not permeate through infected or uninfected skin, which was not 
surprising due to its high molecular weight. Paromomycin sulphate and buparvaquone 
did not permeate through uninfected skin but permeated through infected skin and again 
the permeation increase through infected skin was higher for the hydrophilic 
paromomycin sulphate. These findings led to the hypothesis that the inflammatory 
reaction induced by skin damage of the injection and the presence of parasites in the 
skin, attracted aqueous fluids to the dermis and underlying tissue and hence created a 
rather hydrophilic environment resulting in more selective permeation enhancement of 
hydrophilic compounds through infected skin.  
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3.4 FUTURE WORK  
One of the more important future experiments is to extend the drug permeation 
experiments to drug formulations. In the experiments described in this chapter, the 
permeation of molecules through infected and uninfected skin was compared. However 
a drug is rarely applied to the skin as such. It would be interesting to investigate the 
impact of CL on the permeation of formulations for example fungizone® and 
Leshcutan®. 
Further examination of skin sections using immunostaining could help visualise 
biomarkers that are known to contribute to skin diseases255. This information can be 
linked to specific biological skin processes that are impaired due to Leishmania 
infection. For instance, the use of Ki-67 antibodies would allow to look for epidermal 
proliferation.  
Above, we also hypothesised about the influence of inflammation on the 
physicochemical environment of the skin. It would be useful to determine the solubility 
of compounds in homogenate of infected and uninfected skin and see if there is a 
difference for the compounds that were tested in this chapter.  
Permeation studies with additional compounds with varying partition coefficients would 
allow to further examine the influence of the physicochemical nature of drugs on 
permeation enhancement through infected skin. 
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4 DEVELOPMENT OF A TOPICAL MILTEFOSINE 
FORMULATION 
As described in the general introduction, miltefosine is a known anti-leishmanial drug 
that is already on the market as an oral formulation. The most frequent reported side 
effects are:  
 gastro-intestinal discomfort that is often the cause of poor therapy 
compliance277; 
 teratogenicity that calls for adequate contraception throughout the treatment of 
females of child bearing age; 
 hepato- and nephrotoxicity requiring patient monitoring. 
Compared to systemic treatment, a topical miltefosine treatment offers certain 
advantages. The formulation is directly applied to the target site thereby avoiding or at 
least reducing the potential side effects so that less intense patient follow up is required 
and it is user friendly increasing patient adherence. Moreover miltefosine is already 
approved for clinical use and reformulating miltefosine into a topical treatment would 
save money and time compared to a ‘de novo’ drug discovery process especially in an 
area with little financial incentive of big pharma.  
The question remains whether miltefosine as a compound can be delivered to the skin. It 
is a highly water soluble molecule and its physico-chemical properties (molecular 
weight, solubility, H-bond donors and melting point) are indicative of skin permeation 
(Table 4-1). Moreover the previous chapter showed that the skin barrier of mice 
infected with Leishmania parasites was damaged and the flux of hydrophilic 
compounds through skin was increased compared to lipophilic compounds.  
In contrast, miltefosine has a similar structure to skin lipids suggesting it might be 
retained by the SC (Figure 4-1). Also miltefosine is an amphiphilic and zwitterionic 
molecule at skin pH (pH 5.5) as it contains a permanent positive charge and a negative 
charge (pKa ≈ 2)156.  
 
FIGURE 4-1. CHEMICAL STRUCTURE OF MILTEFOSINE  
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In general, it is accepted that both solubility in the vehicle and the partition coefficient 
of the molecule influence the permeation process of a molecule into the skin. Often a 
compromise between both properties is necessary for a molecule to permeate. In the 
case of ionic compounds with a rather high inherent aqueous solubility, the permeation 
might be more challenging compared to unionized compounds due to the general 
lipophilic properties of the stratum corneum. Recent research also suggested that the 
solubility of the active compound in the vehicle is the main determinant influencing 
skin permeation in finite dose conditions278. The majority of the topical formulations on 
the market such as creams, gels and sprays are finite dose applications.  
TABLE 4-1. PHYSICOCHEMICAL PROPERTIES OF MILTEFOSINE. 
Physicochemical properties Ideal properties Miltefosine 
Molecular weight (g/mol) < 50031 407.6 
Aqueous solubility (mg/ml) -  440 
Melting point < 200°C279 114°C 
H-bond donors/acceptors < 3 donors34 0/4 
Partition coefficient 1-326, 35 -2.38*  
* Clog P octanol –water partition coefficient estimated using ChemBioDraw Ultra software (version 14.0). 
A topical solution Miltex®, containing 6% miltefosine (w/v), used to be on the market to 
treat superficial and flat cutaneous metastases of breast cancer280 indicating activity 
upon topical application. Moreover Schmidt-Ott et al tested the efficacy of this solution 
against L. major and L. mexicana parasites in vivo in mice and after treatment no lesions 
were visible241. This also suggests that miltefosine is able to permeate into the deeper 
layers of the skin. However, these results were not reproducible when conducted in our 
lab (Yardley and Croft, unpublished data), even though the activity of miltefosine 
against a range of Leishmania species was confirmed159.  
Two clinical trials were conducted to evaluate the efficacy of Miltex® against CL 
(Bachmann P., unpublished data). One trial was conducted in Syria and included 16 
patients with nodular CL that received treatment twice daily. The other trial was 
conducted in Colombia where the 19 involved patients received treatment once a day 
for 4 weeks281. Both trials were unable to show efficacy against CL, even though oral 
administration had been shown to cure CL in vivo161, 282. This raises the question if 
miltefosine is able to permeate the skin deep enough to reach parasites and exert its 
activity. 
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The aim of the study described in this chapter was to investigate if miltefosine could be 
used to treat CL upon topical application. In a first stage, the activity of miltefosine 
against a range of intracellular Leishmania amastigotes159 was evaluated in vitro. In a 
second stage, the permeation of miltefosine when applied on the skin in a range of 
solvents was investigated. The investigated solvents were propylene glycol (PG), water, 
dimethyl isosorbide (DMI) and octyl salicylate (OSAL) and are described in the 
introduction (1.3.2). They were chosen because (i) they had a broad range of 
physicochemical properties (see Table 4-2) and (ii) they were reported to enhance 
percutaneous drug delivery through various mechanisms of action (when known).  
TABLE 4-2. THE FOUR SOLVENTS USED AND THEIR PHYSICOCHEMICAL PROPERTIES. 
 Dimethyl isosorbide Octyl salicylate Propylene glycol Water 
 
 
  
 
Mol. Wt. (g/mol) 174 250 76 18 
Log KO/W 0.07 5.97 -1.06 -1.38 
Solubility parameter 
(cal/cm3)1/2 
9.97 10.87 14.07 22.97 
Density at 25°C 
(g/cm3) 
1.16 1.1 1.04 1.0 
In preparation of the permeation experiment, the solubility of miltefosine in these 
solvents was determined. Fick’s law of diffusion describes how the flux of the passive 
diffusion of molecules through a membrane is directly proportional to the concentration 
gradient over this membrane. Consequently, the higher the amount of drug dissolved in 
the vehicle, the higher the flux283. However whilst a high solubility in the vehicle 
potentially increases the flux of the drug through skin, a polarity similar to the SC 
combined to a low affinity for the vehicle increases the partitioning of the drug into the 
SC283. Hence, the partition coefficient was determined to give an indication of the 
affinity of miltefosine for the skin. Furthermore computational modelling was used to 
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estimate the Hoftyzer-Van Krevelen solubility parameter of miltefosine and the 
solvents. Hadgraft suggested that solvents could enhance skin permeability by shifting 
the solubility parameter of the skin towards that of the drug284.  
As explained in the introduction, the application of the drug in a binary and even ternary 
solvent system, this is a mixture of two or three solvents respectively, has shown to 
enhance percutaneous drug permeation62-65, 67, 285. In order to deliver the drug from a 
stable solvent system, the compatibility of solvents was explored in binary and ternary 
phase miscibility studies. Finally the effect of the solvents on the permeation of 
miltefosine through the skin was compared by in vitro permeation studies using Franz 
diffusion cells followed by a mass balance study that allowed the quantification of 
miltefosine that was inside the skin. A radiolabelled assay was developed to quantify 
the amount of miltefosine as it lacks chromophores and can therefore not be detected by 
HPLC-UV. 
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4.1 MATERIALS AND METHODS  
4.1.1 DRUGS AND SOLVENTS  
Miltefosine was kindly donated by Paladin Labs Inc. The [14C]-miltefosine was 
purchased from Nycomed Amersham Pharmacia biotech (Buckinghamshire, UK). 
Details of the solvents and reagents used, are listed below (Table 4-3). 
TABLE 4-3. DETAILS OF SOLVENTS AND REAGENTS USED DURING PERMEATION EXPERIMENTS WITH 
MILTEFOSINE. 
Solvents/ Reagents Specifications Supplier 
Solvents 
Isosorbide dimethyl ether (DMI) 
2-ethylhexyl salicylate (OSAL) 
Propylene glycol (PG) 
Hydrogen peroxide solution 
Phosphate buffered saline 
 
Methylene blue solution 
 
98% purity 
Octyl salicylate, 99% purity 
N/A 
30% in water 
Tablets; NaCl (8g/l), KCl (0.2g/l), Na2HPO4 
(1.15g/l), KH2PO4 (0.2g/l), pH 7.3 
3.126M 
 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Oxoid, Thermo 
Scientific 
Sigma Aldrich 
Radiolabeled assay – reagents/drugs 
Optiphase™ supermix 
Hionic Fluor™ 
Solvable™ 
[14C]-miltefosine 
 
 
Liquid scintillation cocktail 
Liquid scintillation cocktail 
Aqueous based solubilizer 
Specific activity: 36mCi/mmol; 
radiochemical purity: 98.3%; radioactive 
concentration: 900µCi/ml; solvent: ethanol 
 
Perkin Elmer 
Perkin Elmer 
Perkin Elmer 
Nycomed 
Amersham  
Cell and parasite culture 
RPMI-1640 
Schneider’s insect medium 
M199 medium 
Penicillin-streptomycin solution 
Heat-inactivated foetal calf serum  
 
500ml 
500ml 
Powder  
10000 units penicillin- 10mg streptomycin/ml 
500ml 
 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Harlan Sera-Lab 
 
4.1.2 FRANZ DIFFUSION CELLS AND EQUIPMENT  
Franz cell devices with an approximate diameter of 9 mm and a receptor volume of 
approximately 2.5 ml were obtained from Soham Scientific (Fordham, UK). The other 
equipment used for this study is the same as described in 3.1.7.2.  
4.1.3 LEISHMANIA PARASITES AND CELL CULTURE  
Promastigotes of L. major (MHOM/SA/85/JISH118); L. panamensis 
(MHOM/PA/67/BOYNTON); L. aethiopica (MHOM/ET/84/KH); L. mexicana 
(MNYC/ BZ/62/M379) and L. tropica (MHOM/IR/2013/HTD4) were taken from liquid 
nitrogen stocks. All species except L. panamensis were cultured and maintained in 
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Schneider’s Insect medium plus 10% heat-inactivated fetal calf serum (HiFCS) at 26°C. 
L. panamensis was cultured in M199 medium supplemented with 10% HiFCS. KB and 
THP-1 cells were maintained in RPMI-1640 medium supplemented with L-glutamine 
and 10% HiFCS. Both human-derived cell lines were left in an incubator at 37ºC and 
5% CO2 and passaged to new medium once a week (1/10 ratio). 
4.1.4 EVALUATION OF THE ANTI-LEISHMANIAL ACTIVITY  OF 
MILTEFOSINE IN THE INTRACELLULAR AMASTIGOTE –  
MACROPHAGE MODEL  
Mouse peritoneal macrophages (PEM) were isolated from CD-1 mice (Charles River, 
Margate, UK) by abdominal lavage with RPMI-1640 medium containing 1% penicillin 
and streptomycin. The collected cells were washed, re-suspended and seeded in 16-well 
Lab-Tek™ slide in RPMI-1640 supplemented with 10% HiFCS at a density of 4x104 
per well. After 24 hours incubation at 37°C and 5% CO2/95% air mixture, the adhered 
PEMs were infected with stationary phase promastigotes at a ratio of 3 (for L. tropica 
and L. major) or 5 (for L. mexicana, L. aethiopica and L. panamensis) promastigotes to 
1 macrophage and maintained at 34°C in a 5% CO2/95% air mixture. These ratios were 
chosen in order to ensure that at least 75% of the macrophages were infected after 72 
hours of incubation in the untreated controls. 
After 24 hours, the cultures were washed to remove extracellular promastigotes and one 
slide was fixed with methanol and stained with Giemsa to determine the initial level of 
infection. If a sufficient level of infection (i.e. > 75%) was obtained, PBS - miltefosine 
solutions over a range of 30, 10, 3 and 1 μM were added in quadruplicate at each 
concentration. Amphotericin B (Fungizone®) was included as control drug. After 72 
hours incubation, all slides were methanol-fixed and Giemsa-stained.  
The percentage inhibition was determined by microscopically (400x magnification) 
counting the infected macrophages in drug treated cultures compared to untreated 
cultures microscopically. The Hill coefficient, ED50 and ED90 values were calculated by 
non-linear sigmoidal curve fitting (variable slope) using Prism Software (GraphPad, 
Surrey, UK). 
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4.1.5 CYTOTOXICITY TESTING AGAINST KB  AND THP-1  CELLS  
KB/ THP-1 cells were harvested, washed and counted in serum free medium. The cell 
density was adjusted to 5 x 104 /ml in RPMI-1640 supplemented with 10% HiFCS. 100 
µl of the cell suspension was plated in each well of a 96-well plate followed by 
incubation at 37C and 5% CO2 for 24 hours.  
Stock drug solutions of 20 μM in PBS were prepared and diluted to 600 nM in RPMI-
1640 with 10% HiFCS. 300 nM was the top concentration tested and five-fold serial 
dilutions were performed across the plate. Podophyllotoxin was included as positive 
control drugs. Untreated controls and blanks, containing only medium were also 
included. Each test compound was tested in triplicate. Plates were incubated for a 
further 72 hours at 37C and 5% CO2.  
After incubation, the wells were assessed microscopically and 20 μl Alamar Blue® was 
added to each well. The plates were incubated for a further 2-4 hours before reading at 
EX/EM 560/585 (cut off 570) in a Spectramax™ M3 Plate reader. The ED50 value was 
calculated by non-linear sigmoidal curve fitting (variable slope) using Prism Software 
(GraphPad, Surrey, UK). 
4.1.6 EVALUATION OF THE PHYSICOCHEMICAL PROPERTIES OF 
MILTEFOSINE THAT RELATE TO THE PERMEATION PROFILE  
4.1.6.1  DISTRIBUTION COEFFICIENT  
The slow stirring method was adopted to determine the distribution coefficient for 
miltefosine. Prior to the experiment 1-octanol and water (buffered to pH 5 with acetic 
acid) were left to equilibrate for 48 hours at 32°C. Eight ml of the water was used to 
dissolve 100 µg of miltefosine and was placed in a clean vial. Two ml of 1-octanol was 
added and the mixture was left to equilibrate at 32°C for 24 hours. 100 μl aliquots from 
both phases were taken and diluted prior to analysis by LC-MS (conducted by the 
chemistry department at UCL School of Pharmacy). The experiment was conducted in 
triplicate.  
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The distribution coefficient was calculated according to the formula below: 
log 𝐷𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝑤𝑎𝑡𝑒𝑟
= 𝑙𝑜𝑔 [
[𝑚𝑖𝑙𝑡𝑒𝑓𝑜𝑠𝑖𝑛𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙
([𝑚𝑖𝑙𝑡𝑒𝑓𝑜𝑠𝑖𝑛𝑒]𝑤𝑎𝑡𝑒𝑟−𝑖𝑜𝑛𝑖𝑠𝑒𝑑 + [𝑚𝑖𝑙𝑡𝑒𝑓𝑜𝑠𝑖𝑛𝑒]𝑤𝑎𝑡𝑒𝑟−𝑛𝑒𝑢𝑡𝑟𝑎𝑙)
] 
EQUATION 5 
4.1.6.2  SOLUBILITY PARAMETER MODELLING AND MEASUREMENTS OF DRUG 
SOLUBILITY  
The solubility parameter (δ) of miltefosine and the solvents/CPEs were calculated 
according to the Van Krevelen-Hoftyzer method using the Molecular Modelling Pro 
software (version 6.0, Chemistry Software Ltd., Surrey, UK).  
The solubility of miltefosine in PG, DMI, OSAL and water was determined using two 
different methods  
Method 1. The solubility of miltefosine in the different solvents was determined by 
adding an excess amount of drug to the appropriate solvent in a clean vial. A magnetic 
stirrer was added before carefully sealing the vial and the suspension was left to stir for 
48 hours at 32°C269. An aliquot of this mixture containing some solid drug particles was 
centrifuged at 13000rpm at 32°C. The supernatant was taken and analysed by LC-MS.  
Method 2. The solubility was determined by adding weighed amounts of drugs to a vial 
containing the appropriate solvent (1.5 ml) and a magnetic stirrer. Every 2-3 hours the 
status of the mixture was observed and when a visibly clear solution was obtained an 
additional amount of drug was added. Afterwards the vial was carefully sealed and 
returned to the warm water bath (32°C). The approximate solubility of the drug after 48 
hours was calculated by making the sum of the drug added to the solvent until visible 
drug particles remained present and no longer solubilized. 
4.1.7 EVALUATION OF SOLVENT MISCIBILITIES  
Binary and ternary mixtures of the four solvents: PG, DMI, OSAL and water were 
prepared and their miscibilities were determined by adding the appropriate volume and 
ratio of solvents (v/v) into a clean vial (see Appendix 4). The vial was vigorously mixed 
for 2 minutes and left at room temperature. After one hour, the samples were observed 
and marked as immiscible (when phase separation was visible) or miscible (when a 
homogeneous phase mixture was seen). If necessary, Sudan dye red or methylene blue 
Chapter 4 – Development of a topical miltefosine formulation 
 
 
 
 
80 
 
was added to the mixture to non-polar and polar solvents respectively to aid the 
determination of miscibility/immiscibility. Ternary phase diagrams were drawn using 
the OriginPro software (version 9.1; Northampton, USA).  
The stability of the miscible binary and ternary solvent mixtures that were selected for 
the permeation study was tested over a period of 48 hours at 32ºC to ensure no phase 
separation would occur during the permeation experiment. 
4.1.8 THE EFFECT OF SOLVENTS AND SOLVENT SYSTEMS ON THE 
PERMEATION AND DISPOSITION OF MILTEFOSINE IN BALB/C 
MOUSE SKIN  
An initial permeation study using single solvents was conducted in order to compare the 
effect of the different solvents on the permeation of miltefosine through full-thickness 
mouse skin. The most efficient permeation enhancing solvents were then used as such 
or combined in binary and ternary mixtures as a drug carrier. Skin disposition studies 
were performed to quantify the amount of miltefosine that permeated into skin.  
4.1.8.1  PREPARATION OF DONOR SOLUTIONS  
Binary and tertiary system combinations within the miscible area were chosen to assure 
the donor solution did not show phase separation. The solutions/ suspensions were 
prepared by adding the solvent(s) to miltefosine so that a concentration of 6% (w/v) 
(same as Miltex®) was obtained. The mixture was sonicated for 30 minutes after which 
it was left to stir overnight at 32°C. Before application, the solutions were spiked with 
[14C]-miltefosine to a final concentration of 4 µCi/ml and vortexed for 2 minutes. A 
volume of 0.5 ml of donor solution was applied to each cell.  
4.1.8.2  RAPID EVALUATION OF S KIN DAMAGE POST-PERMEATION  
For each tested formulation, two extra Franz diffusion cells were prepared and included 
to test for skin damage after the permeation experiment. After the 48 hours permeation, 
the formulation was removed and 500 µl of a methylene blue-water (1:9) solution was 
applied in the donor compartment. After one hour, the colour of the receptor fluid was 
verified and compared to evaluate skin damage. 
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4.1.8.3  QUANTIFICATION OF AMO UNT OF MILTEFOSINE P ERMEATED 
THROUGH FULL THICKNE SS MOUSE SKIN  
The experiment was set up as described in section 3.1.7.5. The permeation study was 
conducted over a duration of 48 hours. At regular time intervals, 200 µl of receptor 
phase was removed and replaced with fresh PBS at 32°C. For the quantification of 
miltefosine, 100 µl of the sample was transferred in a 96-well flexible Microbeta plate 
and 100 µl of Optiphase™ supermix was added. A standard curve was prepared by 
double-diluting the donor solution in PBS for PG and water and methanol for DMI and 
OSAL, as the latter two solvents are not miscible with water. A blank consisting of 100 
µl PBS or methanol and 100 µl of Optiphase™ supermix was added to each plate. The 
plates were left to incubate on a shaking plate at room temperature for 1 hour. 
Scintillation counting was conducted using a Microbeta2 plate reader equipped with 2 
detectors (Perkin Elmer). 
The cumulative amount permeated per surface area was plotted as a function of time. 
The slope and thus mean flux was calculated by linear regression of the data points 
obtained between 20 and 36 hours following application. Statistical analysis were 
performed using SPSS software version 19.0. 
4.1.8.4  QUANTIFICATION OF THE AMOUNT OF MILTEFOSIN E LEFT ON THE 
SKIN .  
After 48 hours, the remaining donor solution was transferred into a clean vial. The 
remaining fractions on the skin and the donor compartment were removed by carefully 
swiping the surface with a cotton swab, followed by repeatedly pipetting up and down 
with a 1 ml methanol – water solution (3:7(v/v)). This was repeated 3 times. To extract 
the miltefosine absorbed in the cotton, 1ml of a methanol – water solution (3:7(v/v)) 
was added to the recipient that contained the swab. The mixture was left on a shaking 
plate for 5 hours, after which 100 μl was transferred to a flexible Microbeta 24-well 
plate. To quantify the amount of miltefosine, 400 μl of Hionic-fluor™ scintillation fluid 
was added and left to acclimatise before reading with a Microbeta2 plate reader. For 
each donor solution, a standard curve of 12 serial 1:2 dilutions was included and each 
plate also contained 3 methanol – water blanks. The amount of miltefosine in each 
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sample was calculated by linear regression analysis using the miltefosine standard 
curve. Statistical analysis were performed using SPSS software version 19.0. 
4.1.8.5  EXTRACTION AND QUANTI FICATION OF THE AMOU NT OF 
MILTEFOSINE IN THE S KIN  
After dismantling the Franz cell, the skin was transferred to a clean vial and together 
with 1 ml of Solvable™, it was incubated at 50°C and vortexed regularly until a 
homogenous mixture was obtained. A sample of this homogenate was mixed with 
Hionic-fluor™ in a 1:4 ratio followed by analysis using the Microbeta2 plate reader 
(Perkin Elmer). An untreated piece of skin was spiked with a known amount of 
miltefosine to assure no drug breakdown occurred during the extraction procedure and 
was included in triplicate. Also an untreated piece of skin was included in triplicate to 
correct for absorption due to skin components. The amount of miltefosine in each 
sample was calculated by linear regression analysis using the miltefosine standard 
curve. Statistical analysis were performed using SPSS software version 19.0. 
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4.2 RESULTS 
4.2.1 EVALUATION OF ANTI-LEISHMANIAL ACTIVITY  OF MILTEFOSINE  
The ED50 and ED90s of miltefosine against a panel of Leishmania parasites are shown in 
Table 4-4 and ranged from 7.8 to 45.9 µM and 19.5 to 166.3 µM respectively. The rank 
order for the ED50s was L. aethiopica < L. tropica < L. panamensis < L. major < L. 
mexicana. These results were similar to previously obtained sensitivities in our lab159, 246 
except for the ED50 values for L. mexicana. Escobar et al found an ED50 of 6.8 and 10.1 
µM compared to 31.0 and 45.9 µM in this study159. When excluding the results for L. 
mexicana, the rank order was the same in both studies. The difference in ED50s obtained 
for L. mexicana was probably due to the different strains that were used. Escobar et al 
used L. mexicana MHOM/BZ/82/BEL21, while L. mexicana MNYC/ BZ/62/M379 was 
used in this study. The variation in intrinsic susceptibility between and within species is 
not surprising given the molecular and biochemical differences between strains and 
species. Additionally, different test settings might also contribute to differences in 
ED50s obtained
286.  
Amphotericin B was highly active against all species. L. mexicana was less susceptible 
to amphotericin B compared to the other species and again confirmed previously 
obtained results159.  
TABLE 4-4. IN VITRO  ANTI-LEISHMANIAL ACTIVITY AS DETERMINED BY MICROCOPIC COUNTING OF 
LEISHMANIA  INFECTED MACROPHAGES TREATED WITH MILTEFOSINE (30,  10, 3.3 AND 1.1 UM; N= 
NUMBER OF EXPERIMENTS). CYTOTOXICITY AS DETERMINED USING THE FLUORESCENT ALAMAR BLUE.  
Compound n 
Amphotericin B Miltefosine 
ED50 (µM) (95% CI) ED90 (µM) ED50 (µM) (95% CI) ED90 (µM) 
L. tropica 1 
2 
0.07 (0.06-0.07) 
0.08 (0.08-0.09) 
0.29 
0.30 
20.0 (17.4-23.0) 
9.4 (7.78-11.5) 
25.1 
- 
L. major 1 
2 
0.12 (0.11-0.14) 
0.05 (0.04-0.06) 
0.22 
- 
44.9 (26.02-77.3) 
26.6 (21.30-33.2) 
163.1 
29.4 
L. aethiopica 1 
2 
0.12 (0.11-0.12) 
0.11(0.10-0.12) 
0.25 
0.24 
7.8 (6.2-9.8) 
8.0 (7.26-8.7) 
19.5 
22.0 
L. mexicana 1 
2 
0.43 (0.39-0.46) 
0.69 (0.55-0.69) 
1.10 
1.21 
31.0 (28.56-33.7) 
45.9 (36.61-57.5) 
38.0 
102.8 
L. panamensis 1 
2 
0.14 (0.13-0.16) 
0.12 (0.09-0.14) 
0.29 
0.15 
20.0 (16.17-24.7) 
23.1 (20.41-26.2) 
151.3 
166.3 
KB-cells 
THP-1 cells 
   0.7 (0.5-1.0) 
12.9 (7.6-22.0) 
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The ED50 value of miltefosine against THP-1 and KB cells was 12.9 and 0.7 µM 
respectively and indicated that miltefosine was more toxic to KB cells compared to 
THP-1 cells. This was expected because KB cells were already reported to be very 
sensitive to miltefosine (ED50 = 1.6 µM)
287, 288. The cytotoxicity values are in the same 
range compared to the anti-leishmanial activity (ED50 and ED90) which indicated that 
the concentrations required to kill parasites also damage macrophages. In fact when 
using 40 µM as top concentration for miltefosine in the intracellular amastigote-
macrophage assay, clear macrophage damage was observed when evaluating 
microscopically. Ideally, the therapeutic index for a drug is high meaning that there is a 
big difference between the concentration that induces toxicity and the concentration 
required for efficacy. This is not the case for miltefosine. 
4.2.2 SOLUBILITY OF MILTEFOSINE IN DIFFERENT SOLVENTS  
The saturated solubility concentration of miltefosine in different solvents are shown in 
Table 4-5. In general, both methods gave similar results except for the solvent 
propylene glycol. The PG solution saturated with miltefosine was very viscous 
compared to the other miltefosine saturated solvents and it is hypothesized that pipetting 
errors caused deviations when preparing the sample for analysis. The use of a positive 
displacement pipette would allow to correct for this mistake.  
Miltefosine was highly soluble in water and PG, while its solubility in OSAL and DMI 
was approximately 4 and 5 orders of magnitude lower respectively. Miltefosine is an 
ionic compound as it is permanently charged and was therefore expected to be more 
soluble in hydrophilic solvents such as water and PG and less soluble in lipophilic 
solvents such as OSAL. 
TABLE 4-5. SOLUBILITY OF MILTEFOSINE IN PG, H2O, DMI AND OSAL (MEAN, N=3) AS DETERMINED 
USING LC-MS (METHOD 1) OR BY WEIGHT (METHOD 2).  THE SOLUBILITY PARAMETERS WERE 
GENERATED USING MOLECULAR MODELLING PRO. 
 Saturated solubility (mg/ml) 
method 1 
Saturated solubility (mg/ml) 
method 2 
Solubility parameter 
(cal/cm3)1/2 
Miltefosine - - 8.88 
PG 738  1249 - 1342  14.07 
H2O 440  394 - 494  22.97 
DMI 0.005  < 1  9.97 
OSAL 0.036  <1  10.87 
Chapter 4 – Development of a topical miltefosine formulation 
 
 
 
 
85 
 
The solubility parameter of miltefosine was estimated at 8.88 (cal/cm3)1/2. DMI and 
OSAL have a solubility parameter close to miltefosine, whereas the solubility parameter 
of PG and water are higher (Table 4-5). The solubilities of miltefosine in the respective 
solvents are expected to be greater when the solubility parameters are close together289. 
According to this theory, miltefosine should be more soluble in DMI than in water, but 
the contrary was observed. Previous studies have reported similar outcomes and the 
limitations of this theory in formulation design are discussed in the literature53, 290. 
Another explanation might be the fact that miltefosine is an zwitterionic molecule that 
acts as a surfactant and forms micelles (CMCmilt in H2O: 1.1-1.2 µg/ml
291). Ionized 
molecules have a reduced solubility in solvents with low dielectric constant (DMI) and 
high solubility in a solvent with high dielectric constant such as water292.  
4.2.3 DISTRIBUTION COEFFICIENT OF MILTEFOSINE  
The experimental determined distribution coefficient (log D) of miltefosine in water 
buffered at pH 5 was found to be 3.74 (±0.17). In contrast, ChemBioDraw software 
(Perkin Elmer, Coventry, UK) estimates the distribution coefficient at -2.38 indicating it 
is a highly hydrophilic molecule.  
Miltefosine is an amphiphilic molecule composed of a long lipophilic C16 alkane chain 
and a polar phosphocholine group (Figure 4-1). It has surface activity properties and 
will migrate to the interface of non-miscible solvents (octanol and water) to reduce the 
surface tension. Moreover miltefosine spontaneously forms micelles as a result of 
unfavourable interaction between the hydrophobic regions and aqueous solvents. This 
heterogeneous distribution is likely to have interfered with the determination of an 
accurate concentration of the molecule in the two phases when applying the slow 
stirring method to determine the log D. An alternative experimental method to 
determine the distribution coefficient is the HPLC method as described in the OECD 
guidelines293. 
The partition coefficients of the solvents used in this study are shown in Table 4-6. 
When ranked according to increasing lipophilicity, the order is as follows: H2O < PG < 
DMI < OSAL. 
 
Chapter 4 – Development of a topical miltefosine formulation 
 
 
 
 
86 
 
TABLE 4-6. ESTIMATED VALUES FOR THE PARTITION COEFFICIENTS OF THE SOLVENTS. 
Solvent Log Ko/w 
PG -1.06 
H2O -1.38 
DMI 0.07 
OSAL 5.97 
 
4.2.4 SOLVENT MISCIBILITIES  
Miscibilities of two solvents are shown in Table 4-7. OSAL is only miscible () with 
DMI but is immiscible () in water and PG. DMI, PG and H2O are miscible. 
TABLE 4-7. MISCIBILITY OF BINARY SOLVENT MIXTURES. 
 OSAL DMI H2O PG 
OSAL     
DMI     
Water     
PG     
The miscibilities of the ternary mixtures are shown in Figure 4-2. The effects of two 
ternary phase solvent systems on the delivery of miltefosine were tested. The 
compositions (indicated with a pink dot in Figure 4-2) were as follows: OSAL–DMI–
PG (2:5:3) and H2O–DMI–PG (3:4:3). The ratio of the three solvents where chosen so 
that they were away from the miscible/immiscible border. This is also the reason why 
no OSAL–DMI–H2O combination was tested.  
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FIGURE 4-2. MISCIBILITIES OF TERNARY SOLVENT MIXTURES. 
 
4.2.5 COMPARISON OF THE EFFECT OF THE SOLVENTS ON THE 
PERMEATION OF MILTEFOSINE UPON INFINITE DOSE 
APPLICATION  
Ten formulations all containing 6% miltefosine were tested. Four of these formulations 
were applied as suspensions (Table 4-8) because 6% miltefosine exceeded the saturation 
limit. Hence the thermodynamic activity is not the same for all the formulations (Table 
4-8)294-296.  
 
 
 
Miscible 
Immiscible 
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TABLE 4-8. THE COMPOSITION AND SATURATION LEVEL OF THE TEST FORMULATIONS. 
Formulations tested 
Miltefosine 
concentration (w/v) 
Saturated? Yes/no 
(% saturation if known) 
Thermodynamic 
activity 
Single solvent 
H2O 
PG 
DMI 
OSAL 
 
6% 
6% 
6% 
6% 
 
14% 
5% 
Yes 
Yes 
 
<1 
<1 
1 
1 
Binary solvent system 
PG-DMI (1:1) 
H2O-DMI (1:1) 
H2O-PG (1:1) 
OSAL-DMI (1:1) 
 
6% 
6% 
6% 
6% 
 
No 
No 
No 
Yes 
 
<1 
<1 
<1 
1 
Ternary solvent system 
OSAL-DMI-PG (2:5:3) 
H2O-DMI-PG (3:4:3) 
 
6% 
6% 
 
Yes 
No 
 
1 
<1 
 
4.2.5.1  PERMEATION  
Only 4 out of 10 tested formulations resulted in miltefosine permeation through 
BALB/c mouse skin. Three formulations were single solvent mixtures and 1 
formulation was a binary solvent mixture. The cumulative amount of miltefosine that 
permeated per surface area as function of time is shown in Figure 4-3. 
 
FIGURE 4-3. FOR THE 4  OUT OF 10  FORMULATIONS THAT RESULTED IN MILTEFOSINE PERMEATION, THIS 
GRAPH SHOWS THE CUMULATIVE AMOUNT PERMEATED PER SURFACE AREA AS A FUNCTION OF TIME 
(MEAN±SD, N=4). 
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Single solvents. Miltefosine did not permeate when applied in PG, while permeation 
was seen when applied in water, DMI and OSAL. The permeation parameters are 
shown in Table 4-9. A one-way between group analysis of variance was conducted to 
explore the effect of the solvent on the flux of miltefosine through skin. There was no 
statistically significant difference at the p<0.05 level. This is probably due to the high 
variation that was observed because the average miltefosine permeation when applied in 
DMI and OSAL was higher compared to when applied in water. 
The thermodynamic activity of the active compound in its vehicle is the driving force 
for a diffusion across the SC294, 295. Two of the formulations that gave permeation 
(OSAL and DMI) were applied as a suspension and thus the thermodynamic activity 
was equal to 1. Consequently the thermodynamic activity for the miltefosine in water or 
PG solution, that were only at 14% and 5% of the saturated solution respectively, was 
considerably lower than the DMI and OSAL formulation. This might explain why the 
miltefosine permeation was lower when applied in PG or water compared to DMI and 
OSAL.  
The permeability coefficients (Kp) for the water formulation was statistically significant 
lower compared to Kp for the DMI and OSAL formulation. This indicated that 
miltefosine when formulated in water had a low affinity for the skin but a high affinity 
for the vehicle as was reflected by the high solubility of miltefosine in water. Moreover 
the high permeability coefficients for miltefosine in DMI and OSAL indicated a high 
affinity for the skin and favoured partitioning into the BALB/c skin.  
TABLE 4-9. SKIN PERMEATION PARAMETERS OF MILTEFOSINE AND THE INFLUENCE OF CHES (H2O, 
DMI,  OSAL OR DMI-OSAL (1:1)) (MEAN ± SD (N=4)). 
6% miltefosine in H2O DMI OSAL OSAL-DMI 
Permeation parameters 
Jss (µg/cm2/h) 
tlag (h) 
Kp (cm/h) 
 
3.1±2.4 
16.2±2.1 
7.1E-06±5.4E-06 
 
16.6±5.6 
18.0±4.7 
2.7±1.3 
 
15.6±12.4 
21.0±0.5 
0.6±0.4 
 
0.4±0.2 
5.2±4.1 
0.02±0.01 
Binary solvent mixtures. The OSAL-DMI formulation was the only binary solvent 
mixture that was applied as a suspension and thus had a thermodynamic activity of 1. 
There was no statistically significant difference in miltefosine flux when compared to 
the single solvent mixtures water, DMI and OSAL (one-way ANOVA; p>0.05). The lag 
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time for this binary solvent formulation was statistically significant lower compared to 
the single solvent formulations (one-way ANOVA; p<0.05). The Kp for miltefosine 
applied in this OSAL-DMI formulation was significantly lower than the DMI 
formulation and thus indicated a relatively lower affinity for the skin (one-way 
ANOVA; p<0.05).  
When ranking the flux of miltefosine through skin for the different vehicles, the order 
from high to low was DMI > OSAL > H2O > OSAL-DMI (1:1). The flux obtained from 
the binary solvent system is considerably lower compared to the single solvent systems 
but there is no statistically significant difference. Hence, it could be concluded that there 
was no synergetic effect obtained for the flux of miltefosine through mouse skin when 
using a combination of solvents. This was confirmed by other studies that had 
investigated the effect of a combination of solvents on the permeation of drugs and had 
found that not all combinations showed additional or synergetic effects297, 298. 
Based on the cumulative amount that had permeated, it could be stated that only a very 
low fraction of the drugs had permeated for all formulations over 36 hours (<2%). Due 
to an increase in skin permeability 36 hours after application of the formulations, an 
increase in permeation was seen for most formulations in particular for the miltefosine 
in water formulation. This was correlated to the methylene blue test as the receptor 
phase for most formulations had coloured slightly blue, except for the water-miltefosine 
formulation where a heavy blue coloration of the receptor phase was observed. This was 
not unexpected as surfactants and more in particular ionic surfactants such as 
miltefosine are known skin irritants and were reported to damage the skin.  
Research has shown that surfactants cause protein denaturation299 and swelling of the 
stratum corneum300 through keratin interaction. They also have the ability to solubilise 
and deplete lipids from the stratum corneum79. Furthermore contact of epidermal 
keratinocytes with surfactants triggered the release of inflammatory mediators301. All 
these mechanisms contribute to skin barrier impairment302 and sometimes enhancement 
of permeation of drugs303.  
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In addition, Alonso et al showed an increased fluidity of the intercellular lipids of the 
SC upon contact with miltefosine304. The changes occurred at the interface with the 
polar heads and the lipophilic regions of the lipids and suggested that miltefosine 
functions as an acyl-chain spacer. This would suggest that miltefosine on its own 
functions as a chemical penetration enhancer.  
4.2.5.2  MASS BALANCE  
The results of the mass balance study are visualised in Figure 4-4 and the values are 
shown in Table 4-10. Total recovery ranged from 76%-102% which is slightly below 
the generally accepted recovery of 100±20%. This might be explained by the relatively 
high limit of quantification for these radiolabeled assays where the kinetic energy of 
radioactive nuclei (14C-miltefosine) is transformed into light energy (fluorophore) that is 
then quantified. In contrast, direct detection methods for example HPLC-UV or LC-MS 
do not require intermediate steps causing loss or quenching of the signal and would 
therefore be more accurate, allowing a more sensitive drug detection.  
 
FIGURE 4-4. THE RESULTS OF THE MASS BALANCE STUDY FOR THE 10  TESTED FORMULATIONS (MEAN; 
N=4).   
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TABLE 4-10. MASS BALANCE RESULTS FOR THE MILTEFOSINE FORMULATIONS TESTED (MEAN ± SD 
(N=4)). 
 
On skin 
(%) 
In skin 
 (%) 
Through skin 
 (%) 
Total Recovery 
(%) 
Single solvent 
H2O 
PG 
DMI 
OSAL 
 
89 ± 10 
76 ± 7 
99 ± 3 
97 ± 10 
 
0.7 ± 0.3 
0 
1.4 ± 0.9 
0.5 ± 0.7 
 
1.1 ± 1.2 
0 
0.8 ± 0.6 
3.4 ± 2.8 
 
91 ± 12 
76 ± 3 
102 ± 3 
101 ± 6 
Binary solvent system 
PG-DMI (1:1) 
H2O-DMI (1:1) 
H2O-PG (1:1) 
OSAL-DMI (1:1) 
 
82 ± 4 
86 ± 7 
77 ± 3 
79 ± 11 
 
1.3 ± 1.0 
0 
0.5 ± 1.0 
0.9 ± 0.3 
 
0 
0 
0 
0 
 
84 ± 3 
86 ± 7 
77 ± 4 
80 ± 9 
Ternary solvent system 
OSAL-DMI-PG (2:5:3) 
H2O-DMI-PG (3:4:3) 
 
88 ± 8 
86 ± 11 
 
0 
0 
 
0 
0.3 ± 0.5 
 
88 ± 8 
86 ± 9 
As expected, the majority of the drug for all formulations was found on the skin. 
Furthermore only small fractions of miltefosine ranging from 0.48-1.37% were found in 
the skin. The differences were not statistical significant probably due to the large 
standard deviation (one-way ANOVA; p<0.05). For 4 formulations, no miltefosine was 
detectable in the skin (PG, H2O-DMI, and the two ternary phase solvent systems). This 
was not unexpected as miltefosine is an ionised compound that shows little affinity for 
lipophilic vehicles. The SC, composed of lipid bilayers seems to be a major barrier for 
miltefosine permeation. 
 
Chapter 4 – Development of a topical miltefosine formulation 
 
 
 
 
93 
 
4.3 CONCLUSIONS  
This chapter described how we evaluated the permeation of miltefosine when applied 
on the skin in different vehicles. Four solvents, H2O, DMI, PG and OSAL were chosen 
based on their physico-chemical properties and previously reported effects on 
percutaneous drug permeation. The solubility of miltefosine in these solvents was 
determined and indicated that miltefosine exhibited high solubility in water and PG, but 
low solubility in DMI and OSAL. The miscibilities of the solvents were evaluated and 
indicated that OSAL was not miscible with water and PG. DMI, PG and water were 
miscible. 
In a first permeation assay, miltefosine was applied on the skin in single solvent 
vehicles. No miltefosine permeation was detected for the PG formulation, whereas 
permeation was detected when it was applied in water, DMI and OSAL. The flux 
obtained for the OSAL formulation was similar to that of the DMI formulation. Both 
were approximately 5-fold higher than the flux obtained for the water formulation, 
however this difference was not statistically significant. The permeability coefficient 
indicated a significantly lower affinity of miltefosine for the skin when applied in water 
compared to DMI and OSAL. This was expected because miltefosine exhibited a high 
solubility in water, favouring retention of miltefosine in the vehicle.  
OSAL, DMI and water were then combined in miscible binary and ternary mixtures and 
consequently the influence of combination vehicles on the permeation of miltefosine 
was tested. Out the 6 formulations tested, only the vehicle containing equal amounts of 
DMI and OSAL had led to miltefosine permeation. However the flux of miltefosine 
permeation for the binary solvent mixture was 40 times lower than the flux obtained 
when using DMI or OSAL alone. This indicates that the combination of solvents does 
not always lead to permeation enhancement.  
Furthermore, this study showed that regardless of the formulation, only very low 
concentrations of miltefosine were found in the skin. This was probably due to its low 
affinity for the skin as the compound is ionised. 
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4.4 FUTURE WORK  
In this study, the solvents were evaluated using infinite dose applications. However in 
clinical settings, a topical formulation is often applied in a finite dose and depletion of 
solvent and drugs will influence the skin disposition and permeation. Furthermore, mouse 
skin is different from human skin for example mouse skin counts more hair follicles and 
the composition of intercellular lipid mixtures is different. Therefore, the next step would 
be to repeat the permeation and mass balance studies using human skin and finite dose 
applications. Quantification of the amount of miltefosine extracted from the skin upon 
finite formulation application could be linked to the ED90 values obtained for the 
different strains of Leishmania parasites. 
Finite dose application studies require a very sensitive method of analysis. Radiolabelled 
studies require an intermediate step where viscous scintillation fluid is added to the 
analytical sample introducing more error. A more sensitive detection method such as LC-
MS/MS should be developed.  
Since we have shown that miltefosine permeates, an in vivo study where miltefosine is 
applied in the single solvents OSAL and DMI will be conducted:  
 To verify if any of the single solvent formulations allow permeation of 
miltefosine in a sufficient amount to kill Leishmania parasites and cure CL in our 
in vivo model; 
 To verify if our in vitro permeation data confirm in vivo results; 
 To see if the formulation is well tolerated in BALB/c mice; 
 To compare how these results relate to pharmacokinetic parameters. 
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5 DRUG DISCOVERY–BENZOXABOROLES FOR A 
TOPICAL CL TREATMENT  
Please note that the chemical structures of the compounds described below are not 
shown in this thesis as they are subject to confidentiality agreements prior to patent 
evaluation. All compounds were given an LSH number that is different from the Anacor 
Pharmaceuticals number. 
5.1 GENERAL BACKGROUND  
A literature review with the main search criteria for compounds with (i) activity against 
Leishmania parasites or related kinetoplastids, (ii) favourable physico-chemical 
properties to permeate into the skin, (iii) novelty and (iv) availability, was conducted. A 
relatively new group of compounds, the benzoxaboroles were identified as possible 
candidates for a topical CL formulation.  
5.1.1 ACTIVITY OF THE BENZOXABOROLES  
In the 1970s, boron containing drugs were found to react with the serine hydroxyl in the 
active site of certain enzymes resulting in potent inhibition of these enzymes, including 
β-lactamases305-308 and proteasomes309-312. Proteasomes are involved in the degradation 
of misfolded, damaged or no longer useful proteins. In vitro studies have shown that 
their inhibition resulted in apoptosis induction and growth inhibition in multiple 
myeloma cells in vitro312. Bortezomib, a boron containing proteasome inhibitor was 
FDA approved for the treatment of multiple myeloma cancers in 2003. 
Benzoxaborole compounds (Figure 5-1) are different from previously synthesised boron 
based compounds because the boron atom is incorporated in a ring system fused to an 
aromatic ring313. As other boron containing compounds, the benzoxaboroles were found 
to inhibit β-lactamases and proteasomes but they also exhibited activities against 
bacteria, fungi and protozoans such as Trypanosoma brucei and Plasmodium 
falciparum313-318.  
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FIGURE 5-1. GENERAL CHEMICAL STRUCTURE OF BENZOXABOROLES. 
In Streptococcus pneumoniae, the benzoxaborole ZCL039 inhibits leucyl-tRNA 
synthetase (LeuRS), an enzyme that holds an important role in cellular translation317. 
The same enzyme in dermatophytes is targeted by tavaborole, a drug used to treat 
onychomycoses. Tavaborole blocks tRNA translocation and blocks protein synthesis 
leading to cell death319.  
Compounds belonging to another benzoxaborole class, the 6-carboxamides have shown 
in vitro and in vivo activity against T. brucei, the causative agent of human African 
trypanosomiasis (HAT). Moreover, they cured mice with infection of the central 
nervous system indicating that the drugs were able to pass the blood brain barrier. An 
oral treatment for human African trypanosomiasis (HAT) containing the benzoxaborole 
SCYX-7158 is in Phase 1 clinical development7.  
Due to parasite similarities, compounds active against T. brucei were also screened 
against T. cruzi, the causative agent of Chagas disease. Amongst an array of 
compounds, the 6-amido oxaborole compounds showed potent in vitro activity and the 
lead compound, SCYX-6759 demonstrated complete removal of blood parasitaemia in 
mice314, 320.  
A phenotypic screening of a benzoxaborole library against Plasmodium falciparum 
identified potent compounds (defined as IC50 < 1µM) belonging to five chemical 
benzoxaborole classes315, 316. Further tests such as in vitro potency, cytotoxicity, drug-
linked-bioavailability predictors and structure-activity relationship (SAR) analysis 
narrowed the selection to two lead scaffolds for further anti-malarial drug discovery 
research316, 321, 322.  
Finally, a high throughput screening was conducted to identify benchmark compounds 
to treat VL. The in vitro inhibitory activity of more than 2000 compounds were tested 
against L. donovani amastigotes in THP-1 cells and resulted in several hits (IC50 < 1.1 
µM) (Unpublished data). 
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The majority of the bioactive benzoxaboroles are relatively small molecules (Mw 
<500g/mol) with a log P between 1-3 and few H-bond donors minimizing interactions 
with skin components during permeation. In fact, tavaborole (AN2690; Figure 5-1, R1 = 
H and R2 = F) is the active ingredient in a recently-FDA-approved topical treatment for 
onchychomycosis, Keridyn™4,5 and AN2728, an investigational topical anti-
inflammatory benzoxaborole is in development for the treatment of mild-to-moderate 
atopic dermatitis and psoriasis6. Results from the phase 2 clinical studies indicated a 
good dermal penetration profile323, 324.  
The aim of this drug discovery project was to evaluate compounds from different 
structural classes of benzoxaboroles, for their anti-leishmanial activity and suitability 
for topical treatment of CL.  
The experiments discussed in this chapter were mainly conducted at SCYNEXIS Inc. 
(Research Triangle, NC) as part of a collaboration with Anacor Pharmaceuticals Inc. 
(Palo Alto, CA). Some of the work was performed by other team members. This is 
clearly indicated in the sections concerned.  
5.1.2 FROM DRUG DISCOVERY TO A TOPICAL TREATMENT FOR CL  –  
STRATEGY  
During the pharmaceutical profiling in the early stages of drug discovery, multivariate 
techniques are used to assess the physicochemical and physiological properties that 
allow prediction of the performance of the test compounds against hurdles that are to be 
faced by the pharmaceutical agent. The information is used to optimise and select lead 
compounds. It is important to highlight that the required drug profile depends on the 
route of administration.  
The timeframe during which the data are provided should be consistent with the fast-
paced decisions of the early discovery stage. Figure 5-2 indicates the experiments that 
were conducted to profile an array of benzoxaborole compounds and the stages at which 
compounds were eliminated because they exhibited unfavourable properties for a 
topical treatment. 
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FIGURE 5-2. FROM DRUG DISCOVERY TO A TOPICAL TREATMENT FOR CL –  STRATEGY. 
 
 
In vivo mouse studies 
General pharmacokinetics: 
1. Log P (or D) 
2. Solubility 
3. MDR1-MDCK 
Skin pharmacokinetics: 
1. Skin stability 
2. Skin binding 
3. Reconstructed human 
epidermis 
Anacor Pharmaceuticals supplied 25 benzoxaborole 
compounds for evaluation. 
Screening against a panel of five Leishmania spp. that cause CL. 
 
In vitro activity 
18 compounds were subjected to surrogate in vitro ADME tests. 
In vitro ADME 
Three compounds exhibiting acceptable permeation properties were further evaluated. 
Franz cell permeation studies 
Mass balance studies 
Skin disposition profile 
Literature review 
Three lead compounds were selected for in vivo studies. 
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5.1.2.1  ANTI-LEISHMANIAL ACTIVITY  TESTING  
Anacor Pharmaceuticals Inc. provided 25 benzoxaboroles for in vitro anti-leishmanial 
activity testing against a range of five Leishmania species. Species selection was based 
on the geographical distribution, symptoms upon infection and the abundance of 
infections they cause. L. tropica and L. major were selected because together they cause 
the majority of Old World CL. L. aethiopica is the main CL causing agent in Ethiopia 
and causes both LCL and DCL325, 326. L. mexicana and L. panamensis are two New 
World species that belong to different subgenera Leishmania and Viannia respectively. 
L. mexicana can cause DCL, an anergic form that is difficult to treat with frequent 
relapses whereas L. panamensis can lead to MCL also difficult to treat.  
The in vitro assay could not be optimized for L. braziliensis, the principal agent of 
mucocutaneous leishmaniasis. Insufficient infection rates, typically 40% or lower were 
obtained or abundant extracellular promastigotes made microscopic evaluation of 
infection difficult. This species was therefore not included in the screenings. 
Based on the obtained data, 18 compounds belonging to four different chemical 
subclasses of benzoxaboroles were selected for surrogate absorption, distribution, 
metabolism and excretion (ADME) studies. These time-sensitive assays allow a 
preliminary evaluation of simple physicochemical and biophysical parameters that are 
important to profile the disposition of the drug within the body.  
Figure 5-3 (A) shows the general structure of benzoxaboroles. The subclasses are: 
(B) Benzoxaborole-5-amides 
(C) Pyrazole-carboxamides 
(D) Simple benzoxaborole 6-carboxamides  
(E) Benzoxaborole-oxaborininols 
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FIGURE 5-3. A: GENERAL STRUCTURE OF BENZOXABOROLES, B-D ARE CHEMICAL SUBCLASSES. 
5.1.2.2  IN VITRO ADME  ASSAYS .   
General physicochemical properties. Computationally and in vitro experimentally 
derived general physico-chemical properties include H-bond donors and acceptors, 
solubility, log P and general permeability using Madin-Darby canine kidney cells 
transfected with the human mdr1 gene (MDCK-MDR1). 
 The importance of the partition coefficient, aqueous solubility, molecular 
weight, melting point and H-bond donors was already highlighted in the 
Introduction (1.3.1.1).  
 The MDCK-MDR1 assay. The MDCK-MDR1 assay was used to evaluate the 
passive (transcellular) permeability of the test compounds while highlighting 
potential permeability issues. This simple model is composed of a monolayer of 
cells linked by tight junctions and is used as a surrogate for the multi-layered 
reconstructed human epidermis (RHE) model in the early stages of drug 
discovery as it is considerably less expensive. Furthermore, this test allows 
identification of P-glycoprotein (Pgp) substrates. Pgp is an efflux transporter 
that is reported to reduce the intracellular concentration of numerous drugs327, 
328. In man, Leishmania parasites survive and divide inside macrophages 
meaning that Pgp substrate drugs might potentially be less active compared to 
drugs that are not Pgp substrates as they are transported from the inside to 
outside the marcophages.  
A. 
B. C. 
D. E. 
E. 
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Skin pharmacokinetics. In a second stage, more skin specific biochemical characteristics 
such as drug stability and binding in skin homogenate supernatant and permeation 
through RHE were evaluated. 
 Drug stability. Most attention in topical treatment development goes to assuring 
the drug permeates through the SC and reaches the target. Drug degradation by 
metabolising skin enzymes is reported to influence permeation but is often 
neglected in the early stages of development. Kao et al evaluated the metabolism 
of testosterone and benzopyrene during permeation through skin from different 
species, including mouse and human, and detected a variety of drug metabolites 
in the receptor phase329. Further research using other drugs confirmed the 
presence of metabolic activity in the skin330-333.  
For this project the stability of the compounds was tested in full-thickness 
mouse skin homogenate supernatant. The epidermis appears to be the main site 
of enzyme activity331, 334. This is consistent with findings that suggest that 
keratinocytes contain the highest amount of drug metabolising enzymes 
compared to other skin cells335, 336. Skin supernatants have previously been used 
to investigate drug stability332. 
 Drug binding to skin components. It is important to determine the fraction of 
unbound drug present in the skin as it is only the free drug which is available to 
exert anti-parasitic activity. The device used in this project to measure the 
unbound drug fraction is based on equilibrium dialysis and allows the evaluation 
of the affinity of a drug for skin macromolecules. Essentially two chambers, one 
containing skin homogenate supernatant and drug and the other containing PBS 
are separated by a membrane with a particular molecular weight cut-off. After 
equilibration and analysis of the drug concentration in each chamber, the 
unbound drug fraction can be calculated. Equilibrium dialysis has already been 
shown to accurately predict the binding of drugs to tissues such as brain, muscle 
and adipose tissue337.  
 Permeation prediction using reconstructed human epidermis. Artificial skin 
tissue is grown by seeding skin keratinocytes with dermal growth factors and 
leaving them to differentiate at the air-liquid interface. Three RHEs are most 
commonly used for drug permeation testing: EpiSkin® (L’Oréal), SkinEthic® 
(SkinEthic has now been acquired by L’Oréal) and EpiDerm® (MatTek). While 
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the RHEs are similar to human epidermis in terms of structure and composition, 
they are more permeable to drugs338. The permeation of two model compounds, 
testosterone and caffeine through the 3 RHE’s were investigated and compared. 
The Epiderm® model was the only one to show similar caffeine permeation 
compared to human epidermis but all models were able to reproduce the same 
rank order in permeation as when using human epidermis339. In addition a 
slightly lower variability in permeation results was observed compared to 
excised skin340. It should also be mentioned that these models contain 
metabolising enzymes341. In this project, the permeation of the test compounds 
was evaluated using the Epiderm® model. 
5.1.2.3  IN VITRO  PERMEATION STUDIES USING FRANZ D IFFUSION CELLS .   
The data were analysed and 3 compounds were selected for more stringent permeation 
tests using full-thickness BALB/c mouse skin. Full-thickness skin was preferred over 
separated epidermis as although the stratum corneum is considered the main barrier to 
drug permeation, the largely aqueous dermis can act as a significant barrier for 
lipophilic drugs. The skin disposition profile of the benzoxaborole compounds was 
established by analysing the amount of drug left in and on the skin. These results were 
combined with the in vitro ADME study results and three lead compounds were 
selected for in vivo evaluation against CL in BALB/c mice.  
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5.2 MATERIALS AND METHODS  
5.2.1  TEST COMPOUNDS  
The test compounds were synthesised by Anacor Pharmaceuticals Inc. and SCYNEXIS 
Inc. (Research Triangle, NC) and submitted to LC-MS* and 1H-NMR* analysis for 
identification and characterisation before use. One mM stock solutions in dimethyl 
sulfoxide (DMSO) were prepared and used for the in vitro absorption, distribution, 
metabolism and excretion experiments. 
* The chemical synthesis team at Anacor Pharmacueticals Inc. and SCYNEXIS conduct these assays 
as part of their standard compound characterisation. The analyses were not conducted by the PhD 
candidate. 
5.2.2 REAGENTS AND OTHER DRUGS  
HPLC grade solvents were purchased from Fisher Scientific (Pittsburgh, PA). Formic 
acid (≥98% purity, Fluka), caffeine, testosterone, 1-octanol, high grade vacuum silicone 
grease (Dow Corning) were acquired from Sigma-Aldrich (St. Louis, MO). Ammonium 
formate (99% purity, Alpha Aesar) was purchased from VWR International, LLC (West 
Chester, PA). Miglyol 840 (propylene glycol dicaprylate / dicaprate) was obtained from 
Sasol Germany GmbH (Witten, Germany). Phosphate buffered saline (PBS) was 
supplied by Gibco (Invitrogen Corporation, Carlsbad, CA) as well as the Dulbecco’s 
modification of Eagle’s medium with GlutaMAX, the trypsin-EDTA and the Fetal 
Bovine Serum. Penicillin-Streptomycin solution, Hank’s balanced salt solution and 
HEPES buffer were obtained from Sigma Aldrich.  
5.2.3 LEISHMANIA PARASITES AND CELL CULTURE  
MDCKII-hMDR1 cells (Netherlands Cancer Institute, Amsterdam, Netherlands) were 
maintained in Dulbecco’s Modified Eagles Medium (DMEM) and KB cells in RPMI-
1640 medium supplemented with L-glutamine and 10% HiFCS. Both human-derived 
cell lines were left in an incubator at 37ºC and 5% CO2 and passaged to new medium 
once a week (1/10 ratio). The parasite cultures were maintained as explained in section 
4.1.3. 
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5.2.4  IN VITRO SENSITIVITY ASSAYS AGAINST LEISHMANIA PARASITES  
5.2.4.1  INTRACELLULAR AMASTIGOTES  
Mouse peritoneal macrophages (PEM) were isolated from CD-1 mice (Charles River, 
Margate, UK) by abdominal lavage with RPMI-1640 medium containing 1% penicillin 
and streptomycin. The collected cells were washed, re-suspended and seeded in 16 well 
Lab-Tek™ plates (VWR International, Leicestershire, UK) in RPMI-1640 
supplemented with 10% HiFCS at a density of 4x104 per well. After 24 hours 
incubation at 37°C and 5% CO2/95% air mixture, the adhered PEMs were infected with 
stationary phase promastigotes at a ratio of 3 (for L. tropica and L. major) or 5 (for L. 
mexicana, L. aethiopica and L. panamensis) promastigotes to 1 macrophage and 
maintained at 34°C in a 5% CO2/95% air mixture. After 24 hours, the cultures were 
washed to remove extracellular promastigotes and one slide was fixed with methanol 
and stained with Giemsa to determine the initial level of infection. If a sufficient level 
of infection (i.e. > 75%) was obtained, DMSO - oxaborole solutions over a range of 30, 
10, 3 and 1 μM were added in quadruplicate at each concentration. Miltefosine and 
amphotericin B were included as control drugs. After 72 hours incubation, all slides 
were methanol-fixed and Giemsa-stained. The percentage inhibition was determined 
microscopically (400x magnification) by counting the infected macrophages in drug-
treated cultures. This was only conducted if the 72 hours untreated control slide showed 
at least 75% infection. The Hill coefficient, ED50 and ED90 values were determined by 
non-linear sigmoidal curve fitting (variable slope) using Prism Software (GraphPad, 
Surrey, UK). 
5.2.4.2  PROMASTIGOTES  
20 mM drug stock solutions were prepared by dissolving the benzoxaborole compounds 
in DMSO. The final drug concentrations were obtained by serially diluting (1:3) the 
stock solutions in RPMI-1640 medium plus 10% heat-inactivated fetal calf serum 
(HiFCS). Amphotericin B and miltefosine were included as positive controls and each 
plate contained a 72 hours control, a DMSO and a medium only control. 
Exponential phase promastigotes were centrifuged at 2100 rpm for 10 min (4°C) and re-
suspended in RPMI-1640 medium supplemented with 10% HiFCS to a 1x107/ml 
density. 100 μl of promastigote suspension was added to the 100 μl of benzoxaborole 
solutions reaching final oxaborole concentrations of 300-0.27 μM. The plates were left 
to incubate at 26°C for 72 hours.  
Chapter 5 – Drug discovery – benzoxaboroles for a topical CL treatment 
 
 
 
 
105 
Four hours before the fluorescence reading to measure cell viability, 20 μl of Alamar 
Blue® solution (Invitrogen™, Thermo Fisher, Loughborough, UK ) was added to each 
well. The fluorescence (λext/em 544/590 nm, cut off 570 nm) was read using a 
Spectramax™ M3 microplate reader (Molecular Devices, California, US) and the EC50 
values were determined by non-linear sigmoidal curve fitting (variable slope) using 
Prism Software (GraphPad, Surrey, UK). 
5.2.5 CYTOTOXICITY TESTING AGAINST KB  CELLS  
KB cells were harvested, washed and counted in serum-free medium. The cell density 
was adjusted to 5 x 104 / ml in RPMI-1640 supplemented with 10% HiFCS. 100 µl of 
the cell suspension was plated in each well of a 96-well plate followed by incubation at 
37C and 5% CO2 for 24 hours.  
Stock drug solutions of 20 μM in DMSO were prepared and diluted to 600 nM in 
RPMI-1640 with 10% HiFCS. 300 nM was the highest concentration tested and five-
fold serial dilutions were performed across the plate. Podophyllotoxin was included as a 
positive control drug. Untreated controls and blanks, containing medium only were also 
included. Each test compound was tested in triplicate. Plates were incubated for a 
further 72 hours at 37C and 5% CO2.  
After incubation, the wells were assessed microscopically and 20 μl Alamar Blue® was 
added to each well. The plates were incubated for a further 2-4 hours before reading at 
λext/em 544/590 nm (cut off 570 nm) in a Spectramax™ M3 Plate reader. EC50 values 
were calculated by non-linear sigmoidal curve fitting (variable slope) using Prism 
Software (GraphPad, Surrey, UK). 
5.2.6  IN VITRO ADME  STUDIES–GENERAL PHARMACOKINETIC 
PREDICTIONS  
5.2.6.1  COMPUTATIONALLY DERIV ED PHYSICOCHEMICAL P ROPERTIES  
The following descriptors of the test compounds, molecular weight, aqueous solubility 
and number of H-bond donors present were estimated using modelling software 
ChemBioDraw Ultra 13.0 (PerkinElmer, Waltham, MA). 
5.2.6.2  SOLUBILITY IN PBS  (PH  7.4)   
For the solubility determination, 200 μl of PBS (pH 7.4) was transferred into an 
Eppendorf tube. Excess drug was added and the vial was left to shake (800 rpm) at 
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32°C for 48 hours. Subsequently, the mixtures were centrifuged at 13000 rpm for 15 
minutes (32°C). An aliquot of the supernatant was removed and analysed by LC-
MS/MS. Due to the limited availability of the drug, the study was only conducted once 
per test compound. Therefore the results should be considered as an indication rather 
than as an absolute value. 
5.2.6.3  DETERMINATION OF LOG D 
Equal volumes of octanol and PBS (pH 7.4) were left to equilibrate on a shaking plate at 
32°C for 48 hours. The test compound was dissolved in 1-octanol at a concentration of 
1 μg/ml and left to equilibrate with an equal volume of PBS on a shaking plate at 32°C 
for 48 hours. For the experiment to be successful the amount of drugs in each phase 
should not exceed 10% of the solubility limit of that compound in each phase. Aliquots 
of each phase were taken and diluted in mobile phase followed by LC-MS/MS analysis. 
The experiment was conducted in triplicate. The distribution coefficient was calculated 
as shown in Equation 6: 
𝐥𝐨𝐠 𝐃 (𝐩𝐇 𝟕. 𝟒) = 𝐥𝐨𝐠 [
[𝐬𝐨𝐥𝐮𝐭𝐞]𝐨𝐜𝐭
[𝐬𝐨𝐥𝐮𝐭𝐞]𝐩𝐛𝐬
𝐢𝐨𝐧 +  [𝐬𝐨𝐥𝐮𝐭𝐞]𝐩𝐛𝐬
𝐧𝐞𝐮𝐭𝐫𝐚𝐥
] 
EQUATION 6 
5.2.6.4  MELTING POINT DETERMINATION BY DIFFERENTIAL SCANNING 
CALORIMETRY  
Differential scanning calorimetry (DSC) is a technique that measures heat flow to and 
from a sample as a function of time and temperature and is used to determine the 
melting point of the sample. DSC analysis were conducted in duplicate and only for the 
3 lead compounds because it is a destructive method that requires a drug sample in the 
mg range which is quite high for drugs in the developmental stage.  
Before starting the experiment, the instrument was calibrated with indium using the 
Tzero™ calibration wizard. Non-hermetic aluminium Tzero pans (TA instruments, 
Herts, UK) were loaded with the sample and placed in the Q2000 DSC instrument (TA 
instruments, Herts, UK) together with an empty aluminium pan that served as a 
reference. Nitrogen at a flow rate of 50 ml per minute was used as a purge gas. The 
samples were left to equilibrate at -20˚C followed by increasing the temperature to 
300˚C in increments of 10˚C. The results were analysed using the Universal Analysis 
2000 version 4.7A (TA instruments LLC). 
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5.2.6.5  EVALUATION OF PERMEAB ILITY AND PGP-MEDIATED EFFLUX 
TRANSPORT USING THE MDCK-MDR1  ASSAY *  
* This assay was conducted by Dr. Seong Hee Park and Mrs. Sara Schock (Scynexis, Research 
Triangle Park, Durham, NC) and not by the PhD candidate. 
For the experiment (Figure 5-4), the cells were seeded in the apical chamber of a 12-
well Transwell® plate (Corning Inc., Lowell, MA) at a density of 6.6x106 cells/well and 
1.5 mL of medium was applied in the basolateral chamber. After 24 hours, the non-
adhered cells were washed away and new medium was applied in both chambers. The 
cells were left for another 48 hours at 37°C to form confluent monolayers.  
Prior to the addition of the test compounds, the cell culture medium was removed and 
replaced with transport medium that consists of Hanks’s balanced salt solution with 24 
mM of glucose and 24 mM of HEPES buffer. The integrity of the monolayers was 
assured by measuring the trans-epithelial resistance (TEER) for each insert (TEER > 
160 Ω cm2). Assays were performed in triplicate by adding 3 μM drug solutions (1 mM 
DMSO stock solutions diluted in transport medium) in the absence or presence of 2 μM 
GF918 (a potent Pgp inhibitor342) in the transport buffer of the apical chamber. 
Reference drugs for transcellular transport and Pgp efflux, propranolol and amprenavir 
respectively were included in the assay. The Transwell® plates were incubated on a 
shaking plate (160 rpm) at 37°C and 5% CO2 for 1 hour. After incubation, aliquots from 
both chambers were removed for analysis by LC-MS/MS. 
 
FIGURE 5-4. SCHEMATIC REPRESENTATION OF THE MDCK-MDR1  ASSAY FOR PERMEATION. 
Values for mass balance, apparent permeability value for the apical to the basolateral 
side (Papp) (Equation 7), apparent permeability value for the apical to the basolateral in 
presence of GF+918 (Papp+GF918) (Figure 5-5), and the absorption quotient (AQ) 
(Equation 8) were calculated for each compound343-345. Test compounds with an AQ ≤ 
Basolateral (B) 
Apical (A) 
AB 
BA 
LC-MS analysis 
MDCK-MDR1  
cell monolayer 
Porous membrane 
Pgp transporter 
Test compound 
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0.3 were considered no Pgp substrates, while AQ > 0.3 were considered Pgp 
substrates344, 345. Acceptance criterion for mass balance was 70–120%.  
𝑷𝒂𝒑𝒑 =  
𝒅𝑸 𝒅𝒕⁄
𝑪𝟎 × 𝑨
 
EQUATION 7 
𝑨𝑸 =  
𝑷𝒂𝒑𝒑+ 𝑮𝑭𝟗𝟏𝟖  −  𝑷𝒂𝒑𝒑
𝑷𝒂𝒑𝒑+ 𝑮𝑭𝟗𝟏𝟖
 
EQUATION 8 
 
 
 
 
 
FIGURE 5-5. SCHEMATIC REPRESENTATION OF THE EFFECT OF A PGP GLYCOPROTEIN ON THE 
PERMEATION OF A PGP SUBSTRATE DRUG. 
 
5.2.7 IN VITRO ADME  STUDIES–SKIN PHARMACOKINETICS 
PREDICTION  
5.2.7.1  SKIN HOMOGENATE SUPER NATANT PREPARATION  
For the preparation of the homogenate, 20 ml of ice-cold Dulbecco’s modified PBS (pH 
7.4) was added to fine pieces of approximately 2 g of shaved dorsal full-thickness 
BALB/c skin (Bioreclamation LLC., Westbury, NY). The mixture was homogenized 
using an OMNI probe homogenizer (Kennesaw, GA) and centrifuged for 10 minutes at 
800g to remove big pieces. The protein content of the supernatant was determined using 
the Pierce BCA protein assay kit (Pierce, Rockford, IL) and adjusted to 2.5 mg/ml. The 
supernatant was stored at -80°C until further use.  
5.2.7.2   IN VITRO DRUG STABILI TY IN MOUSE SKIN HOMOGENATE 
SUPERNATANT  
The stability of the compounds was measured at two different protein concentrations 
namely 0.6 mg/ml and 2.5 mg/ml. Each compound (10 μM) was incubated in mouse 
skin homogenate on a shaking plate at 32°C. An aliquot of the fortified supernatant was 
Apical 
Basolateral 
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taken at 0, 10, 20, 30 minutes, 1 hour and 2 hours and quenched with 4 volumes of ice-
cold methanol containing 0.1% formic acid. After centrifugation at 3000xg for 10 
minutes at 15°C, the obtained supernatant was analysed for the parent compound by 
LC-MS/MS. Prism 6 (GraphPad, La Jolla, CA) was used to fit the data and to estimate 
the half-lives. Ethyl- and propylparaben, ester compounds known to undergo 
degradation due to enzymatic hydrolysis to yield hydroxybenzoic acid were included as 
positive controls.  
5.2.7.3  IN VITRO BINDING TO S KIN COMPONENTS  
Rapid equilibrium dialysis (RED) devices (Pierce, Rockford, IL - Figure 5-6) were used 
to investigate the drug binding to the skin homogenate supernatant.  
  
 
 
 
FIGURE 5-6. SHOWS A RED DEVICE INSERT (LEFT) AND THE 96  WELL PLATE HOLDER (RIGHT). 
A day prior to the experiment, the Teflon plate was washed with 30% ethanol and 
rinsed twice with deionized water before leaving it to dry. On the day of the experiment, 
skin supernatant was thawed and the drug compound was added to a final concentration 
of 10 μM. After adding 300 μl of fortified tissue in the sample chamber and 500μl of 
PBS (Pierce, Rockford, IL) to the buffer chamber, the plate was incubated on a shaking 
plate at 32°C for 2 hours. Aliquots of both phases were collected and treated with 4 
volumes of ice-cold methanol with 0.1% of formic acid to precipitate proteins. After 10 
minutes of centrifugation at 3000xg at 15°C, the supernatants were assayed for the 
parent drug by LC-MS/MS. 
5.2.7.4  IN VITRO PERMEABILITY EVALUATION THROUGH RHE 
The EpiDerm™ Skin Model EPI-606-X was obtained from MatTek Corporation 
(Ashland, MA, USA). The EPI-606-X model is characterised by an enhanced barrier 
function and was specifically designed to conduct permeability assays. Upon receipt, 
the skin tissue (lot 17860) was stored overnight at 2-8°C. On the day of the experiment, 
the skin inserts were transferred to a 6 well plate containing 2ml of Dulbecco’s 
Sample chamber 
Buffer chamber 
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modified PBS and left to acclimatise on a heated shaking plate. The temperature was set 
at 36.6°C which corresponded to a skin temperature of 32°C.  
Due to a low water solubility, the test compounds were applied in an ethanol/ Miglyol 
840 (1:9) vehicle, a solution that has been used for permeation studies for poorly soluble 
drugs346. After 1 hour, 1.14 ml of a 100 μg/ml donor solution was applied on the model 
skin using a positive displacement pipette. The plates were left to shake at 95 rpm. Two 
reference permeation drugs with different lipophilicities were included; caffeine is a 
hydrophilic compound (log P= -0.08), while testosterone is more lipophilic (log P= 
3.32). They were applied at the same concentration and in the same vehicle as the test 
compounds, except for caffeine was dissolved in Dulbecco’s modified PBS. Aliquots 
were removed from the receiver fluid and replaced with fresh PBS at regular time points 
over a period of 6 hours. The samples were analysed by LC-MS/MS. The permeation of 
each compound was tested in triplicate. Statistical analysis were performed using SPSS 
software version 19.0. 
 
 
 
 
 
FIGURE 5-7. A SCHEMATIC REPRESENTATION (LEFT- ADAPTED FROM347) AND PICTURE (RIGHT) OF THE 
SETUP OF THE RHE PERMEATION ASSAY.  
5.2.8 IN VITRO PERMEATION THROUGH FULL-THICKNESS BALB/C 
MOUSE SKIN USING FRANZ DIFFUSION CELLS  
Two FDC studies were conducted. The first FDC study evaluated the permeation of the 
test compounds through BALB/c mouse skin in order to compare them to the results 
obtained with the RHE assay. Therefore, the experimental conditions of the RHE and 
FDC 1 study were similar. The objective of the second FDC study was to evaluate the 
permeation of the test compounds upon real-life topical treatment i.e. using a low 
application volume and a 1% (w/v) drug formulation.  
RHE 
membrane 
Insert 
Medium microporous 
support 
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Skin of female BALB/c mice was ordered from BioreclamationIVT (Westbury, NY, 
USA) and stored at -80°C. Prior to the experiment the skin was thawed and clipped 
carefully to avoid skin damage. Any excess fat and muscle tissue was removed and skin 
discs of approximately 2.5cm diameter were cut. The skin was mounted between the 
donor and receptor compartment and kept in place by the use of a clamp. Vacuum 
silicone grease was applied to seal gaps and prevent leakage. The cells were left to 
equilibrate until the skin temperature stabilised at 32°C.  
The donor and receptor solutions (Table 5-1) were prepared as described in paragraph 
5.2.7.4. For FDC 1, the test compounds were mixed together so that LSH001 and 
LSH002 were applied to skin samples 1 to 3; and LSH003 and LSH0034 (good 
permeating benzoxaborole control compound) were applied to skin samples 4 to 6. 
Receptor fluid samples were taken at time intervals over a period of 6 hours. Each test 
compound was tested in triplicate. Statistical analysis were performed using SPSS 
software version 19.0. 
TABLE 5-1. SUMMARY OF THE EXPERIMENTAL CONDITIONS FOR THE DIFFERENT PERMEATION 
EXPERIMENTS. 
Permeation 
experiment 
Compounds Donor vehicle 
Concentration 
(µg/ml) 
Volume/ skin 
surface 
(µl/cm2) 
RHE 1 
LSH011; LSH012; LSH029; 
LSH001: LSH031; LSH034; 
LSH023; LSH024; LSH003; 
caffeine; testosterone 
Ethanol – 
Miglyol 840 
(1:9) 
Except for 
caffeine 
100 300 
FDC 1 Mix1: LSH001; LSH002 
Mix2: LSH003; LSH034 
Ethanol – 
Miglyol 840 
(1:9) 
100 300 
FDC 2 LSH001; 
LSH002; LSH003 
Ethanol – PG 
(1:1) 
10 000  
(1% w/v) 
28.4 
Permeation studies were conducted in a semi-automated system with 6 static vertical 
type Franz Cells from Logan Instruments Ltd. (Somerset, NJ) (Figure 5-8).  
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FIGURE 5-8.THE SEMI-AUTOMATED LOGAN SYSTEM WITH SIX STATIC FRANZ CELLS, THE WATER 
RESERVOIR AND TEMPERATURE CONTROL UNIT. 
5.2.9 DETERMINATION OF THE BENZOXABOROLE CONCENTRATION IN 
THE SKIN  
A mass balance study was conducted for the FDC 2 permeation experiment. The 
amount of drug that did not permeate into or through the skin was obtained by gently 
swabbing the skin surface with a cotton bud at the end of the permeation experiment. 
This was repeated a second time. The cotton buds were placed in a tube with 1ml of 
MeOH/PBS (70:30) and left overnight on a shaker (800 rpm). An aliquot of the 
extraction fluid was analysed by LC-MS/MS. 
The cells were dismantled and the mouse skin was removed and placed in a vial. Three 
rounds of extraction with 1ml of MeOH-PBS (7:3) were conducted. At each time, the 
vial was left to shake overnight before analysis by LC-MS/MS to extract the amount of 
drug that permeated into the skin. A drug recovery of 80-120% was decided to be 
acceptable. Statistical analysis were performed using SPSS software version 19.0. 
5.2.10 LC-MS/MS  -  METHOD DEVELOPMENT AND OPTIMISATION  
Sample analysis was performed by high-performance liquid chromatography with 
tandem mass spectrometry (LC-MS/MS). The instrumentation consisted of a CTC Pal 
Autosampler (Leap Technologies, Carrboro, NC), two Agilent 1100 series pumps 
(Agilent Technologies Inc., Santa Clara, CA), a CH-30 column heater (Eppendorf, 
Hauppauge, NY) and an API-3000 triple quadrupole mass spectrometer (Applied 
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Biosystems, Foster City, CA) equipped with a turbo-ion electrospray interface for 
detection (Figure 5-9). Samples were loaded and separated on a Luna C18 column (50 x 
2 mm; 3 µm) from Phenomenex (Torrance, CA) protected by a corresponding guard 
column. The instrument and peripheral devices were controlled using Analyst® 
Software version 1.4.2 (Applied Biosystems, Foster City, CA). The mobile phase used 
to elute the compounds consisted of 5 mM ammonium formate and 0.1% (v/v) formic 
acid in water (A) and 5 mM ammonium formate and 0.1% (v/v) formic acid in methanol 
(B). 
 
FIGURE 5-9.  THE LC-MS/MS INSTALLATION AT SCYNEXIS  (RESEARCH TRIANGLE PARK, NC). 
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5.3 RESULTS AND DISCUSSION 
5.3.1 IN VITRO SENSITIVITY ASSAYS 
Amastigotes. All compounds were screened against intracellular amastigotes, the most 
clinically relevant Leishmania form. The ED50 values for each compound tested against 
five Leishmania species are indicated in Table 5-3. It is observed that the majority of the 
test compounds exhibited higher activity against L. tropica compared to other species. 
40% of the compounds had an ED50 below 5μM compared to 24% when tested against L. 
major and 3% for L. panamensis (Table 5-2). L. mexicana and L. aethiopica were least 
susceptible to the tested benzoxaboroles; no compounds had an ED50 below 5μM and 
86% and 72% had an ED50 above 25μM respectively.  
TABLE 5-2. ED50 VALUES OF THE BENZOXABOROLE COMPOUNDS AGAINST 
INTRACELLULAR AMASTIGOTES SORTED BY ACTIVITY RANGE. 
 Activity range 
 < 5μM 5-25μM > 25μM 
L. tropica 40% 33% 27% 
L. major 24% 29% 48% 
L. aethiopica 0% 28% 72% 
L. mexicana 0% 14% 86% 
L. panamensis 3% 21% 76% 
 
In the amastigote assay, LSH001, LSH023, LSH024, LSH003 and LSH025 were the only 
compounds active against at least one Old World (L. major, L. tropica and L. aethiopica) 
and one New World (L. mexicana and L. panamensis) species. For these compounds, the 
rank order of sensitivity was L. tropica > L. major > L. panamensis > L. aethiopica and 
L. mexicana.  
Promastigotes. The drug sensitivity of benzoxaboroles against extracellular 
promastigotes was only tested for LSH001, LSH002 and LSH003, the three compounds 
that were selected for in vivo studies (Table 5-4) to complete the data. The compounds 
were about 100 times more active against L. tropica promastigotes than amastigotes. 
There was little difference in sensitivity between the other Leishmania strains for 
LSH001 and LSH003 with ED50s ranging from 1.28 to 5.24 and 2.57 to 5.30 respectively. 
The ED50s for LSH002 against Leishmania promastigotes are in general higher compared 
to the other two lead compounds. In the promastigote assay, the rank order of sensitivity 
was the same for the tested compounds and was different to the sensitivity rank order in 
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the amastigote assay: L. tropica > L. panamensis > L. aethiopica > L. major > L. 
mexicana. 
Control drugs. Amphotericin B, included as positive control, had a high activity 
(nanomolar range) across the promastigotes and amastigotes of different species. The 
ED50s for the latter ranged from 0.049 to 0.685μM, indicating a tenfold difference in 
sensitivity between L. major/L. tropica and L. mexicana. For promastigotes, the ED50 
values ranged from 0.011 to 0.300μM and are similar to the ED50s described by Escobar 
et al159. Miltefosine was less active than amphotericin B against Leishmania amastigotes 
and promastigotes with ED50s ranging from 7 to 45 μM and 10 to 35 μM respectively. 
The ED50s for both control drugs were similar to values reported in literature bearing in 
mind that differences in assay methodology and Leishmania species can cause shifts in 
ED50 values. 
The Hill coefficient shown in Table 5-5 is an indicator of the steepness of the dose 
response curves and is also an indicator of cooperativity in drug binding to the receptor. 
The coefficient was well below 1 for all the test compounds which indicated that there 
was a negative cooperative binding. This suggests that upon binding with the first 
molecule, the affinity of the drug target (likely an enzyme) for other drugs will decrease. 
Only for the activity testing of amphotericin B against L. tropica a Hill coefficient higher 
than 1 was obtained. This suggests that the binding of amphotericin B to the target 
increases its affinity for other drug molecules. Moreover this might indicate that the 
target in this L. tropica strain differs from the target in the other strains. 
Cytotoxicity. Cytotoxicity of the benzoxaborole compounds was tested against the human 
KB cell line and ED50s for LSH001, LSH002 and LSH003 were 46.28, 61.58 and 10.09 
μM respectively (Table 5-5). The ratio of the ED50 against amastigotes to the ED50 
against KB cells for LSH001, LSH002 and LSH003 ranged from 2-23, 2-4 and 0-4 
respectively. This shows that the margin between efficacy and toxicity is largest for 
LSH001 >LSH002 >LSH003 based on these in vitro assays. However research has 
highlighted the limited relevance of in vitro data as they correlate poorly to in vivo 
data348, which is not surprising as there are many factors that influence both efficacy and 
toxicity in humans.  
 
The results described above were discussed with all the collaborators and based on the 
findings, 18 compounds were selected for in vitro ADME studies. 
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TABLE 5-3. ACTIVITY OF BENZOXABOROLE COMPOUNDS AGAINST INTRACELLULAR LEISHMANIA  AMASTIGOTES - ED50 VALUES (µM) AND 95% CI. 
Compound ID n L. tropica L. major L. aethiopica L. mexicana L. panamensis 
Amphotericin B 
1 
2 
0.066 (0.062-0.070) 
0.083 (0.078-0.089) 
0.043 (0.037-0.049) 
0.049 (0.043-0.056) 
0.115 (0.107-0.122) 
0.107(0.096-0.119) 
0.430 (0.394-0.460) 
0.685 (0.553-0.692) 
0.143 (0.131-0.156) 
0.115 (0.093-0.142) 
Miltefosine 1 
2 
19.99 (17.40-22.97) 
9.44 (7.78-11.45) 
44.85 (22.02-77.28) 
26.58 (21.30-33.15) 
7.79 (6.20-9.78) 
7.95 (7.26-8.69) 
31.04 (28.56-33.73) 
45.86 (36.61-57.45) 
19.98 (16.17-24.69) 
23.11 (20.41-26.18) 
LSH001 1 
2 
2.01 (1.52-2.67) 
3.12 (2.38-4.09)) 
4.26 (2.97-6.11) 
7.61 (5.48-10.57) 
22.10 (15.07-32.41) 
26.83 (19.40-37.11) 
23.04 (15.99-33.19) 
16.94 (9.62-29.83) 
18.82 (14.08-25.14) 
13.96 (10.06-19.44) 
LSH002 1 14.96 (11.38-19.67) 16.52 (11.56-23.61) > 30 > 30 > 30 
LSH003 1 
2 
2.46* (1.78-3.41) 
3.94 (2.96-5.25)) 
3.93 (3.32-4.64) 
3.10 (2.25-4.26)) 
11.12 (7.67-16.13) 
> 30 
18.94 (10.78-33.29) 
> 30 
8.09 (6.56-9.96) 
19.05 (15.03-24.16) 
LSH004 1 16.08 (13.70-18.80) - 29.97 (19.04-47.16) > 30 > 30 
LSH005 1 6.81 (5.84-7.94) - 21.25 (13.18-34.26) > 30 > 30 
LSH006 1 > 30 - 25.36 (15.88-40.50) > 30 > 30 
LSH007 1 5.71 (4.39-7.43) - 27.18 (17.16-43.04) > 30 > 30 
LSH008 1 > 30 - > 30 > 30 > 30 
LSH009 1 3.08 (2.51-3.79) - 17.66 (12.10-25.76) > 30 > 30 
LSH010 1 6.23 (5.49-7.06) > 30 11.71 (7.22-19.00) > 30 > 30 
LSH011 1 
2 
2.31 (1.73-3.08) 
3.08* (2.12-4.48) 
9.92 (8.49-11.59) 
- 
> 30 
19.47 (11.41-33.23) 
> 30 
> 30 
> 30 
28.09 (22.50-35.07) 
LSH012 1 
2 
24.61 (14.31-42.30) 
4.61* (3.53-6.01) 
9.52 (6.80-13.32) 
- 
> 30 
> 30 
> 30 
> 30 
> 30 
> 30 
LSH013 1 > 30* > 30 > 30  > 30 > 30 
LSH014 1 5.91* (4.63-7.54) 4.15 (3.42-5.04) > 30 > 30 29.59 (20.59-42.53) 
LSH015 1 6.92 (4.95-9.66) > 30 > 30 > 30 > 30 
LSH016 1 5.40 (4.02-7.26) > 30 21.84 (14.60-32.66) > 30 > 30 
LSH017 1 > 30 > 30 > 30 > 30 > 30 
LSH018 1 > 30 > 30 > 30 > 30 > 30 
LSH019 1 21.01 (4.07-108.4) > 30 > 30 > 30 > 30 
LSH020 1 > 30 > 30 > 30 > 30 > 30 
LSH021 1 28.81 (17.03-48.74) > 30 > 30 > 30 > 30 
LSH022 1 > 30 > 30 > 30 > 30 > 30 
LSH023 1 1.19* (0.78-1.80) 1.57 (1.17-2.10) 23.05 (10.09-52.62) 6.31 (4.18-9.54) 2.98 (2.28-3.90) 
LSH024 1 4.72* (3.31-6.74) 13.96 (11.52-16.91) > 30 > 30 22.34 (17.66-28.25) 
LSH025 1 2.21* (1.51-3.25) 5.93 (5.08-6.92) > 30 25.39 (15.81-40.78) 15.85 (12.85-19.56) 
* The ED50 was obtained using a clinical isolate of L. tropica instead of the L. tropica AO21/p strain that is generally used for screening purposes. 
Where possible, the experiment was repeated. Clearly inactive compounds were not repeated. N=number of experiment repeats 
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TABLE 5-4. ACTIVITY OF BENZOXABOROLE COMPOUNDS AGAINST LEISHMANIA  PROMASTIGOTES - ED50 VALUES (µM) AND 95% CI. 
Compound ID n L. tropica L. major L. aethiopica L.mexicana L. panamensis 
Amphotericin B 1 
2 
0.011(0.002-0.066) 
0.040 (0.036-0.044) 
0.19 (0.16-0.22) 
0.032 (0.030-0.035) 
0.021 (0.018 0.023) 
0.048 (0.047-0.048) 
0.29 (0.22-0.39) 
0.30 (0.19-0.49) 
0.035 (0.030-0.042) 
0.041 (0.040-0.041) 
Miltefosine 1 10.90 (10.32-11.46) 33.64 (26.25-43.10) 10.19 (9.50-12.21) 23.48 (18.82-29.28) 17.64 (15.27-20.39) 
LSH001 1 0.030 (0.010-0.060) 3.80 (3.00-4.82) 2.27 (2.00-2.58) 5.24 (5.14-5.33) 1.28 (1.10-1.49) 
LSH002 1 - 52.71  15.57 (13.54-17.91) 57.5 0.66 (0.50-0.85) 
LSH003 1 0.03 (0.010-0.037) 4.55 (3.87-5.33) 3.76 (3.22-4.40) 5.30 (5.23-5.36) 2.57 (2.14-3.07) 
TABLE 5-5. SUMMARY OF THE ED50, ED90, HILL COEFFICIENT AND CYTOTOXICITY AGAINST KB  CELLS FOR THE THREE LEAD BENZOXABOROLE COMPOUNDS. 
Compound ID L. tropica L. major L. aethiopica L.mexicana L. panamensis 
Amphotericin B 
EC50 
EC90 
Hill coefficient (EC50) 
 
0.066; 0.083 
0.290; 0.297 
2.1/1.5 
 
0.049; 0.043 
0.216 
0.47/0.34 
 
0.115; 0.107 
0.247; 0.239 
0.21; 0.19 
 
0.430; 0.685 
1.095; 1.211 
0.26; 0.29 
 
0.413; 0.115 
0.286; 0.150 
0.39; 0.42 
Miltefosine 
EC50 
EC90 
Hill coefficient (EC50) 
 
19.99; 9.44 
25.13 
0.27 
 
26.58; 44.85 
29.44; 163.1 
0.21; 0.18 
 
7.79; 7.95 
21.99; 19.50 
0.18; 0.19 
 
31.04/45.86 
38.02/102.8 
0.58/0.59 
 
19.98; 23.11 
166.3; 151.3 
0.65; 0.67 
LSH0014 
EC50 
EC90 
Hill coefficient (EC50) 
Cytotoxicity ED50 
 
2.01; 3.12 
48.49 
0.08 
46.28 
 
4.26; 7.61 
12.74; 37.14 
0.14; 0.10 
46.28 
 
22.10/26.83 
26.85 
0.12; 0.10 
46.28 
 
23.04/16.94 
82.16 
0.09; 0.10 
46.28 
 
18.82; 13.96 
85.61; 84.74 
0.13; 0.16 
46.28 
LSH002 
EC50 
EC90 
Hill coefficient (EC50) 
Cytotoxicity ED50 
 
14.96 
- 
0.05 
61.58 
 
16.52 
17.79 
0.09 
61.58 
 
>30 
95.46 
- 
61.58 
 
> 30 
25.47 
- 
61.58 
 
> 30 
- 
0.22 
61.58 
LSH003 
EC50 
EC90 
Hill coefficient (EC50) 
Cytotoxicity ED50 
 
2.46; 3.94 
19.74 
0.07 
10.09 
 
3.93; 3.10 
14.21; 12.70 
0.10; 0.07 
10.09 
 
11.12; > 30 
10.10 
0.11; 0.27 
10.09 
 
18.94; > 30 
- 
0.10; 0.94 
10.09 
 
8.09; 19.05 
365.7 
0.09; 0.11 
10.09 
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5.3.2 IN VITRO ADME  STUDIES-GENERAL PHARMACOKINETIC 
PREDICTIONS  
Overall the benzoxaborole compounds had a good physicochemical profile for skin 
permeation (Table 5-6). All compounds had the desirable properties (1.3.1.1): a 
molecular weight below 500 g/mol, a log D (at pH 7.4) between 1-3, except for LSH002 
and LSH032 and no more than 2 H-bond donor groups. 
The experimental solubility of the test compounds in PBS (pH 7.4) ranged from 0.356 
to over 250 μg/ml. Logically, the compounds with a more lipophilic character indicated 
by a high log D, demonstrated limited solubility in PBS as was seen for LSH001 and 
LSH031. On the other hand test compound LSH002 on the other hand exhibited a low 
log D and a high solubility in PBS.  
TABLE 5-6. PHYSICOCHEMICAL PROPERTIES OF BENZOXABOROLE COMPOUNDS. 
Compound Molecular 
weight 
H bond 
donor/acceptor* 
Aqueous solubility** 
(μg/ml) 
Aqueous solubility*** 
(μg/ml) 
Log D 
(pH 7.4) 
LSH011 273 2/3 304 259 1.56±0.03 
LSH012 339 2/7 31 105 2.24±0.03 
LSH026 306 2/4 22 29.5 1.86±0.07 
LSH027 325 2/8 103 ND 1.53*** 
LSH028 334 2/6 53 ND 1.86±0.02 
LSH029 393 2/11 14 ND 1.95±0.10 
LSH001 387 2/5 9 0.356 > 2.63 
LSH030 373 2/5 13 ND 1.94±0.06 
LSH031 433 2/5 31 0.529 > 2.72 
LSH002 421 2/5 37 > 250 0.44±0.06 
LSH032 386 2/5 11 21.4 0.88±0.15 
LSH033 400 2/5 7 122 1.70±0.15 
LSH023 334 2/5 103 2.63 2.45±0.04 
LSH024 368 2/6 45 6.69 2.16±0.07 
LSH003 321 2/7 165 6.24 2.18±0.08 
*/** Data obtained using ChemBio 3D Ultra 13.0 modeling software 
*** Experimental data, based on 1 sample 
DSC analysis revealed an endothermic peak indicating a melting point at 220ºC, 244ºC 
and 196º for LSH001, LSH002 and LSH003 respectively (see Appendix 2 for the 
respective DSC profiles).  
The MDCK-MDR1 assay was conducted to assess the in vitro intrinsic permeability of 
the test compounds and to identify Pgp substrates. Compounds with a Papp+GF918 >50 
nm/s were reported to have high intrinsic permeability across the intestine345. The 
intrinsic permeability of all compounds ranged from 141-699 nm/s and is considered 
high. Only compound LSH002 showed a low intrinsic permeability of 16.5 nm/s, Based 
on the AQ test results, it was suggested that there were no Pgp substrates (indicated by 
Chapter 5 – Drug discovery – benzoxaboroles for a topical CL treatment 
 
 
 
 
119 
an AQ value < 0.3) amongst the test compounds, except for LSH031 and LSH002 that 
had an AQ of 0.598 and 0.492 respectively. Amprenavir, the Pgp substrate control 
showed an AQ value of 0.846.  
 
Chapter 5 – Drug discovery – benzoxaboroles for a topical CL treatment 
 
 
 
 
120 
 
FIGURE 5-10. MDCK – MDR1 ASSAY – PAPP (AB) VS PAPP (AB IN PRESENCE OF GF918) FOR EACH TEST COMPOUND. 
TABLE 5-7. SHOWS THE PAPP VALUES WITH AND WITHOUT GF918  AND THE ABSORPTIVE QUOTIENT (AQ) FOR THE MDCK-MDR1 ASSAY
Compound Papp(nm/s) Papp +GF918 (nm/s) AQ 
Amprenavir 58.3 378 0.846 
Propranolol 395 441 0.104 
LSH011 699 688 -0.016 
LSH012 474 520 0.088 
LSH026 652 655 0.005 
LSH034 543 538 -0.009 
LSH027 209 247 0.154 
LSH028 397 424 0.064 
LSH029 229 268 0.146 
LSH001 583 599 0.027 
Compound Papp (nm/s) Papp +GF918 (nm/s) AQ 
LSH030 436 524 0.168 
LSH031 141 351 0.598 
LSH002 16.5 32.5 0.492 
LSH035 660 603 -0.095 
LSH032 232 327 0.291 
LSH033 404 482 0.162 
LSH023 605 593 -0.020 
LSH024 236 314 0.248 
LSH003 626 635 0.014 
LSH036 322 349 0.077 
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5.3.3 IN VITRO ADME  STUDIES-SKIN PHARMACOKINETIC 
PREDICTIONS  
5.3.3.1  METABOLISATION  IN SKIN HOMOGENATE S UPERNATANT  
The metabolisation of the test compounds in skin supernatant at 0.6 and 2.5 mg/ml 
protein content shown in Figure 5-12 and Figure 5-13 respectively. The paraben 
compounds are known substrates for skin esterases and were expected to break down 
quickly in presence of the skin supernatant (Figure 5-11). Propyl paraben was 
metabolised more quickly than ethyl paraben. This correlates with a previous report of 
its faster breakdown compared to butyl-and ethyl-paraben by rat skin microsomes where 
a series of parabens were tested332. The skin fractions were prepared using a similar 
methodology except for the extra step necessary to isolate the microsomes.  
    
FIGURE 5-11. STRUCTURES OF ETHYL PARABEN (LEFT) AND PROPYL PARABEN (RIGHT). 
Rapid drug metabolisation was seen during the first 30 minutes, followed by slower 
drug metabolism. As expected drug degradation occurred at a faster rate and to a greater 
extent at the higher skin protein concentration (2.5 mg/ml); the supernatant with lower 
protein concentrations is likely to contain less metabolising enzymes quickly leading to 
saturation. After two hours, compound recovery was 40 to 80% for the 0.6mg/ml and 25 
to 60% for the 2.5mg/ml protein content skin supernatant respectively (Figure 5-12 and 
Figure 5-13).  
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FIGURE 5-12. REMAINING TEST COMPOUND (%) IN SKIN SUPERNATANT (PROTEIN CONTENT 
0.6MG/ML) AS A FUNCTION OF TIME (MEAN±SD;  N=3). 
 
FIGURE 5-13. REMAINING TEST COMPOUND (%) IN SKIN SUPERNATANT (PROTEIN CONTENT 
2.5MG/ML) AS A FUNCTION OF TIME (MEAN±SD;  N=3). 
Full-thickness BALB/c mouse skin was used to prepare skin tissue homogenate for two 
main reasons. First, epidermal membranes were reported to have reduced enzymatic 
activity in previous studies349. The process of heat separation was thought to have 
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damaged the enzymes and therefore care was taken to not overheat the skin homogenate 
at any stage of preparation. Second, the efficacy study will be conducted in female 
BALB/c mice and full-thickness female mouse skin was used to assure consistency 
between the in vitro – in vivo data set.  
As for other in vitro pharmacokinetic data, these results should be interpreted with 
caution especially when translating to in vivo animal and human studies. The stability 
results presented here were obtained by incubating drugs in skin homogenate 
supernatant. Due to the homogenate preparation methodology, intracellular enzymes 
might have been released contributing to the breakdown of drugs in which case these 
results represent an overestimation of drug metabolism333. Furthermore the difference in 
mouse and human skin might contribute to additional error. A study comparing paraben 
breakdown in rat and human skin, observed a higher metabolism, in the order of 
magnitudes, for rat skin350.  
5.3.3.2  DRUG B INDING TO SKIN COMPONENTS  
The binding assay showed large variations in unbound fractions among the 
benzoxaboroles; unbound fractions from 34% to 92% were observed (Table 5-8). In 
general, a high percentage unbound drug is preferable as it is the free fraction of the 
drug that is available to exert anti-parasitic activity351. However, contrary to oral drugs 
where tissue binding decreases the concentration of systemically available drugs, the 
binding of topically applied drug to skin components might be desirable as it could 
prolong the drug residence in the skin, preventing the drug being taken up in the 
bloodstream, which would lead to its eventual metabolism and excretion. In addition, 
drug binding to skin could provide a sustained release of free drug and thus sustained 
anti-parasitic activity. 
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TABLE 5-8. FRACTIONS OF UNBOUND COMPOUND AFTER 2 HOURS 
INCUBATION WITH MOUSE SKIN SUPERNATANT. 
Compound % unbound 
LSH011 85 
LSH012 77 
LSH026 92 
LSH027 62 
LSH028 60 
LSH029 79 
LSH001 87 
LSH030 67 
LSH031 92 
LSH002 59 
LSH035 74 
LSH032 57 
LSH033 65 
LSH023 34 
LSH024 50 
LSH003 44 
LSH036 66 
No clear tendency was visible when trying to link stability or binding data to the 
structures of the compounds. A greater selection of test compounds would help to 
identify trends amongst the influences of different functional groups.  
5.3.3.3  IN VITRO PERMEATION E XPERIMENT USING THE RHE  MODEL  
The permeation profiles of the compounds through RHE membrane are shown in Figure 
5-14. The permeation of LSH002 was statistically significant higher compared to 
LSH001, LSH012, LSH029, LSH031 and LSH033 (one-way ANOVA, p<0.05). 
Caffeine showed the highest permeation which was significantly higher compared to all 
the test compounds and testosterone after 6 hours (one-way ANOVA; p < 0.05).  
When ranking the cumulative amount permeated over 6 hours, the rank order from high 
to low was as follows: caffeine > LSH002 > LSH003 > LSH011 > LSH023 > 
testosterone > LSH024 > LSH033 > LSH001 > LSH012 > LSH029 > LSH031.  
The compounds caffeine and LSH002 were the two more hydrophilic compounds 
amongst the test compounds as was indicated by their log D value of -0.08 and 0.44 
respectively. Hence, LSH002 even though in solution, might have been closer to 
saturation in the ethanol-Miglyol 840 (1:9) vehicle exhibiting a higher thermodynamic 
activity compared to the test compounds with a higher log D. Additionally, the higher 
permeation of LSH002 could involve the higher affinity of this compound for the RHE 
compared to the lipophilic vehicle thereby stimulating its partitioning into the RHE 
membrane.   
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FIGURE 5-14. PERMEATION OF THE BENZOXABOROLE COMPOUNDS ACROSS THE RHE EXPRESSED AS THE 
CUMULATIVE AMOUNT PERMEATED PER SURFACE AREA AS A FUNCTION OF TIME (MEAN±SD; N=3).  
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Based on the overall data set collected at this stage, it was decided to select three 
compounds for further study. These compounds were LSH001, LSH002 and LSH003. 
LSH002 was included despite the fact that its activity against intracellular amastigotes 
was not evaluated but due to its higher solubility in water. LSH003 was selected 
because it was active against the 5 Leishmania species tested and it was ranked second 
from the top in the permeation assay. LSH001 was included because it showed good 
anti-leishmanial activity and was a more lipophilic compound compared to the other 
two selected compounds. Its permeation, however, was slightly below the permeation of 
our lipophilic reference permeant testosterone.  
LSH023 was not selected as there was conflicting interest with a different project that 
was ongoing at Anacor Pharmaceuticals. Limited availability of LSH036 meant that this 
compound could not be taken further.  
5.3.4 IN VITRO PERMEATION EXPERIMENTS USING BALB/C MOUSE 
SKIN  
The objective of the first permeation study (FDC 1) was to verify the rank order of the 
three selected compounds and compare them with the results obtained from the previous 
permeation experiment where a RHE model was used. Therefore the experimental 
conditions were similar to the RHE experiment (Table 5-1). The results are shown in 
Figure 5-15 and indicate that the rank order LSH002 > LSH003 > LSH001 is 
maintained when using BALB/c mouse skin instead of the RHE membrane. 
Furthermore, the permeation of LSH002 through BALB/c mouse skin was significantly 
higher compared to LSH001, LSH003 and testosterone (one-way ANOVA, p<0.05).  
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FIGURE 5-15.  PERMEATION PROFILES OF THE 3  SELECTED BENZOXABOROLE COMPOUNDS THROUGH 
BALB/C MOUSE SKIN MEASURED IN FRANZ DIFFUSION CELLS (FDC 1) (MEAN±SD; N=3). 
The overall permeation and thus flux of the test compounds and testosterone were lower 
when using mouse skin compared to the RHE (one-way ANOVA, p < 0.05) (Table 5-9). 
The lag time was not statistically significant for the test compounds when using 
different skin membranes (ANOVA, p > 0.05). This is not surprising as several studies 
have indicated that RHE is more permeable than animal or human skin339, 352, 353.  
TABLE 5-9. THE PERMEATION PARAMETERS: FLUX AND LAG TIME WHEN USING RHE AND BALB/C 
MOUSE SKIN (MEAN±SD; N=3  EXCEPT FOR *  WHERE N=2) 
 RHE BALB/c 
testosterone  
flux (ng/cm2/h) 
lag time (h) 
 
28.0±0.8 
0.7±0.1 
 
2.2±0.8 
1.1±0.6 
LSH001 
 flux (ng/cm2/h) 
lag time (h) 
 
21.8±0.1 
2.2±0.1 
 
6.6±0.3* 
2.4±0.4 
LSH002  
flux (ng/cm2/h) 
lag time (h) 
 
143.9±44.2 
1.7±0.8 
 
35.8±0.9* 
2.8±0.3 
LSH003 
flux (ng/cm2/h) 
lag time (h)  
 
45.1±5.9 
2.1±0.1 
 
8.0±1.5* 
2.5±0.3 
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A second permeation (FDC 2) using BALB/c mouse skin aimed to assess the 
permeation and skin disposition of the compounds after application of 1% drug in 
Ethanol-PG (1:1) solution (28µl/cm2). The permeation of the test compounds is shown 
in Figure 5-16. A one-way between groups analysis of variance was conducted to 
explore the permeation differences between the test compounds. There was a 
statistically significant difference at the p<0.05 level for LSH001 compared to LSH002.  
 
FIGURE 5-16.  PERMEATION PROFILES OF THE 3 SELECTED BENZOXABOROLE COMPOUNDS 
ACROSS BALB/C MOUSE SKIN MEASURED IN FRANZ DIFFUSION CELLS (FDC2) (MEAN±SD; 
N=3). 
The flux and lag time for the 3 different benzoxaboroles are indicated in Table 5-10. 
When ranking the flux from high to low, there is a difference in order when compared 
to the previous permeation experiments: LSH001 > LSH003 > LSH002. Interestingly 
the permeation for LSH002 was statistically significant lower compared to the other two 
compounds (one-way ANOVA; p < 0.05), in contrast to its higher permeation shown in 
Figure 5-14 and Figure 5-15. 
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TABLE 5-10. THE PERMEATION PARAMETERS: FLUX AND LAG TIME FOR FDC2  
(MEAN±SD; N=3  EXCEPT FOR *  WHERE N=2). 
 
Flux 
(ng/cm2/h) 
Lag time (h) 
LSH001 88.7±8.8 2.7±0.5* 
LSH002 13.5±8.7* 2.7±0.7 
LSH003 71.8±18.0 2.7±0.9 
 
LSH001 and LSH003 where applied as suspensions with a maximal thermodynamic 
activity, while LSH002 was applied as a solution at about 80% of saturation and thus a 
suboptimal thermodynamic driving force (Table 5-11). Furthermore due to its 
hydrophilic nature, LSH002 is likely to have a higher affinity for the Ethanol-PG 
vehicle compared to the skin causing the drug to remain in the vehicle on the skin 
surface. There was no difference observed in the lag time for the different compounds 
(ANOVA; p >0.05).  
TABLE 5-11. SOLUBILITY OF LSH001,  LSH002  AND LSH003  IN THE PG/ETHANOL (1:1)  VEHICLE (N=1). 
 Solubility in PG 
(mg/ml) 
Solubility in PG-Ethanol (1:1) 
(mg/ml) 
LSH001 1.74 7.90 
LSH002 5.87 12.63 
LSH003 5.02 7.90 
A mass balance study was conducted to quantify the amount of test compound that had 
permeated, was left on or inside the skin. The results are shown in Figure 5-17. Whilst 
there was no statistical significant difference between the amounts of compounds that 
had permeated over 24 hours, the amount of LSH001 in the skin was significantly 
higher in comparison to LSH002 and LSH003 (one-way ANOVA; p<0.05). In fact, 
about half of the applied drugs had permeated into the skin. Logically, the amount of 
LSH001 retrieved from the skin surface was significantly lower than for LSH002 and 
LSH003 (one-way ANOVA; p<0.05). Based on the solubility data presented in Table 
5-11, it is clear that LSH001 and LSH003 were applied as a suspension. This means that 
the driving force for permeation was maximal. There was no statistical significant 
difference for the amounts of LSH002 and LSH003 that was found in and on the skin. 
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FIGURE 5-17. RESULTS OF THE MASS BALANCE STUDY WITH THE RETRIEVED AMOUNTS OF 
BENZOXABOROLES EXPRESSED AS PERCENTAGES. 
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5.4 CONCLUSION  
Out of 25 benzoxaboroles tested for anti-leishmanial activity a few had appreciable 
activity against the 5 species tested. The benzoxaboroles were most potent against L. 
tropica. The Hill coefficient showed negative cooperativity and there was a two-fold 
difference between the drug-efficacy to cell cytotoxicity for two compounds tested. 
The physico-chemical properties of the benzoxaboroles were favourable for skin 
permeation and the MDCK-MDR1 assay indicated good overall permeability and no 
Pgp substrates except for two compounds: LSH002 and LSH031.  
The benzoxaboroles were degraded to some extent by skin enzymes but were more 
stable than the paraben compounds. Drug binding to skin components was variable and 
unbound fractions ranged from 34 to 92%. Permeation evaluation of the benzoxaboroles 
through reconstructed human epidermis showed LSH002 to be most permeable 
followed by LSH003 and LSH001. The rank order was replicated in Franz diffusion 
cells using BALB/c mouse skin when the same experimental conditions were used.  
A second assay tested permeation of the compounds after finite dose application in a 
different vehicle. LSH001 showed the highest permeation followed by LSH003 and 
LSH002. Furthermore the amount of LSH001 in the skin was statistically significant 
higher compared to the two other compounds. 
Ideally, the outcomes of each experiment would have been related to the chemical 
structures of the compounds. However it was difficult to allocate one specific outcome 
to a functional group. 
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6 EFFICACY OF BENZOXABOROLES AGAINST CL - IN 
VIVO STUDY 
6.1 INTRODUCTION  
The previous chapter explains how a range of benzoxaborole compounds was narrowed 
down to a selection of 3 compounds to be tested in vivo against experimental CL.  
First, the activity of a series of benzoxaboroles with different chemical structures were 
tested against intracellular amastigotes of 5 different Leishmania species Based on the 
efficacy results, 18 compounds were subjected to a batch of in vitro ADME experiments 
that focussed on general permeability properties. The partition/distribution coefficient 
and solubility were determined and the permeability was measured in the MDCK-
MDR1 assay. In a second phase, more stringent in vitro ADME experiments focussed 
on dermatopharmacokinetic parameters including stability and binding in skin 
supernatant and permeation assays with the EpiDerm® model. Finally, a last permeation 
using BALB/c mouse skin was conducted followed by a mass balance study, whereby 
the amounts of drug left in and on the skin where analysed.  
To summarize, the 3 selected compounds showed (i) anti-leishmanial activity against a 
range of species, (ii) a physico-chemical profile conductive to skin permeation, (iii) 
acceptable stability in skin homogenate supernatant; (iv) variable binding in skin 
homogenate supernatant and (v) different skin disposition profiles from one another. 
The next step is the in vivo efficacy testing of the selected benzoxaborole compounds 
LSH001, LSH002 and LSH003 against experimental CL upon oral and topical 
administration. Literature describes different CL rodent models, however, mainly mice 
are used. Generally, the course of infection and clinical symptoms depend on the 
genetic background of the mouse, the parasite strain, the place of injection and 
inoculum injected354, 355. For this study, susceptible BALB/c mice were infected 
subcutaneously with L. major (MHOM/SA/85/JISH118) which resulted in the 
development of large ulcers that did not heal without intervention.  
There are different methods available to assess the leishmanicidal effect of a treatment 
in models. As a minimum, the progression of the lesion size is followed by measuring 
the diameter in two directions using callipers. This technique is non-invasive and allows 
daily evaluation. Expansion of the lesion, however, is three dimensional and therefore, 
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volume measurements would be more correct. Unfortunately they are difficult to obtain 
in practical situations.  
Moreover lesion size could misrepresent the parasite load as inflammation and 
secondary infection contribute to volume and diameter increase354. Hence, 
determination of parasite loads in addition to lesion size measurements represent a more 
rigorous way to evaluate drug efficacy. The establishment of the parasite burden, as 
described below, requires tissue sampling and thus requires extra animals or is only 
performed at the end of the treatment to compare parasite loads between different 
treatment groups at the end of the study. 
Determination of the parasite burden can be performed by microscopic techniques that 
determine the viable parasite counts with356 or without357 prior staining but these 
methods are time consuming, subjective and accuracy can vary when the parasites are 
not homogeneously dispersed358. Limiting dilution assays355, 359, 360 are more sensitive 
but remain labour-intensive361. More recently recombinant bioluminescent Leishmania 
parasites were generated to follow the infection in vivo 362-365 but is limited by a lengthy 
optimisation. We therefore developed a real-time quantitative polymerase chain reaction 
(qPCR) method as it allows quick, sensitive and accurate quantification of the parasite 
load in a CL lesion. 
6.1.1 REAL-TIME QUANTITATIVE PCR 
The traditional end-point polymerase chain reaction (PCR) is a semi-quantitative 
technique that produces a high number of target sequences that can be visualised by 
subsequent agarose gel separation with ethidium bromide. This type of PCR typically 
has poor precision and low sensitivity and real-time qPCR was developed to circumvent 
these limitations.  
The first report on the use of real-time qPCR originated in the early 1990’s and 
described how a video camera recorded the increase in fluorescence for each PCR 
cycle366. Further use of this technique was delayed by the high price and limited 
commercial availability of thermocyclers but now, qPCR is widely used for a number of 
applications including measuring mRNA expression levels, DNA copy numbers and 
allelic discrimination367.  
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Real-time qPCR allows the detection and quantification of the target products as they 
are generated during each cycle of the polymerase chain reaction. The numbers of DNA 
copies are proportionate to the amount of template in the sample prior to the start of the 
PCR process when measured in the exponential phase of the reaction. The use of a 
standard curve that is prepared from dilution series of a known concentration of 
template, allows the quantification of the DNA material in the unknown sample.  
The amount of DNA generated is measured using a fluorescent signal that is obtained 
by adding dyes to the reaction. Two main groups of dyes are available: probes and 
SYBR® Green. SYBR® Green displays a relatively low fluorescence that increases by 
1000-fold when bound to double-stranded DNA. The more binding sites available for 
the dye, the higher the fluorescent signal.  
Alternatively, a more specific level of detection is obtained using probes with a specific 
target sequence. When unbound, the fluorescent probe is not hybridized and remains 
quenched. There is no fluorescence detectable. Upon the presence of the target 
sequence, the probe will bind to the DNA and the quencher will be removed. A 
fluorescent signal is detectable (Figure 6-1). 
 
FIGURE 6-1. DUAL-LABELLED PROBE CHEMISTRY MECHANISM . THE PROBE RELIES ON THE 5’-3’ 
NUCLEASE ACTIVITY OF THE DNA POLYMERASE TO RELEASE THE FLUOROPHORE DURING THE 
HYBRIDISATION TO THE TARGET SEQUENCE (ADAPTED FROM 368) 
The first real time qPCR methods used to quantify Leishmania parasites in tissue were 
described a little over 10 years ago358, 369. Bretagne et al designed a qPCR assay using 
TaqMan probes targeting Leishmania and mouse DNA sequences to relatively quantify 
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the number of L. infantum present in mouse liver. The outcome of the assay was 
compared with the results obtained from a culture microtitration conducted in parallel 
and showed a correlation coefficient of 0.66358. Another publication described how a 
conventional PCR method was adapted into a real-time qPCR method. This method 
targeted kinetoplast DNA (kDNA) and used SYBR® green I to follow the amplification 
of the target sequence in time. They reported successful quantification up till 0.1 
parasite per reaction for four different Leishmania species in mouse tissue369.  
Later, Van Der Meide et al compared 3 methods for the detection and quantification of 
Leishmania parasites in blood and CL skin tissue from patients in Brazil370. All methods 
targeted an 18S ribosomal gene, a multiple-copy gene that is homologous for all 
Leishmania species371. Two methods, quantitative nucleic acid sequence-based 
amplification (QT-NASBA) and quantitative real-time reversed transcriptase PCR 
(qRT-PCR) detected and amplified ribosomal RNA (rRNA), while the other method, 
real-time qPCR, amplified ribosomal DNA (rDNA). Because rRNA copy numbers are 
approximately 100 times more abundant than rDNA372, a lower sensitivity was expected 
for the latter method.  
qRT-PCR is similar to qPCR but the reaction requires a reversed transcriptase step that 
transcribes the RNA into the complementary DNA. QT-NASBA is similar to the qRT-
PCR method but it is based on an isothermal reaction and does not require a 
thermocycler. Overall QT-NASBA and qRT-PCR performed better than real-time 
qPCR with a higher regression coefficient and a higher reaction efficiency for qRT-
PCR. Furthermore they showed a 10-fold higher sensitivity with a limit of detection of 
100 parasites/ml compared to the real-time qPCR method as was expected because the 
latter only targeted DNA.  
The real-time qPCR that we developed for our project targeted the same 18S ribosomal 
target gene that was described in the Van Der Meide paper discussed above. We chose 
to target DNA and not RNA because the data obtained when using real-time qPCR is 
more robust and generally applicable373. This is because the information within the 
genome is the same for every cell whereas the transcriptome (RNA) expression is 
variable.  
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6.2 MATERIALS AND METHODS  
6.2.1 MATERIALS  
TABLE 6-1. DETAILS OF THE MATERIALS USED FOR THE EXPERIMENTS DESCRIBED IN CHAPTER6. 
Compound Specifications Supplier 
Chemicals and test reagents 
LSH001, 002, 003 
Leshcutan 
AmBisome®  
Propylene glycol 
Ethanol 
Dextrose 
Sodium carboxymethylcellulose 
Benzylalcohol 
TWEEN® 80 
Sodium chloride  
 
LC-MS/MS and 1H-NMR identification 
15% paromomycin sulfate, Teva (Israel) 
- 
500 ml 
99.7-100%, AnalaR 
Anhydrous 
Mw ~ 250,000 
99.8%, anhydrous 
- 
> 99.5%, anhydrous 
 
Anacor Pharmaceuticals 
IsraelPharm 
DNDi donation 
Sigma Aldrich 
VWR International 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
PCR and qPCR 
DNeasy® Blood and Tissue kit 
KAPA probe fast universal  
KAPA 2G Hot Robust mix 
Forward primers mouse/leish 
Leishmania probe 
 
50 reactions 
500 reactions, KK4702 
100 reactions, KK5532 
Sequences specified below, 25nmoles 
FAM fluorophore, 100µM 
 
Qiagen 
Anachem 
Anachem 
Sigma Aldrich 
LifeTechnologies 
Other materials 
Bunion cushions 
 
Self-adhesive, Superdrug 
 
Superdrug 
 
6.2.2 DRUGS AND FORMULATION PREPARATION 
AmBisome®, a liposomal formulation of amphotericin B for injection was kindly 
provided by DNDi (Geneva) and prepared according to manufacturer’s 
recommendations. Briefly, AmBisome® powder was reconstituted with 12ml of cold 
sterile MilliQ water to produce a 4 mg/ml amphotericin B liposomal suspension. This 
suspension was vigorously shaken and incubated at 65ºC for 10 minutes after which it 
was allowed to cool to room temperature. This dispersion was diluted with sterile 5% 
dextrose solution (w/v) to obtain a final suspension of 0.5mg of amphotericin B/ml. 
The experimental topical formulations containing LSH001, LSH002 and LSH003 
respectively were prepared 24 hours prior to the start of dosing. For each test 
compound, the following procedure was conducted. An excess amount of the test 
compound was added to a 1:1 (v/v) mixture of propylene glycol (PG) and ethanol 
(Ethanol). The mixture was left to stir overnight after which it was centrifuged at 13000 
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rpm for 15 minutes. The supernatant, i.e. a saturated solution was pipetted into a clean 
vial and used to apply on mice.  
The standard suspension vehicle used to prepare the oral formulations was prepared by 
weighing and adding each component (0.5% (w/v) carboxymethylcellulose, 0.5% (v/v) 
benzyl alcohol, 0.4% Tween 80 (v/v) in a 0.9% (v/v) NaCl solution) into a clean 
recipient. The mixture was left to stir overnight at room temperature prior to 
sterilisation by autoclaving. The experimental oral formulations containing either 
LSH001, LSH002 or LSH003 in the vehicle were prepared by adding the appropriate 
amount of test compound to the vehicle in order to obtain a final concentration of 
2.5mg/ml. The suspension was sonicated for 30 minutes and was used as such. All 
formulations were stored at 4˚C throughout the experiment. 
6.2.3 EXPERIMENTAL CL  MODEL  
For this study, 60 female BALB/c mice (6-8 weeks old; Charles River Ltd., UK) were 
infected as described previously in section 3.1.3. Approximately 7 days post infection, 
small nodules were visible. The lesion size was recorded daily and when they reached a 
diameter of 5 mm, the mice were randomly allocated in groups of 6 and drug 
administration was started.  
In an attempt to increase the contact time between the 
topical formulations and the CL lesion, an auto-adhesive 
corn plaster was cut to appropriate size and stuck on the 
skin around the nodule as seen in Figure 6-2. This 
prevented the mice from licking and thus removing the 
topical formulation.  
FIGURE 6-2. CORN PLASTER ON 
THE RUMP OF A MOUSE. 
Formulations were administered over a period of 10 days. The details of the 
administration regimens are shown in Table 6-1. Figure 6-3 shows the experimental 
design of the in vivo study including the different test groups. 
Treatment efficacy was evaluated by lesion size progression. To do so, the lesion 
diameter was measured in 2 directions on a daily basis using digital callipers. The 
average diameter was plotted as a function of time. Statistical differences between the 
average diameters per group on the last day of treatment was performed using one-way 
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ANOVA with post-hoc Tukey test (SPSS software version 19.0). Three days after the 
end of treatment, the mice were sacrificed and the lesion was excised and stored at-80ºC 
until the parasite load was quantified using real-time qPCR. Statistical differences in the 
average parasite numbers amongst different groups were analysed using one-way 
ANOVA with Tukey post-hoc test (SPSS software, version 19.0)   
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6.2.4 EXPERIMENTAL DESIGN  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-3 SHOWS THE DESIGN OF THE IN VIVO STUDY CONDUCTED WITH THREE COMPOUNDS OF INTEREST LSH001,  LSH002 AND LSH003. 
 
 
Day 0 - Infection 
• L. major JISH 118 
• 200µl - 2x10
7
promastigotes 
• s.c injection on rump  
 
Day 11 – Start drug administration 
Controls: 
Group 1 - Untreated control (negative control) 
Group 2 - Topical vehicle control  
Group 3 - AmBisome® (positive control) 
Group 4 - Leshcutan® ointment (topical positive control) 
Experimental formulations: 
Group 5 - Topical administration with LSH001 
Group 6 - Topical administration with LSH002 
Group 7 - Topical administration with LSH003 
Group 8 - Oral administration with LSH001 
Group 9 - Oral administration with LSH002 
Group 10 - Oral administration with LSH003 
Day 20 – Last dose Day 23 – Sacrifice animals 
Collection lesions 
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TABLE 6-2. SHOWS THE DIFFERENT STUDY GROUPS WITH THEIR TREATMENT REGIMENS. 
Group Formulation 
Active 
compound 
Vehicle 
Administration 
route 
Treatment 
regimen 
1 Untreated control None None None None 
2 AmBisome® 
Amphotericin 
B 
Dextrose 5% IV 
25mg/kg/b.i.d,  
5 doses 
3 Leshcutan® 
Paromomycin 
sulphate 15% 
Methylbenzethonium 
chloride 12% in 
vaseline 
Topical 
0.1ml 2/day for 
10 days 
4 Vehicle control N/A PG/Ethanol (1:1) Topical 
2x50µl/day for 
10 days 
5 
Topical formulation 
1 
LSH001 
Saturated drug 
solution in 
PG/Ethanol (1:1) 
Topical 
2x50µl/day for 
10 days 
6 
Topical formulation 
2 
LSH002 
7 
Topical formulation 
3 
LSH003 
8 Oral formulation 1 LSH001 
Standard suspended 
vehicle 
Oral 
2x25mg/kg/day 
for 10 days 
9 Oral formulation 2 LSH002 
10 Oral formulation 3 LSH003 
 
6.2.5 QUANTIFICATION OF THE PARASITE LOAD IN A CL  SKIN LESION  
1.1.1  PRIMERS AND PROBES  
The primer pair and probe, previously designed and validated by Van Der Meide et al370 
targeted a 170-bp region in the Leishmania 18S ribosomal gene and are specific for all 
Leishmania species. The respective sequences are shown in Table 6-3. 
TABLE 6-3. THE SEQUENCES OF THE PRIMER AND PROBES USED IN THE PCR AND QPCR REACTIONS. 
 Gene Primer/probe Primer Sequence 
Leishmania 
species 
18S rDNA 
(170-bp) 
Forward primer 
Reverse primer 
Probe 
5’-C CAA AGT GTG GAG ATC GAA G-3’ 
5’-GGC CGG TAA AGG CCG AAT AG-3’ 
5’-6FAM ACCATTGTAGTCCACACTGC-NFQ-MGB 
 
6.2.5.1  DNA  EXTRACTION FR OM THE CL  LESION  
On the day of extraction the lesions were defrosted and cut into 2. One half was 
weighed and cut into fine pieces with a surgical blade before placing in a 
microcentrifuge tube. The DNA was then extracted using the DNeasy® blood and tissue 
kit (Qiagen). 
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Briefly, for each 25mg of tissue, 20µl of proteinase K and 180µl of ATL buffer were 
added and mixed, after which the mixture was incubated in a water bath at 56°C for 5 
hours. At regular time intervals, the sample was vortex-mixed to obtain a 
homogeneously digested sample. Subsequently, AL buffer was added in the appropriate 
ratio followed by a further 10 minutes incubation at 56°C. The DNA was precipitated 
by adding ethanol and the sample was transferred onto a spin column. The DNA was 
retained on the column during the multiple washing steps and then eluted with the AE 
buffer. The purity and concentration of DNA was analysed using the nanodrop ND1000 
spectrophotometer. 
6.2.5.2  CONFIRMATION OF THE P RODUCT SIZE BY PCR   
Conventional PCR was performed to confirm the presence of PCR product of the 
correct size and hence to verify primer efficacy. 1µl of a 1/100 dilution of the DNA 
extract was amplified in a final volume of 10µl containing 2µl of KAPA 2G buffer 
(Kapa Biosystems, Wilmington, MA) and primers at a concentration of 0.4µM. The 
samples were run in a G-Storm GS4 machine (Somerset, UK). The amplification cycle 
started with a denaturation step at 95°C for 3 minutes followed by 40 cycles of 95°C for 
15s, 60°C for 1 minute and 72°C for 30 seconds with a final extension of 72°C for 30 
seconds. Each run contained a negative sample whereby the extracted DNA was 
replaced by MilliQ water and positive cDNA control. The PCR products were separated 
on a 3% agarose gel stained with ethidium bromide and visualised under UV light. A 
100-bp DNA ladder was run in parallel with the samples. The band obtained for the 
Leishmania target sequence was 170bp long.  
6.2.5.3  EXPERIMENTAL SETTINGS  FOR REAL-TIME QPCR 
For the amplification reaction, 2µl of a 1/100 diluted DNA sample was added to 8µl 
mix containing 5µl KAPA Probe Fast qPCR master mix (2x) (Kapa Biosystems, 
Wilmington, MA), 0.4 µM of each primer and 0.25µM of the appropriate probe. The 
tubes were placed in the 72 sample rotor of the instrument (Rotor Gene 3000, Qiagen) 
and the reaction with the following conditions was initiated: 95°C for 3 minutes 
followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Each run 
contained a standard curve, a no-template-control and a negative control.  
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6.2.5.4  STANDARD CURVES FOR LEISHMANIA TARGET DNA 
The standard curves were prepared and validated prior to the start of the experiment and 
were stored at -80ºC.  
In preparation of the standard curves, amastigotes were extracted from a BALB/c CL 
lesion. To do so, the lesion was homogenised in RPMI-1460 medium containing 1% 
penicillin/streptomycin. The homogenate was centrifuged at 800rpm for 10 minutes in 
order to remove pieces of skin tissue and other cellular material. The supernatant was 
transferred to a new vial and centrifuged for 15 minutes at 1500rpm. The amastigotes 
were washed and re-suspended in PBS. 
They were microscopically counted using a Thoma haemocytometer and diluted to 
1x108 amastigotes/ml. The DNA of 200µl of this suspension was extracted and purified 
using the DNeasy® Blood and Tissue kit from Qiagen as explained above (6.2.5.1). The 
amount of DNA and purity of the sample were verified using the Nanodrop ND1000 
spectrophotometer. Ten-fold serial dilutions (from 1x108/ml to 1 amastigote/ml) were 
made and analysed in duplicate by real-time qPCR in order to determine: (i) the 
analytical sensitivity i.e. the minimum number of copies in a sample that can be 
measured accurately; (ii) the repeatability i.e. the precision and robustness of the assay 
when the same samples are analysed in the same run, (iii) the reproducibility of the 
assay i.e. the variation between different runs and (iv) the efficiency of the qPCR assay.  
Two quality control samples were prepared by spiking skin homogenate with either a 
high (2x107) or low (2.5x103) number of amastigotes. The samples were processed in 
the same way as the standard curve samples and were included in duplicate to verify the 
accuracy of the assay. The target variation for accuracy was 80-120%. 
Quantification of Leishmania parasites was obtained by plotting the parasite 
concentrations against the CT values with linear regression (Rotor-Gene Analysis 
Software 6.1). The amplification efficiency and r2 value were calculated based on the 
slope and the intercept of the equation describing the standard curve. The intra- and 
inter-assay variability was established and calculated as the coefficient of variation for 
each concentration of parasites and for each duplicate.  
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6.3 RESULTS AND DISCUSSION 
6.3.1 VALIDATION OF THE QPCR  METHOD  
6.3.1.1  TARGET SEQUENCE VERIF ICATION BY PCR 
The Leishmania DNA sequence band of 170bp was visible. This indicated that the 
primers had successfully amplified the target sequence.  
 
 
 
 
 
 
 
 
FIGURE 6-4. GEL ELECTROPHORESIS RESULTS SHOWING SUCCESSFUL MULTIPLICATION OF THE 
LEISHMANIA  DNA TARGET SEQUENCE BY PCR. 
6.3.1.2  VALIDATION OF THE STA NDARD CURVES FOR THE  LEISHMANIA 
TARGET SEQUENCE  
Table 6-4 shows the coefficient of variation (CV) (standard deviation/average x 100) 
that was calculated for each amastigote concentration of the standard curve within one 
run (intra-assay variation) and between three separate runs (inter-assay variation). The 
intra-and inter-assay variability ranged from 0.11-2.24% and 4.94-15.06% respectively. 
Both are comparable with values found in literature370, 372, 374. The inter-assay is higher 
especially towards the dilutions that contain more amastigotes. Due to the higher 
variation seen in the inter-assay variability, it was decided to include a standard curve in 
each run.  
The fluorescent signal for the no-template and negative control did not reached the 
detection threshold indicating that there was no contamination of reagents and primer 
dimer did not occur.  
 
100 bp 
200 bp 
300 bp 
400 bp 
170 bp – Leishmania target sequence 
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TABLE 6-4. INTRA- AND INTERASSAY VARIATIONS CALCULATED AS (STANDARD DEVIATION/MEAN X 
100%)  FOR EACH AMASTIGOTE CONCENTRATION OF THE STANDARD CURVE.  
Log input 
(parasites/ml) 
Intra-assay variation (%) Inter-assay 
variation (%) Run 1 Run 2 Run 3 
8 1.63 1.80 0.05 15.06 
7 1.49 0.98 1.19 10.47 
6 0.94 2.04 0.68 9.41 
5 0.73 0.34 0.69 7.90 
4 0.22 0.14 1.45 6.86 
3 0.11 2.24 0.34 4.94 
2 1.95 0.46 0.68 6.06 
The CV of accuracy of the method near the detection limits was 8.3 and 17.5% for the 
sample containing a high and low number of amastigotes respectively. The accuracy 
was lower for the low amastigote number sample, this could have been caused by a 
relatively higher loss of DNA for samples containing a low count of amastigotes 
compared to samples with initially higher DNA material during the 
extraction/purification process.  
Table 6-5 shows the amplification parameters for the qPCR reaction targeting the 
Leishmania 18S rDNA. The high r2 values confirm the linearity range of the 
amplification reaction for serial dilutions ranging from 1x108 parasites to 100 
parasites/ml with the latter as limit of detection. The efficiency of the reaction ranged 
from 0.88-0.89, these were similar to values found in literature370.  
TABLE 6-5. QPCR PARAMETERS - REGRESSION COEFFICIENTS (R2), AMPLIFICATION EFFICIENCY AND 
EQUATIONS OF THE STANDARD CURVES TESTED.  
(* E= (101/SLO PE-1)X100%; ** Y=CT VALUE; X=LOG(NUMBER OF PARASITES))  
Parameter Run 1 Run 2 Run 3 
r2 0.996 0.998 0.998 
Efficiency (%)* 89 88 88 
Equation** y=3.606x+42.197 y=-3.654x+39.163 y=-3.662x+42.084 
 
6.3.2 EXPERIMENTAL FORMULATIONS  
The 3 topical formulations (Figure 6-5) were applied as saturated solutions with 
maximal thermodynamic activity of 1. The solubility of the test compounds in the 
vehicle (PG-Ethanol 1:1) was not measured due to little compound availability. 
However, LSH002 was more soluble in the vehicle compared to LSH001 and LSH003 
and required more drug to obtain a saturated solution. When applying Fick’s law to the 
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passive process of diffusion that occurs upon application of the topical formulation, the 
concentration gradient between the formulation and the SC is expected to be higher for 
LSH002 compared to LSH001 and 003.  
The oral formulations are shown in Figure 6-5. Even though they are all suspensions, 
LSH002 was clearly more soluble in the vehicle compared to LSH001 and LSH003. 
This could influence the bioavailability of the drugs upon administration. 
   
FIGURE 6-5. SHOWS THE EXPERIMENTAL TOPICAL AND ORAL FORMULATIONS.  
6.3.3 EVALUATION OF THE LESION SIZE PROGRESSION 
Figure 6-6 shows the evolution of the mean lesion size for each group as a function of 
time. A reduction of lesion size is seen for the groups receiving the AmBisome® and 
LSH003 oral treatment. LSH001 halted the lesion size growth upon topical application. 
All other groups showed disease progression as the lesion size increased in time.  
 
FIGURE 6-6. MEAN LESION SIZE PROGRESSION PER GROUP IN FUNCTION OF TIME POST INFECTION (N=6) 
(SEE APPENDIX FOR GRAPH WITH ERROR BARS). 
The difference in lesion sizes between the groups on day 20 (= last day of drug 
administration) is also demonstrated in Figure 6-7. A statistically significantly lower 
lesion size for the experimental groups LSH001 topical and LSH003 oral compared to 
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the relevant control groups was observed on the last day of treatment (One-way 
ANOVA, p<0.05). Moreover, there was a statistically significant difference between the 
average lesion diameter for the AmBisome® and all the other groups (p<0.05) except for 
the LSH001 topical and LSH003 oral groups (p>0.05). 
 
FIGURE 6-7. LESION SIZES (MEAN ±SD,  N=6) ON THE LAST DAY OF TREATMENT (ONE-WAY ANOVA,  
P<0.05 ( *)). 
When injected with Leishmania parasites, the BALB/c mice developed fulminating 
infections with ulcers that quickly progress to death if left untreated. The LSH001 
compound applied topically was able to halt the lesion growth which showed that the 
drug was able to permeate through the SC and reach the parasites situated in the lower 
epidermis and dermis. This non-healing BALB/c model is a rigorous test for drugs 
especially because these drugs were only applied after establishment of the lesion354. 
Therefore lesion size reduction or halt of lesion growth should be regarded as a 
promising result 354. Moreover the efficacy of the formulation was probably 
significantly reduced as the mice were able to quickly remove the formulation by 
licking the site from day 3-4 of the start of the treatment. Initially, the corn plaster 
prolonged contact between the formulation and the CL lesion for up to 30 minutes. 
However as the study progressed, mice were able to remove the plaster quicker and 
licking the administration site was observed in all groups that received topical 
administration including the vehicle control group as early as 5-10 minutes after 
application. As there was no effect on CL progress observed in the LSH001 oral group, 
it is suggested that the activity seen in the LSH001 topical group is solely due to the 
drug that was able to permeate the skin.  
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These results correlate well with the data obtained in chapter 5. An in vitro permeation 
experiment using BALB/c mouse skin followed by a mass balance study showed a 
higher permeation for LSH001 compared to LSH002 and LSH003. This was only 
statistically significant higher for LSH001 compared to LSH002. In fact, the main 
difference between LSH001 and LSH003 was demonstrated in the mass balance study 
where LSH001 showed to concentrate in the skin after topical application.  
It is somewhat surprising that LSH001 and LSH003 showed no effect on the lesion size 
progression after oral and topical administration respectively. However as mentioned 
before, this infection model is a real challenge for drugs because it progresses so 
quickly. Further discussions with the project collaborators revealed that glycol ethers 
for example PG are known to give rise to peroxide formation which enhances the 
benzoxaborole ring cleavage375. Since PG was only present in the topical formulations, 
drug degradation most likely reduced the efficacy of the topical formulations. The 
formulations were analysed by HPLC-UV after the study but this method was not 
sensitive enough to detect and/or separate the metabolites from the parent compound. 
Figure 6-8 shows the CL lesions after 6 days of treatment with Leshcutan® ointment. 
The application of Leshcutan ointment was stopped 4 days after the start of dosing 
because of severe skin irritation. Lesion sizes were no longer measurable since the 
initial nodule was no longer visible. Leshcutan® ointment is formulated with 12% 
methylbenzethonium chloride, a cationic quaternary ammonium penetration enhancer 
that facilitates permeation of paromomycin sulfate (Mw > 700g/mol) into the skin by 
interacting with the intercellular lipid matrix of the stratum corneum74, 376. Cationic 
surfactants are known to damage skin resulting in an increase in transdermal flux377 and 
have been reported to be more damaging than anionic or non-ionic surfactants378. 
Therefore they are typically used at a concentration of 0.5-1%, while Leshcutan® 
ointment contains 12%. Clinical trials using this ointment have frequently reported skin 
irritation136. This study shows that Leshcutan® should not be used as positive control for 
experiments in mice. 
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FIGURE 6-8. THE IRRITATIVE EFFECT OF LESHCUTAN OINTMENT ON MOUSE SKIN 5  DAYS AFTER THE 
START OF APPLICATION. 
6.3.4 QUANTIFICATION OF LEISHMANIA DNA  IN THE CL  LESIONS 
AFTER DRUG DOSING  
Figure 6-9 shows the numbers of amastigotes in the CL lesions three days after 
application of the last dose. A one-way between-groups analysis of variance was 
conducted to explore the influence of drug treatment on the reduction of parasite burden 
per lesion. There was a statistically significant reduction of the parasite burden for the 
LSH003 oral group compared to the topical vehicle control, LSH001 oral, LSH002 oral 
and LSH002 topical groups. This indicates that when administered orally, LSH003 was 
more efficacious killing Leishmania parasites in vivo compared to the other oral groups. 
The in vitro activity against intracellular L. major amastigotes was ten times lower for 
LSH002 compared to LSH001 and LSH003 (based on the ED50 values). This might 
explain the difference in activity between LSH003 and LSH002 upon oral 
administration. However LSH001 and LSH003, exhibited the same in vitro activity 
against L. major. It is thus suggested that the difference in efficacy upon oral 
administration is due to pharmacokinetic variations between LSH001 and LSH003. An 
oral vehicle control group had not been included as previous experience with this group 
showed no influence on CL lesions (unpublished data).  
The parasite load for the Leshcutan® group was statistically significant lower compared 
to all groups except LSH003 oral (one-way ANOVA, p<0.05). However it is uncertain 
if the reduction in parasite load was caused by the activity of PM and/or MBCL, that 
had shown in vitro activity against Leishmania parasites379. 
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AmBisome® reduced the parasite burden significantly compared to LSH001 and 
LSH002 oral and the topical vehicle control group (one-way ANOVA, p<0.05). There 
was no statistically significant difference compared to LSH003 oral (one-way ANOVA, 
p>0.05), indicating they exhibited a similar in vivo anti-leishmanial activity. AmB was 
reported to reduce parasite burden in CL lesions in mice before380. 
The parasite burden per lesion was not statistically significant reduced for the LSH001, 
LSH002 and LSH003 groups after topical application even though LSH001 topical 
showed a lower mean parasite burden compared to the other two topical groups.  
 
FIGURE 6-9. NUMBER OF AMASTIGOTES PER LESION (MEAN±SD,  N=6) THREE DAYS AFTER THE LAST 
DOSING (ONE-WAY ANOVA,  P>0.05). 
The relationship between the lesion size and the parasite load per lesion on day 23 
(three days after last dosing) was investigated using Pearson correlation coefficient 
(Figure 6-10). There was a strong, positive correlation between the two variables 
(r=0.57, p<0.05) with large lesion sizes associated with high parasite load. A stronger, 
positive correlation (r=0.73, p<0.05) was obtained between the logarithm of the parasite 
load and lesion size.  
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FIGURE 6-10. CORRELATION BETWEEN LESION SIZE AND PARASITE BURDEN ON DAY 23  (R=0.73,  P<0.05). 
Besides parasite clearance, lesion size reductions can also be caused by anti-
inflammatory action of the test compounds. Some benzoxaboroles were reported to 
show anti-inflammatory activity. In fact AN2728 is currently in phase 3 clinical trials 
for atopic dermatitis characterised by inflammation323. This possible additional anti-
inflammatory activity of the benzoxaboroles might explain the statistically significant 
differences for lesion size reduction while this was not the case for parasite burden per 
lesion. 
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6.4 FINAL DISCUSSION  
LSH001 and LSH003 exhibited high passive transcellular permeability characterised by 
a high Papp in the MDCK-MDR1 assay. As the Leishmania parasites are situated inside 
the phagolysosome of the macrophage, a high transcellular permeability could give rise 
to a higher drug concentration inside the macrophage and thus a higher anti-leishmanial 
activity. For example LSH002 unlike LSH001 and LSH003 showed a low Papp and was 
active against only two Leishmania species with an ED50 that was 4-fold higher 
compared to LSH001 and LSH003.  
Overall, the in vivo study outcome correlates with the results obtained in chapter 5. 
Amongst the three test compounds, LSH001 showed the highest unbound fraction 
(87%) in skin supernatant. Moreover, a mass balance study showed that more drug was 
present in the skin for LSH001 compared to LSH002 and LSH003 and was correlated 
with a lower lesion size in the in vivo study. It could be hypothesized that a high 
unbound fraction indicates a high anti-leishmanial activity in the dermis.  
Additionally, the performance of the LSH001 topical formulation was likely to be 
enhanced by the reduced barrier integrity of CL affected mouse skin as was indicated in 
chapter 3.  
Yet another important question remains, how the outcome of the in vivo mouse study 
would translate into humans. First, there are physical differences between human and 
mouse skin for example full-thickness mouse skin appears to be four times thinner 
compared to human skin while the mouse SC is half the thickness of human skin381. 
Furthermore the number of hair follicles and differences in the composition of the 
intercellular SC lipids382 also contribute to the overall higher permeability of mouse 
skin compared to human skin383-385.  
Skin drug delivery is a complicated multi-factorial process that is affected by drug, 
formulation and skin related factors386 including physico-chemical properties of the test 
compound, drug-vehicle and vehicle-skin interactions, skin physiology etc. For certain 
factors, data are available and if lucky, in vitro or in vivo assays with good correlation to 
humans exist. Developing a topical formulation for CL is therefore not a simple matter 
of designing one drugs to fit the target but a rational and performance based selection 
procedure where a collection of compounds with a range of physico-chemical properties 
are screened and taken forward stepwise. In our project, the selection procedure based 
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on in vitro experiments allowed us to narrow down thirty compounds to a handful of 
promising candidates for in vivo studies thereby increasing the chance of obtaining 
suitable drug candidates for our formulation and reducing the number of animals 
required 
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6.5 FUTURE WORK  
Two lead compounds were active in vivo, one when administered orally, the other when 
applied topically. As mentioned before, there is a tendency of peroxide formation in 
ether solvents such as propylene glycol and polyethylene glycols. This is known to 
cause instability of the benzoxaboroles. It would be interesting to redo the in vivo study 
but with a different vehicle or repeat the study with the same formulation vehicle but 
with fresh drug formulations for each day in order to minimise drug metabolism and 
thus breakdown. When the formulation is optimised, the study will be repeated to assure 
the effect is reproducible and other New World species might be included for example 
L. mexicana.  
LSH003 gave cure, defined as no visible lesion, in 4 out of 6 mice when administered 
orally. The general in vitro ADME tests performed in chapter 5 are suggestive of good 
membrane permeability. It would be interesting to measure plasma concentrations after 
oral administration to see if they correlate with these in vitro ADME test results and 
with the outcome of the in vivo study.  
The mass balance study had shown that high concentrations of LSH001 were found 
inside the skin. When separating the epidermis and dermis prior to drug extraction, it 
would be possible to see in which skin layer LSH001 concentrates in particular. Ideally, 
it would concentrate in the dermis because there is where the parasites reside.  
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7 FINAL DISCUSSION  
Amongst the leishmaniases, CL is perhaps the most neglected disease. It does not cause 
fatalities but does lead to significant morbidity related to disfiguration and social stigma. 
A selection of drugs, mainly repurposed, are available to treat these diseases but their 
usage is limited by toxicity, inefficacy and high cost. Due to these limitations, patients 
delay seeking treatment and allow the infection to progress increasing the risk of parasite 
spreading and multiple lesion development, expansion of lesion size, development of 
ulcers and contribution to transmission. Even if treatment is successful at this stage, scar 
formation will occur. An effective and safe treatment that the patient can apply or take 
themselves is expected to change treatment seeking behaviour and hence, avoid scar 
formation.  
To date, there is no literature available on the influence of Leishmania infection on the 
skin barrier integrity and thus drug delivery to the skin. This information is extremely 
useful as the aim of this work was to investigate drugs that could potentially be used in a 
topical formulation to treat CL at an early stage. To do so, it was important to know if the 
barrier function of the skin affected with CL was more or less permeable. Consequently 
the skin barrier integrity of Leishmania-infected mouse skin was compared with 
uninfected skin. A histopathological evaluation of CL lesions in the nodular stage, before 
ulceration and skin disruption was observed, indicated epidermal hyperplasia and 
disruption of the dermal layer by the ingress of abundant inflammatory cells. CL also 
affected the skin barrier integrity characterised by an increased TEWL value suggesting a 
damaged inside-outside barrier. More importantly, the permeability of Leishmania-
infected skin was higher compared to uninfected skin as was shown when performing in 
vitro Franz cell diffusion studies. This was tested for a lipophilic and hydrophilic model 
permeant and while the permeation of both drugs was enhanced in infected skin, the 
hydrophilic drug showed a 66 times higher flux through infected compared to uninfected 
skin, whereas this was only 2-fold higher for the lipophilic drug. 
When testing the permeation of leishmanicidal drugs through infected and uninfected 
skin, this trend was confirmed and indicated that hydrophilic drugs permeated more 
through infected skin compared to lipophilic drugs. This led to the hypothesis that the 
inflammatory reaction caused a more hydrophilic environment in the dermis compared to 
uninfected skin and hence selectively enhancing the permeability of hydrophilic drugs. It 
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should be mentioned that infected skin remained impermeable for amphotericin B 
indicating that the barrier integrity was damaged, but not absent. These findings were 
obtained using mouse skin and as generally known, mouse skin is more permeable than 
human skin. This work, while it needs to be repeated using human skin, provides the first 
evidence that Leishmania infection of the skin alters the barrier integrity and therefore the 
dermatopharmacokinetics of drug delivery to skin target sites. This information is 
valuable in early stages of drug discovery for example when modifying lead molecules, 
the addition of hydrophilic groups might enhance drug permeation into the Leishmania-
infected skin. 
In a following chapter, the reformulation of miltefosine, an established anti-leishmanial 
drug, into a topical formulation was evaluated. This drug, available as an oral formulation 
to treat VL has been increasingly used to treat CL, however, the benefit-risk profile of CL 
is different compared to VL and due to toxicity and resistance development, the oral 
administration of miltefosine for CL should be avoided.  
This study investigated the permeability of miltefosine formulated in solvents that were 
reported to enhance permeability of other drugs. For all solvents, miltefosine permeation 
was limited and mass balance studies showed low concentrations in the skin combined 
with high amounts left on the skin. The chemical structure of miltefosine indicates 
similarities with skin lipids and possibly explains the retention of the compound on the 
skin surface. Moreover this molecule behaves as a surfactant and when used in high 
concentrations (25% w/v) it was found to solubilise skin (unpublished data). 
In parallel, we applied a rational based strategy to evaluate the potential use of 
benzoxaboroles in a topical formulation to treat CL. Drug discovery requires a 
multidisciplinary approach and in an area with little pharmaceutical incentive, this 
methodology has not been described/applied before. Chapter 5 describes the approach 
that was taken to select lead compounds from a range of benzoxaboroles with different 
physico-chemical characteristics. First the anti-leishmanial activity of the compounds was 
evaluated in an in vitro intracellular amastigote-macrophage model. The compounds were 
tested against 5 Leishmania species because ideally the lead compounds should show 
broad range activity. Five compounds had shown activity against at least two Old World 
and one New World species. Overall, the active benzoxaboroles were less potent than 
amphotericin B (Fungizone®) but exhibited lower ED50 values compared to miltefosine. 
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L. tropica was more susceptible to the benzoxaboroles compared to the other species. A 
first series of in vitro ADME tests were conducted to determine general physico-chemical 
properties that are important to establish an overall PK profile for the compound. This 
included water solubility, log P determination and permeability testing in the MDCK-
MDR1 assay. The obtained parameters were similar for the entire range of 
benzoxaboroles and no ‘red flags’ were identified.  
A second series of in vitro tests were more skin specific and determined stability in 
mouse skin homogenate supernatant and binding to skin components. In the skin 
supernatant, all benzoxaboroles showed higher stability compared to the paraben 
compounds that are known substrates for skin esterases and are therefore expected to 
breakdown. The binding assay demonstrated a range of unbound fractions. At that stage, 
it was not clear whether a high unbound fraction was beneficial for topically applied 
drugs as a certain skin retention is required to maintain the compound in the dermis 
where the parasites reside. The last test in this series of assays evaluated the permeation 
of the compounds in a reconstructed human epidermis model. This model is readily 
commercially available in a 6-well format and requires no Franz diffusion cell 
equipment. Based on the outcome of this study, 3 compounds with a higher permeation 
compared to testosterone, the lipophilic model permeant that was included, were selected.  
The permeation of these 3 compounds was evaluated using full-thickness mouse skin and 
Franz diffusion cells. At the end of the experiment the amount of drug that was left on the 
skin was removed by applying several wash and swab cycles. The amount of drug in the 
skin was recovered by extraction. LSH001 showed high permeation and a high fraction of 
drugs was recovered from inside the skin. LSH002 and LSH003 showed lower 
permeation and indicated a high fraction of drugs that was left on the skin. 
This chapter described how the efficacy of the selected compounds were tested in vivo 
against CL in BALB/c mice upon topical or oral administration. LSH001 halted the 
lesion size progression and showed a lower mean parasite burden compared to the topical 
vehicle control group. These findings led to the conclusion that a high unbound fraction 
combined with a high skin concentration are important to obtain parasite killing in the 
dermis. Upon oral administration, LSH003 reduced the lesion size more than 
AmBisome®. Both results are promising as the non-healing BALB/c model is a rigorous 
test for drugs 
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A general body of knowledge on CL is available and in vitro PK experiments can be 
adapted to obtain more target-related information. There is a lack of disease specific in 
vitro models that combine both the activity testing against Leishmania parasites and 
preliminary PK profile evaluation. The current in vitro models to test anti-leishmanial 
activity rely on 2D culture systems that demonstrate activity against the intracellular 
parasite correlate poorly with results obtained in animal models387. This “disconnect” is 
likely to be caused by the oversimplification of the in vitro model that is unable to 
account for pharmacokinetic drug barriers that occur in vivo. In vitro 3D culture systems 
are receiving increasing attention and have demonstrated a better correlation to in vivo 
drug activity.  
Dermatopharmacokinetic evaluation of drug formulations after topical application often 
involves invasive sampling. The two main techniques used are tape stripping, whereby 
consecutive SC cell layers are mechanically removed and extracted for drugs, and 
microdialysis, that allows the measurement of unbound drug in the extracellular fluids of 
skin tissue. A more recent trend involves the use of non-invasive spectroscopy techniques 
such as Raman spectroscopy and allows the evaluation of drug permeation into the skin 
layers. This could be used to follow drug permeation in CL models upon application of 
topical formulations.  
The research described in this thesis focused mainly on the development of a 
conventional topical formulation such as an ointment or cream. Alternatively, a topical 
formulation may be delivered in spray form. This mode of application could be 
particularly useful when treating patients with multiple lesions spread over the body. An 
additional advantage of this contactless application is that it minimises the likelihood of 
the formulation’s contamination by human microflora. Of course, repeated application of 
the spray on large areas of the body particularly on ulcerated lesions that lack barrier to 
permeation, may lead to increased absorption of drugs in the systemic circulation 
resulting in toxicity.  
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APPENDIX 
 
APPENDIX 1:  VALIDATION OF HPLC  METHODS 
- Caffeine, ibuprofen, amphotericin B and buparvaquone - 
Preparation of standard solutions 
A stock solution of 1 mg/ml was prepared by accurately weighting 10 mg of the drug and 
diluting that with HPLC grade water in a 10 ml volumetric flask. Standard solutions were 
obtained by diluting the stock solution. The data is presented as mean ± standard 
deviation from three different sets of standard solutions.  
Details of the HPLC method 
TABLE 1. SUMMARY OF THE HPLC ASSAY USED FOR THE DETECTION OF CAFFEINE , IBUPROFEN, 
AMPHOTERICIN B  AND BUPARVAQUONE. 
Compound ID HPLC column 
Injection 
volume 
Mobile phase Flow 
rate 
Detector 
wavelength A B 
Caffeine 
Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
20 
0.1% TFA in 
water (15%) 
ACN (85%) 1.3 273 
Ibuprofen 
Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
20 
0.1% TFA in 
water (30%) 
ACN (70%) 1 227 
Amphotericin B 
Phenomenex; Synergi–Hydro 
RP (250x4.6mm; 5µm) 
80 
2.5mM EDTA 
in water (68%) 
ACN (37%) 1 407 -380 
Buparvaquone 
Luna C18 (4.6x250mm; 5µm) 
with Luna guard column 
20 
5% Water+ 
acetic acid 
(pH3.5) (5%) 
MeOH (95%) 1.7 250 
 
 
FIGURE 1. TYPICAL RP-HPLC CHROMATOGRAM OF 100  µG/ML OF CAFFEINE. 
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FIGURE 2. TYPICAL RP-HPLC CHROMATOGRAM OF 10   µG/ML IBUPROFEN, 
 
 
FIGURE 3. TYPICAL RP-HPLC CHROMATOGRAM OF 160  NG/ML AMPHOTERICIN B 
 
 
FIGURE 4. TYPICAL RP-HPLC CHROMATOGRAM OF 125  µG/ML BUPARVAQUONE. 
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Retention time and capacity factor 
A compound is eluted from the HPLC column after a period of time known as the 
retention time (tR). The retention time is dictated by the flow and nature of the mobile 
phase as well as the length of the column. If the mobile phase is flowing slowly or the 
HPLC column is relatively long, then the mobile phase residence time (t0) is also large. 
Therefore, the capacity factor (k’) which express the elution time of the compound of 
interest relative to the solvent front is often preferred because it is independent of the 
column length and mobile phase flow rate 388.  
0
0'
t
tt
k R

            EQUATION 9 
A capacity factor between 1 and 5 is often preferred as this implies good separation of the 
solvent from and the analysed compound without an overly long detection time. The 
retention time of caffeine, ibuprofen, amphotericin b and buparvaquone are 5.2, 5.6, 8.2 
and 5.1 min respectively with corresponding capacity factors of 1.7, 1.9, 3.3 and 1.8 
respectively. 
 
Linearity 
The linearity of the HPLC detection assays was assessed by plotting the peak area against 
concentration. The calibration graphs obtained have a linear regression coefficient of > 
0.99 for all drugs. The methods are therefore linear over the analysed concentration 
ranges (1-500 µg/ml for caffeine, 0.5-500 µg/ml for ibuprofen, 0.75-100ug/ml for 
amphotericin b and 0.1 to 250ug/ml for buparvaquone).  
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FIGURE5. CALIBRATION CURVES OF: A) CAFFEINE, B) IBUPROFEN, C) AMPHOTERICIN B  AND D) 
BUPARVAQUONE. 
 
Accuracy and precision 
Accuracy can be defined as the degree to which a measured value conforms to the true 
value 389. In pharmaceutical analysis, an assay is said to be accurate if the mean result is 
the same as the true value. The accuracy of the analysis obtained for each drug (n=3) 
expressed as a percentage of the expected concentration, also known as percentage 
recovery, according to the following equation: 
100
s
c
C
C
Accuracy          EQUATION 10 
Where Cc is the calculated concentration and Cs is the nominal standard concentration. 
Precision, on the other hand, is described as the variability of a set of measurements 389. 
Unlike accuracy, this does not provide any indication of the closeness of the obtained 
results from the true value. High precision is indicative of low variability in 
y = 29.089x + 90.434
R² = 0.9994
0
5000
10000
15000
20000
25000
0 200 400 600
A
re
a
 (
a
.u
.)
Concentration (ug/ml)
y = 41.969x + 2.4376
R² = 1
0
5000
10000
15000
20000
25000
0 200 400 600
A
re
a
 (
a
.u
.)
Concentration (ug/ml)
y = 38.525x + 1.0603
R² = 1
0
5000
10000
15000
20000
25000
0 100 200 300
A
re
a
 (
a
.u
.)
Concentration (ug/ml)
y = 72.398x - 4.9217
R² = 1
0
5000
10000
15000
20000
25000
0 50 100 150
A
re
a
 (
a
.u
.)
Concentration (ug/ml)
A B 
C D 
Appendix 
 
 
 
 
178 
measurements usually demonstrated by low standard deviation values. This is usually 
reported as a percentage relative standard deviation (%RSD) 389: 
 
100% 
Drug
SD
RSD            EQUATION 11 
The precision of the method was determined by repeatability (intra-day) and intermediate 
precision (inter-day). Repeatability was determined by performing three repeated analysis 
of the same standard solution on the same day, under the same experimental conditions. 
The intermediate precision of the HPLC methods was assessed by carrying out the 
analysis on three different days (inter-day). For each drug, the percentage relative 
standard deviation (%RSD) and the percentage recovery of the standard solutions are 
reported for each drug (Table 2, 3, 4, 5, 6, 7, 8 and 9). 
TABLE 2. THE PRECISION OF THE CAFFEINE HPLC ASSAY. 
Standard 
Concentration (µg/ml) 
Intra-day 
calculated 
concentration (µg/ml) 
Inter-day 
Calculated 
concentration (µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RSD 
0.5 0.53±0.02 0.51±0.05 3.5 8.87 
1 1.02±0.02 1.03±0.09 1.63 9.20 
10 9.99±0.07 10.12±0.15 0.73 1.47 
25 24.51±0.26 24.83±0.28 1.04 1.13 
50 50.49±0.54 50.35±0.73 1.08 1.45 
75 75.27±1.86 74.25±1.06 2.47 1.43 
100 99.68±1.05 100.42±0.43 1.05 0.42 
 
TABLE 3. THE ACCURACY OF THE CAFFEINE HPLC ASSAY. 
Test solutions 
Concentration (µg/ml) 
Calculated concentration 
(µg/ml) 
% recovery 
0.75 0.79±0.01 97.1 
7.5 21.34±0.17 107.7 
80 80.10±0.03 100.0 
 
TABLE 4. THE PRECISION OF THE IBUPROFEN HPLC ASSAY. 
Standard 
Concentration 
(µg/ml) 
Intra-day 
calculated 
concentration (µg/ml) 
Inter-day 
Calculated 
concentration (µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RSD 
0.5 - 0.49±0.05 - 9.62 
1 0.92±0.01 1.02±0.08 1.46 8.08 
5 5.12±0.17 5.21±0.32 0.21 6.20 
10 10.26±0.02 10.32±0.51 0.15 4.98 
50 50.40±0.05 49.98±1.11 0.09 2.22 
100 99.62±0.02 100.04±0.47 0.02 0.47 
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TABLE 5. THE ACCURACY OF THE IBUPROFEN HPLC ASSAY. 
Test solutions 
Concentration (µg/ml) 
Calculated concentration 
(µg/ml) 
% recovery 
0.75 0.73±0.01 97.1 
20 21.54±0.17 107.7 
80 80.10±0.03 100.0 
 
TABLE 6. THE PRECISION OF THE BUPARVAQUONE HPLC ASSAY. 
Standard 
Concentration (µg/ml) 
Intra-day 
calculated 
concentration (µg/ml) 
Inter-day 
Calculated 
concentration (µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RSD 
0.1 0.11±0.01 0.19±0.01 8.71 6.98 
0.25 0.25±0.02 0.33±0.01 6.68 3.73 
0.5 0.49±0.03 0.55±0.01 6.42 2.03 
1 0.99±0.04 0.99±0.01 4.33 0.56 
5 5.08±0.24 4.89±0.00 4.09 0.09 
25 25.00±0.08 24.55±0.11 0.07 0.44 
125 127.09±0.33 125.77±2.17 0.26 0.02 
 
TABLE 7. THE ACCURACY OF THE BUPARVAQUONE HPLC ASSAY. 
Test solutions 
Concentration (µg/ml) 
Calculated concentration 
(µg/ml) 
% recovery 
2 2.10±0.39 109.3 
60 55.57±1.32 92.6 
120 121.85±0.03 101.5 
 
TABLE 8. THE PRECISION OF THE AMPHOTERICIN B HPLC ASSAY. 
Standard 
Concentration (µg/ml) 
Intra-day 
calculated 
concentration (µg/ml) 
Inter-day 
Calculated 
concentration (µg/ml) 
Intra-day 
% RSD 
Inter-day 
% RSD 
0.75 0.71±0.07 0.79±0.02 9.63 1.97 
1 1.03±0.08 0.98±0.01 7.63 0.6 
10 9.84±0.10 9.40±0.05 1.04 0.49 
50 51.46±1.31 49.96±2.57 2.55 5.14 
100 99.29±0.65 100.08±1.29 0.65 1.28 
 
TABLE 9. THE ACCURACY OF THE AMPHOTERICIN B HPLC ASSAY. 
Test solutions 
Concentration (µg/ml) 
Calculated concentration 
(µg/ml) 
% recovery 
1 0.92±0.07 91.9 
50 50.29±1.91 100.1 
100 99.90±0.97 99.9 
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APPENDIX 2:  DSC  PROFILE 
- LSH001, LSH002 and LSH003 - 
 
FIGURE 6. DSC PROFILE FOR LSH001. 
 
FIGURE 7. DSC PROFILE FOR LSH002. 
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FIGURE 8. DSC PROFILE FOR LSH003. 
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APPENDIX 3:  IN VIVO  STUDY 
- Progression of lesion size diameter in function of time - 
 
 
FIGURE 9. AVERAGE LESION SIZE PROGRESSION PER GROUP IN FUNCTION OF TIME POST INFECTION. 
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APPENDIX 4:  MISCIBILITY STUDIES  
- Solvent ratios for binary and ternary solvent mixtures - 
 
TABLE 10. SOLVENT RATIOS TESTED FOR 
BINARY SOLVENT MIXTURES. 
Ratio 
(v/v) 
Volume (ml) 
Solvent A Solvent B 
1/9 0.1 0.9 
2/8 0.2 0.8 
3/7 0.3 0.7 
4/6 0.4 0.6 
5/5 0.5 0.5 
6/4 0.6 0.4 
7/3 0.7 0.3 
8/2 0.8 0.2 
9/1 0.9 0.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 11. SOLVENT RATIOS TESTED FOR 
TERNARY SOLVENT MIXTURES. 
Ratio 
(v/v) 
Volume (ml) 
Solvent A Solvent B Solvent C 
1/1/8 0.1 0.8 0.8 
1/2/7 0.1 0.7 0.7 
1/3/6 0.1 0.6 0.6 
1/4/5 0.1 0.5 0.5 
1/5/4 0.1 0.4 0.4 
1/6/3 0.1 0.3 0.3 
1/7/2 0.1 0.2 0.2 
1/8/1 0.1 0.1 0.1 
2/1/7 0.2 0.7 0.7 
2/2/6 0.2 0.6 0.6 
2/3/5 0.2 0.5 0.5 
2/4/4 0.2 0.4 0.4 
2/5/3 0.2 0.3 0.3 
2/6/2 0.2 0.2 0.2 
2/7/1 0.2 0.1 0.1 
3/1/6 0.3 0.6 0.6 
3/2/5 0.3 0.5 0.5 
3/3/4 0.3 0.4 0.4 
3/4/3 0.3 0.3 0.3 
3/5/2 0.3 0.2 0.2 
3/6/1 0.3 0.1 0.1 
4/1/5 0.4 0.5 0.5 
4/2/4 0.4 0.4 0.4 
4/3/3 0.4 0.3 0.3 
4/4/2 0.4 0.2 0.2 
4/5/1 0.4 0.1 0.1 
5/1/4 0.5 0.4 0.4 
5/2/3 0.5 0.3 0.3 
5/3/2 0.5 0.2 0.2 
5/2/3 0.5 0.1 0.1 
5/1/4 0.5 0.3 0.3 
6/1/3 0.6 0.2 0.2 
6/2/2 0.6 0.1 0.1 
6/3/1 0.6 0.2 0.2 
7/1/2 0.7 0.1 0.1 
7/2/1 0.7 0.1 0.1 
8/1/1 0.8 0.1 0.1 
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